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PLP-Dependent α-Oxoamine Synthases: Phylogenetic Analysis, Structural 
Plasticity, and Structure-Function Studies on 5-Aminolevulinate Synthase 
 
Tracy Dawn Turbeville 
 
Abstract 
 
 5-Aminolevulinate synthase (ALAS) and 8-amino-7-oxononanoate synthase (AONS) 
are two of four homodimeric members of the α-oxoamine synthase family of pyridoxal 
5’-phosphate (PLP)-dependent enzymes.  The evolutionary relationships among α-
oxoamine synthases representing a broad taxonomic and phylogenetic spectrum have 
been examined to help identify residues that may regulate substrate specificity. 
The structural plasticity of ALAS has been documented in studies of functional 
circularly permuted ALAS variants and the single polypeptide chain ALAS dimer 
(ALAS/ALAS) exhibiting a greater turnover number than wild-type ALAS.  An 
examination of the contribution of each ALAS/ALAS active site to the enzymatic activity 
shows that each active site makes distinct contributions to the steady-state activity of the 
enzyme.  Chimeric ALAS/AONS proteins exhibited an oligomeric structure with two 
sites having ALAS activity and two sites having AONS activity.  Remarkably, the 
steady-state rates for both the ALAS and AONS activities were lower than that observed 
in the parent enzymes, while the reactivity of the ALAS sites in ALAS/AONS was 
similar to that of wild-type ALAS.  We propose that the different contribution of each 
active site to the steady-state activity of ALAS/ALAS and the reduced steady-state 
 x
activities of the ALAS/AONS chimera, compared to the parent enzymes, relate to 
different extents of conformational changes associated with product release due to the 
strain caused with the linking the two ALAS (or ALAS and AONS) subunits.  Thus, the 
extensive plasticity seen in ALAS extends to another member of the α-oxoamine family, 
AONS.    
In the α-oxoamine synthase family a conserved histidine hydrogen bonds with the 
phenolic oxygen of PLP and may be significant for substrate-binding, PLP-positioning, 
and maintaining the pKa of the imine nitrogen.  The replacement of this conserved 
histidine, H282, with alanine in murine erythroid ALAS has multiple effects on the 
spectral, binding, and kinetic properties of the enzyme and supports the conclusion that 
H282 plays multiple roles in the enzymology of ALAS.  Altogether, these results imply 
that amino acid H282 coordinates the movement of the pyridine ring with the 
reorganization of the active-site hydrogen bond network and acts as a hydrogen bond 
donor to the phenolic oxygen to maintain the protonated Schiff base and enhance the 
electron sink function of the PLP cofactor. 
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Chapter One 
Introduction 
Historical Perspectives on Vitamin B6  
Cellular metabolism involves a series of multi-step reaction pathways which are 
necessary for the maintenance of life.  Catabolic pathways break down substances to 
yield energy, whereas anabolic pathways assemble complex products.  The diverse 
reaction pathways are intertwined with each pathway requiring a unique set of enzymes.  
Enzymes allow reactions to proceed rapidly and are essential to push thermodynamically 
unfavorable reactions by coupling them to favorable ones.  While many of the enzymes 
involved in carrying out this vast array of chemical reactions do not need any additional 
components, some require a non-protein constituent or cofactor for activity.  Cofactors 
can be inorganic or organic and many are essential for optimal health and disease 
prevention.  Most vitamins are precursors for metabolically essential cofactors with 
diverse biochemical functions.   
The wide availability of vitamins in the form of inexpensive pills has contributed 
to a modern day fascination with vitamin supplementation by many, making it hard to 
imagine that a century ago the existence of such “accessory food factors” was heavily 
debated.  The first vitamin was isolated in 1913; by the mid 1930’s the first multivitamin 
products were available in pharmacies and grocery stores and milk was fortified with 
vitamin D.  Today an average of 35% of Americans report the recent use of multivitamins 
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(Panel, 2006).  Many diseases associated with vitamin deficiencies that were 
commonplace a century ago are virtually unknown to today’s generation. 
Vitamin B6 is among the many vitamins in which the nutritional importance has 
been recognized and the metabolic and biochemical significance has been well 
characterized.   Vitamin B6 is a collective term for a group of pyridine derivatives that 
serve as precursors for the coenzyme pyridoxal phosphate, which has been recognized as 
the cofactor for over 100 enzyme catalyzed reactions (Percudani and Peracchi, 2003).  
The scientific discoveries and developments leading to the isolation of vitamin B6 are 
common to all vitamins.  
 
Discovery of vitamins  
 “Hard work on interesting problems is enjoyable and preferable to 
aimless wasting of leisure time.  It may also lead to unexpected 
findings that give insights into important related problems. Such 
unexpected findings—sometimes called ‘luck’—frequently happen to 
the active researcher, but only rarely to those who prefer talk to study 
and work.  So one should study and work hard, on interesting problems 
of any nature, with the purpose of explaining nature and helping others 
(Miles and Metzler, 2004).”  
             Esmond Snell 
In the last days of the 19th century, when Christian Eijkman was sent to the Dutch 
colony in Java to identify the microbe responsible for beriberi, a nervous system ailment 
that would eventually be linked to a deficiency of thiamine (vitamin B1) in the diet, the 
link between diet and disease was almost unimaginable (Carpenter, 2003).  During this 
period, the recent sucesses of Robert Koch in identifying microorganisms responsible for 
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several diseases had scientist around the globe searching for other links between disease 
and microorganisms (Carpenter, 2003).  Eijkman attempted to replicate the disease and 
isolate the microbe by injecting blood from sick soldiers into animals, yet he was unable 
to replicate the disease or identify any associated microorganism.  While Eijkman’s work 
did not find the source of beriberi, his rather serendipitous observation in the 1890’s 
would eventually link beriberi to dietary insufficiencies.  He observed that “uninfected” 
chickens began exhibiting leg weakness (polyneuritis), a characteristic observed in 
beriberi patients.  He carefully characterized the chickens’ illness, including their 
unexpected spontaneous recovery (Carpenter, 2003).   
Eijkman soon began an inquiry to understand the chickens’ extraordinary 
recovery.  He would learn that, prior to the appearance of the polyneuritis symptoms, the 
chickens’ diet was changed from unpolished brown rice to polished white rice and the 
recovery of the chickens coincided with the addition of brown rice back into the diet.  
After a series of carefully designed experiments, replicating the symptoms and recovery 
of the chickens, he confirmed that the observed polyneuritis was directly attributable to 
diet (Carpenter, 2003).  Although Eijkman mistakenly reasoned that the white rice 
contained a toxin and the brown rice the antidote or “the anti-beriberi factor”, his inquiry 
into his chance observation would begin the transformation of the nutritional paradigm of 
the period.  Eijkman’s health would prevent him from continuing his research and force 
him to return to Holland; however, he had laid the groundwork that led his successor and 
colleague, Gerret Grijns, to theorize in 1901 that white rice "lacked a certain substance of 
importance in the metabolism of the central nervous system"(Rosenfeld, 1997; Carpenter, 
2003).   
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Sir Frederick G. Hopkins had begun his career during the same period as Eijkman 
when the prevailing nutritional paradigm was that calories alone were sufficient for 
animals to survive.  His 1901 observation that mice lacking the amino acid tryptophan 
died within a “fortnight” (two weeks) would be Hopkins first challenge to this theory 
(Hopkins, 1912).  Through a classic series of experiments, Hopkins unveiled evidence 
that there was an unknown constituent found in normal diets that was not found in a diet 
of purified proteins, carbohydrates, fats, and salts, in 1906 and 1907. However,  it would 
be five years before Hopkins published his unorthodox findings in the 1912 article, 
"Feeding Experiments Illustrating the Importance of Accessory Food Factors in Normal 
Dietaries (Hopkins, 1912).”  
By the time Hopkins research was finally published, other sceintists had begun 
working to find the elusive “anti-beriberi” factor contained in the rice polishings.  Among 
them was London chemist Casmir Funk, who believed he had isolated a nitrogen-
containing factor that cured beriberi and assumed it to be an amine.  Thus, Funk 
“suggested the name vitamine for it as being one of those nitrogenous substances, minute 
quantities of which are essential in the diet of birds, man and some other animals (Funk, 
1912).”  Although the anti-beriberi factor was only a contaminant and was eventually 
demonstrated to not be an amine, the name stuck (Carpenter, 2003). 
As long as the nature of Hopkins and Funk dietary components remained elusive, 
the existence of “vitamines” would remain in doubt.  Fortunately, a great deal of attention 
was focused on the “vitamine” question leading to the two groups simultaneously 
reporting the discovery of the first accessory food substance in the Journal of 
Biochemistry in 1913 (McCollum, 1913; Osborne, 1913).  Both groups identified a fat-
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soluble organic substance that was an essential nutritional component for rats.  It was 
termed fat-soluble A and was the first dietary constituent to be recognized as a 
“vitamine.”(Rosenfeld, 1997)    
As scientist began to distill the various fat soluble and water-soluble 
requirements, the number of essential nutritional components isolated and characterized 
grew.  It soon became clear that these dietary factors were not in fact amines and 
subsequently the “e” was dropped.  Thus the early nomenclature, fat soluble A and water 
soluble B and C, would eventually be shortened and referred to as vitamins A, B and C, 
respectively (Drummond, 1920). 
While the nutritional significance of vitamins is widely understood today, in the 
early 20th century the mere suggestion that accessory dietary factors were important was 
revolutionary and controversial.  Though neither Eijkman or Hopkins actually isolated 
the “anti-beriberi factor” or any “accessory food factors,” it was their observations and 
research that would ultimately led to the discovery of vitamins, thereby transforming 
nutritional research.  The characterization of these trace nutrients not only revolutionized 
nutritional science, but contributed greatly to other scientific disciplines.  In 1929, 
Eijkman and Hopkins would share the Noble prize in “Physiology or Medicine” for their 
work leading to the “discovery of growth-stimulating vitamins.”  By 1965, nine other 
scientists would be awarded the Nobel Prize for their work with vitamins and another 
seven Nobel Laureates would make significant contributions to vitamin research.   
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Unraveling the Vitamin B complex 
 
“[T]he history of B6 is a further proof that success usually is preceded 
by trials, tribulations, and recurrent disappointment. The most helpful 
factor, apart from perseverance and timeliness of the line of research, 
is the deliberate recognition of a principle that is paramount in 
scientific research; it is often almost beyond our control and touches 
closely on intuition.  It is Walter B. Cannons’s ‘serendipity’(Gyorgy, 
1971).”  
Paul Gyorgyy, M.D. 
 Water-soluble vitamin B, the “anti-beriberi” factor, was initially believed to be a 
single compound. The 1919 JBC review by Mitchell was the earliest suggestion that 
vitamin B likely contained multiple compounds of nutritional significance (Mitchell, 
1919; Carpenter, 2003).  It was not until 1926 that Dutch scientists in Java isolated the 
first vitamin B component, thiamine, Grijns’ “anti-beriberi” factor (Jansen, 1926; 
Carpenter, 2003).  Thiamine, also called Vitamin B1, would be the first B vitamin 
identified and the first vitamin to be recognized as an enzyme cofactor. 
Seven additional chemically distinct components of the vitamin B complex would 
eventually be isolated and identified (Table 1.1).  Ultimately, all eight would be identified 
either as an enzyme cofactor or an essential cofactor component.  The discovery that 
vitamins functioned as enzyme cofactors demonstrated that vitamins play essential roles 
in various aspects of metabolism and began to bridge the gap between nutritional science 
and the then seemingly remote fields of cellular metabolism and enzymology.  
 Among the vitamin B components that would eventually illicit the attention of 
nutritionists, biochemists and enzymologists, was pyridoxine.  First identified as a 
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substance present in a crude supplement that cured or prevented florid dermatitis in rats, 
pyridoxine was initially given the name vitamin B6 by Paul Gyorgy (Gyorgy, 1934).  This 
new vitamin was eventually isolated, synthesized, and ultimately given the name 
pyridoxine (Gyorgy, 1971).  An amine and an aldehyde form of vitamin B6, 
pyridoxamine and pyridoxal, respectively, was eventually identified by Esmond Snell, a 
biochemist studying microbial metabolism (Snell, 1942).  Snell also identified the 
respective 5´-phosphate esters of pyridoxal, pyridoxal 5´-phosphate (PLP) as the major 
biological active form of the vitamin B6 (Christen and Metzler, 1985).  
 
Characterization of Vitamin B6 as a cofactor and coenzyme  
 “Pyridoxal phosphate holds an exceptional place among the 
coenzymes with regard to both the unparalleled diversity of its 
catalytic function and to their paramount significance in biochemical 
transformations of amino acids and in integral nitrogen metabolism 
(Boyer, Lardy et al., 1960).”  
A. E. Braunstein 
Scientists studying vitamin B6 began unraveling the significance of its role as a 
cofactor in cellular metabolism.  Snell eventually demonstrated that heating pyridoxal 
with various amino acids would produce an oxo-acid and pyridoxamine in a reversible 
fashion, prompting the proposal that vitamin B6 derivatives might be involved in 
enzymatic transaminations (Christen and Metzler, 1985).  Almost simultaneously, 
tyrosine decarboxylase activity and enzymatic transamination between glutamate and 
oxaloacetate in Streptococcus faecalis cells were found to be dependent on the 
availability of pyridoxal by another group (Christen and Metzler, 1985).   
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 However, it was the non-enzymatic catalytic activity of pyridoxal that would give the 
most insight into the magnitude of its role as a coenzyme.  Pyridoxal demonstrated an 
ability to catalyze amino acid transaminations, racemization, and α, β eliminations  
(Metzler and Snell, 1952; Olivard, Metzler et al., 1952; Christen and Metzler, 1985; 
Miles and Metzler, 2004).  The electron-withdrawing property of the heterocyclic 
nitrogen was ultimately recognized as a fundamental element to all pyridoxal-catalyzed 
reactions (Christen and Metzler, 1985).  This led to a proposed mechanism based on the 
utilization of the electron withdrawing properties of the PLP-cofactor in the labilization 
of an α-carbon bond of the amino acid substrate, which was eventually found to be 
common for both non-enzymatic and PLP-assisted enzymatic reactions (Christen and 
Metzler, 1985).   
The catalytic diversity of PLP-dependent enzymes arises from modulation and 
enhancement of the intrinsic chemical properties of PLP by the active site environment.  
In PLP-dependent enzymes, the PLP forms an imine bond with the ε-amino group of an 
active site lysine; this Schiff base linkage is termed the “internal aldimine” and is 
outlined in Scheme 1.1.  The reactions begin with a transaldimination in which the amino 
group of the amino acid substrate replaces the ε-amino of the lysine.  This PLP-substrate 
complex is common to all reactions and is termed the “external aldimine”.  Subsequently, 
the cleavage of an amino acid α-carbon bond leads to a resonance stabilized quinonoid 
intermediate in which the extended pi-system of the coenzyme acts as an electron sink, 
storing electrons from the cleaved bond through the conjugated system of the Schiff base 
and pyridinium ring.  Ultimately, the electrons are dispensed back to the α-carbon 
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allowing the formation of new linkages (Christen and Metzler, 1985; Christen and Mehta, 
2001).   
 The fact that this essential and ubiquitous coenzyme is associated with at least 145 
different enzymatic activities attests to the versatility and demonstrates the biological 
importance of this cofactor (Percudani and Peracchi, 2003).  PLP-dependent enzymes 
include amino acid racemases, transaminases, decarboxylases, synthases and aldolases.  
These enzymes play a key role in the synthesis, interconvertion, and degradation of 
amino acids and are also involved in the synthesis of nucleic acids and protein cofactors 
such as NAD+, biotin and heme (Mehta and Christen, 2000).   
 
Medical significance of Vitamin B6 
Vitamin B6 would eventually be recognized by the medical field for being 
involved in significantly more bodily functions than any other nutrient, with over 100 
essential biochemical reaction catalyzed by PLP-dependent enzymes in human 
metabolism (Tambasco-Studart, Titiz et al., 2005).  A number of disorders have been 
associated with PLP-dependent enzymes, some of which are overviewed in table 1.2.   
Because of the wide availability of vitamin B6 in both plant- and animal-derived 
food, B6 deficiencies are uncommon.  However, several different mechanisms can lead to 
an increased requirement for vitamin B6, including depletion by various drugs, renal 
dialysis, malabsorption, and hereditary errors in B6 metabolism (Holman, 1995).  With 
the wide range of reactions that are catalyzed by PLP-dependent enzymes, it is not 
surprising that vitamin B6 deficiency has been associated with an array of symptoms 
including weakness, reduced resistance to infections, weight loss, depression, irritability, 
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sleeplessness, peripheral neuropathy, seborrhoea-like dermatosis regions, pellagra-like 
dermatitis, glossitis/stomatitis, however, weakness, sleeplessness, and depression are the 
most prominent effects (Holman, 1995).   
 11
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SCHEME 1.1 - Reactions of PLP-dependent enzymes 
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Vitamin B6-dependent enzymes 
Reactions catalyzed by PLP-dependent enzymes play key roles linking different 
metabolic pathways and are thought to have been essential in the last universal ancestor 
of contemporary cells, in which the major metabolic pathways were likely established 
(Ouzounis and Kyrpides, 1996; Mehta and Christen, 2000).  Thus, it has been proposed 
that this class of enzymes were already present in a universal progenitor cell 1000 to 
1500 millions of years ago (Mehta and Christen, 1998).  The sequence similarities among 
this highly divergent class of enzymes have generally been too low to establish a 
common ancestry.  However, after considerable progress was made in the three-
dimensional structure determination of a representative number of PLP-dependent 
enzymes, Christen and Mehta were finally able to use the high structural conservation of 
PLP-dependent enzymes to verify an evolutionary relationship (Christen and Mehta, 
2001).   
Initially, PLP-dependent enzymes were classified according to reaction specificity 
relative to the Cα, but as the database of PLP-enzyme structures grew it became possible 
to classify according to fold-types derived from three-dimensional structures (Alexander, 
Sandmeier et al., 1994; Christen and Mehta, 2001; Eliot and Kirsch, 2004).   There are 4 
fold-types of PLP-dependent enzymes and each corresponds to an independent 
evolutionary lineage.  The aspartate aminotransferase superfamily corresponds to the 
fold-type I, α−family is the largest and most diverse lineage of PLP-dependent enzymes, 
of which the members outnumber the combined total of the other families (Mehta and 
Christen, 1998; Mehta and Christen, 2000; Paiardini, Bossa et al., 2004).   
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The high structural conservation displayed by the α-family, despite a low degree 
of sequence identity (1.1), is not unusual among proteins sharing a common ancestor 
(Paiardini, Bossa et al., 2004).  The dimer is the minimal functional unit for this family 
and each monomer consists of three domains (1.2), a short N-terminal domain (~50 
residues), a central catalytic core (~250 residues), and a C-terminal domain (~100 
residues) (Alexeev, Alexeeva et al., 1998; Astner, Schulze et al., 2005; Yard, Carter et 
al., 2007).  Each dimer contains two identical active sites which lie at the interface 
between the two subunits. Both active sites interact with the PLP cofactor through a 
Schiff base linkage with an active site lysine (Christen and Mehta, 2001).  In all known 
structures of the α-family, the pyridine ring of the PLP cofactor is nearly superimposible 
(Kack, Sandmark et al., 1999).  The pyridoxal moiety interacts with the enzyme in a 
common motif, which also includes a salt-bridge between the pyridinium ring nitrogen 
and an aspartate, and a hydrogen bond with the phenolic oxygen which occurs through a 
variety of amino acids in addition to Schiff base linkage with an active site lysine (Kack, 
Sandmark et al., 1999).  Interestingly, the active site lysine and aspartate are the only two 
perfectly conserved amino acids in the α-family (Mehta and Christen, 1998).  
 The α-oxoamine synthases are a small group of enzymes within the α-family that 
catalyze reactions between amino acids and CoA thioesters.  5-Aminolevulinate synthase 
(ALAS) and 8-amino-7-oxononanoate synthase (AONS) belong to this α-oxoamine 
synthase subfamily, along with serine palmitoyltransferase (SPT) and 2-amino-3-
oxobutyrate CoA ligase (KBL) (Alexeev, Alexeeva et al., 1998; Schneider, Kack et al., 
2000; Schmidt, Sivaraman et al., 2001; Astner, Schulze et al., 2005; Yard, Carter et al., 
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2007).  These four members of the α-oxoamine family share about 12% identity, with the 
sequence identity around 30% between any pair (Alexeev, Alexeeva et al., 1998).   
ALAS, AONS and SPT catalyze condensations between amino acids and acyl-
CoA thioesters with the concomitant decarboxylation of the amino acid, while KBL only 
catalyzes the condensation between the acyl-CoA thioester and the amino acid 
(Schneider, Kack et al., 2000).  ALAS and AONS function in the biosynthesis of 
prosthetic groups essential for proteins that play fundamental roles in many biochemical 
processes. ALAS catalyzes the first committed and rate limiting step of heme 
biosynthesis in non-plant eukaryotes and the alpha subdivision of purple bacteria (Jordan, 
1991) and AONS catalyzes the first committed step in biotin biosynthesis (Alban, Job et 
al., 2000).  
 18
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 1.1  
Ribbon diagrams of representative enzymes of Fold Types I - IV. Each 
structure depicts a homodimer with the individual monomers distinguished 
by color.  A. Fold-type I (aspartate aminotransferase family), 2-amino-3-
oxobutyrate CoA ligase, 1FC4, B. Fold-type II (tryptophan synthase 
family), tryptophan synthase, 1EX5, C. Fold-type III (alanine racemase 
family), Alanine racemase, 1FST, D. Fold-type IV (D-amino acid 
aminotransferase family), branch chain aminotransferase, 1KTA,  (In A,B 
and E the PLP cofactor is shown in red, while in C the active site lysine is 
shown in red.) Images were generated with Deep View (Guex and Peitsch, 
1997; Kaplan and Littlejohn, 2001).  
 
 
A.                                         B. 
 
 
 
 
 
 
C.                                          D. 
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FIGURE 1.2  
PLP-dependent enzymes of the α-family are homodimers.  The ALAS 
homodimer from R. capsulatus (PDB code: 2BWN)  in ribbon 
representation with one subunit shown in yellow and the central catalytic 
core, N-terminal domain, and C-terminal domain of the second subunit 
rendered in dark, medium and light blue, respectively.  Depicted in ball-and-
stick are the PLP cofactor (red), the active site lysine (green) involved in the 
Schiff base linkage with PLP and the active site residue F342 (purple), 
which is contributed by the adjacent chain.  Image was generated with Deep 
View (Guex and Peitsch, 1997; Kaplan and Littlejohn, 2001).   
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Biotin 
 
 
 
SCHEME 1.2-Biotin 
 
Biotin Biosynthesis 
Biotin (Vitamin H or B7) is a cofactor for a small number of carboxylases and 
decarboxylases and is essential for life in all organisms (Scheme 1.2) (Alban, Job et al., 
2000).  Biotin biosynthesis occurs in most bacteria and archea as well as some fungi and 
plants.  Animals and most fungi are biotin auxotrouphs (Alban, Job et al., 2000; Streit, 
W. R. and Entcheva, P., 2003).   The first common precursor in biotin biosynthesis is 
pimeloyl-CoA (Alban, Job et al., 2000; Streit, W. R. and Entcheva, P., 2003).  The 
precursors for pimeloyl-CoA are not uniform and are not known for all microbes that 
synthesize biotin.  In plants and gram-positive bacteria, pimeloyl CoA is synthesized 
from pimelic acid by pimeloyl-CoA synthetase.  The four steps that convert pimeloyl-
CoA to biotin are conserved among all organisms known to produce biotin (Alban, Job et 
al., 2000; Streit, W. R. and Entcheva, P., 2003).  
 The first enzyme of the common pathway is AONS, which catalyzes the 
decarboxylative condensation of alanine and pimeloyl-CoA in the first committed step of 
biotin biosynthesis, Scheme 1.3 (Schneider, G. and Lindqvist, Y., 2001).  The next step is 
the conversion of 8-amino-7-oxopelargonic acid to 7, 8-diaminopelargonic acid (DAPA) 
catalyzed by DAPA aminotransferase.  Both AONS and DAPA aminotransferase belong 
S
N
H
NHOH O
H
H
O
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to the α-family of PLP-dependent enzymes.   DAPA aminotransferase is the only known 
aminotransferase that uses s-adenosylmethionine (SAM) as the NH2 donor (Kack, 
Sandmark et al., 1999; Schneider, G. and Lindqvist, Y., 2001).  In the following reaction, 
which is catalyzed by dethiobiotin synthetase, an uriedo ring is formed via a 
carboxylation reaction and requires ATP, Mg2+ and CO2  (Schneider, G. and Lindqvist, 
Y., 2001).  The final step of biotin biosynthesis involves the insertion of a sulfur atom 
between the non-reactive methyl and methylene carbon atoms adjacent to the ureido ring 
of dethiobiotin (Schneider, G. and Lindqvist, Y., 2001) and is catalyzed by biotin 
synthase which functions as a homodimer.  Biotin synthase is a s-adenosylmethionine 
dependent-enzyme with one 2Fe-2S cluster per monomer when isolated anerobically 
(Schneider, G. and Lindqvist, Y., 2001; Lotierzo, Tse Sum Bui et al., 2005).  There is 
disagreement surrounding the identity of the sulfur donor, while free cysteine has been 
the generally accepted donor, recent studies indicate that the Fe-S cluster may be the true 
sulfur source (Schneider, G. and Lindqvist, Y., 2001). 
 
Medical significance of biotin 
Biotin (Vitamin H or B7), another component of the vitamin B complex isolated 
by the physician Paul Gyorgy, is a cofactor for a small number of carboxylases and 
decarboxylases  (Alban, Job et al., 2000).  Biotin-dependent carboxylases add carbon 
dioxide to substrates and require ATP hydrolysis.  The general mechanism for biotin 
dependent carboxylases is shown in Figure 1.3. Biotin-dependent carboxylases play 
essential roles in the metabolism of cholesterol, amino acids, and leucine degradation 
(Pacheco-Alvarez, Solorzano-Vargas et al., 2002). 
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In humans, there are five biotin-dependent carboxylases: propionyl-CoA-, β-
methylcrotonyl-CoA-, two forms of acetyl-CoA and pyruvate carboxylase (Pacheco-
Alvarez, Solorzano-Vargas et al., 2002). The absolute requirement for biotin rests in the 
central role that these four enzymes play in cell metabolism, which is summarized in 
Figure 1.4.  The two most notable examples of biotin dependent-enzymes are acetyl-CoA 
carboxylase and pyruvate carboxylase.  Acetyl-CoA carboxylase catalyzes the production 
of malonyl-CoA from acetyl-CoA, the first and rate-limiting step in fatty acid synthesis 
(Pacheco-Alvarez, Solorzano-Vargas et al., 2002).  Pyruvate carboxylase is an 
anaplerotic enzyme involved in the formation of oxaloacetate from pyruvate,   and 
oxaloacetate is a key intermediate in both gluconeogenesis and the TCA cycle (Pacheco-
Alvarez, Solorzano-Vargas et al., 2002).    
Humans, like other animals, are unable to synthesize biotin and depend on diet to 
fulfill their need for this vitamin.  The primary source of dietary biotin is protein-bound 
and biotin must be cleaved.  Pancreatic biotinidase cleaves the protein-bound biotin from 
the ε-amino group of the lysine residue to which it is attached (Suzuki, Aoki et al., 1994).  
Higher organisms have evolved an efficient biotin cycle to survive with the low 
concentrations of biotin found in natural food sources(Pacheco-Alvarez, Solorzano-
Vargas et al., 2002).  During carboxylase turnover, biotin is cleaved by cytosolic plasma 
and biotinidase (Gravel and Narang, 2005). Once the biotin is inside the cell, 
holocarboxylase synthetase covalently attaches biotin to carboxylases (Gravel and 
Narang, 2005).  
Both biotinidase and holocarboxylase synthase deficiencies result in Multiple 
Carboxylase Deficiency, MCD.  The symptoms for MCD include; alopeica, 
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developmental delay, organic aciduria, seizures, skin rashes, mild hyperammoneima, and 
breathing problems.  Because biotinidase deficient patients only lack the ability to 
generate free biotin, it is easily treated by biotin supplementation (5–20 mg per day) 
(Leon-Del-Rio and Gravel, 1994; Suzuki, Aoki et al., 1994).  In holocarboxylase 
synthetase deficient patients, carboxylase biotinylation is compromised globally, 
resulting in lethal consequences if not diagnosed and treated rapidly.  Since 
holocarboxylase synthase deficiency leading to MCD is due to mutations resulting in 
decreased biotin affinity, the  addition of pharmacologic doses of biotin (10–100 mg per 
day) to the diet can reverse the symptoms if treated promptly (Pacheco-Alvarez, 
Solorzano-Vargas et al., 2002). 
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FIGURE 1.3 
Biotin-dependent carboxylases. A similar catalytic mechanism is shared by biotin-
dependent carboxylases.  Most biotin-dependent enzymes have three functional 
domains, the biotin carboxylase (or decarboxylase) domain, the 
carboxyltransferase domain and the biotin carboxyl carrier domain.  The reaction 
occurs in two steps in two separate subsites.  The first step occurs at the first 
subsite on the carboxylase domain and involves the partial fixation of CO2 to 
biotin. The carboxybiotin then swings to the second subsite on the 
carboxyltransferase domain where a carboxylated compound is formed with the 
carboxylases or the generation of free CO2 for the decarboxylases (Jitrapakdee 
and Wallace, 2003). 
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FIGURE 1.4: Biotin-dependent carboxylases in metabolism 
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Heme 
 
 
 
SCHEME 1.4 
 
 
 
 
 
 
Heme Biosynthesis  
Tetrapyrroles are indispensable to various biological processes, including oxygen 
transport (heme), photosynthesis (chlorophyll), electron transport (cytochromes), 
methionine and methylmalonyl CoA synthesis (colabalamin) and nitrate reduction 
(siroheme) (Frankenberg, Moser et al., 2003).   The universal precursor of heme (Scheme 
1.4) and other tetrapyrroles is 5-aminolevulinic acid, ALA.  There are two distinct 
pathways leading to ALA formation and both require PLP.  The C5 pathway, found in 
plants, algae, and most bacteria, utilizes the 5C -skeleton of glutamate and involves the 
action of two enzymes, the NADPH-dependent glutamyl-tRNA reductase (GluTR) and 
the PLP-dependent glutamate-1-semialdehyde-2,1-aminomutase (GSAM)  (Frankenberg, 
Moser et al., 2003).  The Shemin, or C4 pathway, identified in non-plant eukaryotes and 
the α-subdivision of purple bacteria requires a single PLP-dependent enzyme, 5-
HOOC
N N
NN
Fe
HOOC
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aminolevulinate synthase (ALAS) (Shemin, Russell et al., 1955).  The Shemin pathway 
for heme biosynthesis begins with the condensation of succinyl-CoA and glycine to 
produce carbon dioxide, CoA and ALA (Shemin, Russell et al., 1955; Ryter and Tyrrell, 
2000).   
 In humans and other mammals, heme biosynthesis has been well characterized and 
begins in the mitochondria with the biosynthesis of ALA (Thunell, S. , 2000). The prime 
location of heme biosynthesis occurs in the bone marrow and liver, however, the 
mechanisms controlling synthesis differ.  Because heme demands vary significantly 
according to the unique requirements of different tissues, it is not unexpected that there is 
not a ubiquitous regulatory pathway.   While the major control of heme biosynthesis in all 
cells is the production of the initial precursor ALA by ALAS, regulation of ALAS varies 
in various cell types (Thunell, S. , 2000).  
Two cytosolic ALAS isoenzymes are encoded by separate genes; the general 
housekeeping form, ALAS-1, and the erythroid specific form ALAS-2 and each are 
regulated by different mechanisms.  The housekeeping isoenzyme, ALAS-1, has a short 
half-life and can be rapidly turned over in response to the drain of the free cellular heme 
pool by present metabolic needs (Thunell, S. , 2000).  The erythroid isoenzyme, ALAS-2, 
regulation machinery is designed for uninterrupted production and induced only during 
the period of active hemoglobin synthesis.  ALAS-2 is regulated transcriptionally and 
post-transcriptionally by erythropoietin action and the amount of free iron present 
(Thunell, S. , 2000; Zoller, Decristoforo et al., 2002).  The regulation of ALAS-2 by 
intracellular free iron involves a mRNA stem loop structure in the 5’ untranslated region 
which contains an iron responsive element (IRE).  The binding of iron regulatory 
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proteins, IRP-1 and IRP-2, to the IRE inhibits ALAS-2 mRNA translation under iron-
poor conditions.  High intracellular iron availability induces the post-translational 
modification of  IRP-1 and degradation of IRP-2 to permit ALAS-2 mRNA translation 
ALA then moves into the cytosol, where ALA dehydratase (or porphobilinogen 
synthase) catalyzes the condensation of two ALA molecules to form the pyrrole ring of 
porphobilinogen, Scheme 1.5 (Thunell, S., 2000). Four porphobilinogen molecules are 
polymerized by porphobilinogen deaminase to form the linear tetrapyrrole of 
hydroxymethylbilane, which is then cyclized to uroporphyrinogen III  by 
uroporphyrinogen III synthase (Frankenberg, Moser et al., 2003).  The decarboxylation of 
4 acetate groups of uroporphyrinogen III by uroporphyrinogen III decarboxylase yields 
coproporphyrinogen III (Ferreira, 2004).  Heme biosynthesis then moves back into the 
mitochondria where two propionate side chains are oxidized by coproporphyrinogen III 
oxidase to yield protoporphyrinogen IX (Ferreira, 2004).  Protoporphrinogen IX oxidase 
then catalyzes a six electron oxidation completing the conjugated system of the 
tetrapyrrole microcycle yielding protoporphyrin IX (Ferreira, 2004).  In the final step of 
heme biosynthesis, iron is inserted into protoporphyrin IX by ferrechelatase to produce 
heme (Ferreira, 2004).   
While the biosynthesis of the different tetrapyrroles can require between 7 and 30 
reactions, the three reactions following ALA biosynthesis leading to uroporphyrinogen 
III found in heme biosynthesis are common for all tetrapyrroles (Figure 1.5).   The steps 
leading from uroporphyrinogen III to protoporphyrin IX are common to both heme and 
chlorophyll biosyntheses.   In plants, the major site of tetrapyrrole biosynthesis is in the 
plastids, although there is some debate regarding biosynthesis of heme in the 
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mitochondria.  Specifically, the co-localization of the three terminal enzymes of heme 
biosynthesis may occur in both the plastid and the mitochondria, however there is not 
consensus among researchers (Tanaka and Tanaka, 2007).   
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FIGURE 1.5: Overview of tetrapyrroles biosynthesis 
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Medical significance of hemoproteins and heme biosynthesis  
In humans, the role of heme as a prosthetic group for the erythrocyte oxygen 
transporter protein hemoglobin is, perhaps, the most commonly known role.  In fact, 85% 
of the body’s heme is synthesized in the erythroblast.  While hemoglobin is found 
exclusively in erythrocytes, other specialized globins also function as oxygen carriers in 
fetal erythrocytes, neurons, cardiac muscle, and skeletal muscle.  Once molecular oxygen 
is captured by the heme prosthetic group in hemoglobin, it can be transported via the 
bloodstream to the other oxygen chaperones, such as myoglobin in muscle cells, where 
ultimately it can be used as an electron acceptor.  Impaired globin synthesis is associated 
with thalassemia syndromes and sickle cell disease is caused by mutations in the β-globin 
gene (Cecil, Goldman et al., 2008). 
In addition to the ability of heme to interact with oxygen, heme can readily 
convert between oxidation states, Fe2+ and Fe3+, allowing heme to function as an electron 
carrier that may alternatively be reduced or oxidized.  This characteristic makes heme an 
essential cofactor for a number of enzymes that catalyze redox and single electron carrier 
reactions during cellular processes such as cellular respiration, steroid metabolism and 
oxidative metabolism of foreign compounds such as drugs.  The role of hemoproteins in 
various biological processes is summarized and examples are given in Table 1.3.  Heme 
can also function as a regulatory molecule in some transcription factors and proteins 
involved in various biochemical pathways by controlling the activity by binding “heme 
regulatory motifs” (Rodgers, 1999).   
Cytochrome P450s (CYPs) are a large class of hemoproteins and at least 27  
functioning human CYPs have been identified (Nelson, Zeldin et al., 2004).   CYPs 
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utilize the redox and electron carrier potential of heme and are involved in a variety of 
reactions.  CYPs play key roles in cholesterol homeostasis and in the metabolism of 
drugs and environmental chemicals (Agundez, 2004).  CYP gene polymorphisms have 
been associated with cancer (Agundez, 2004) and altered regulation of CYPs occurs in 
diseases such as obesity, diabetes, and non-alcoholic steatohepatitis (Luoma, 2008).   
The interruption of heme biosynthesis is also associated with a variety of diseases 
which include X-sideroblastic anemia and porphyrias.   Sideroblastic anemias are a group 
of hematological disorders which is characterized by microcytic hypochromic anemia 
with ringed sideroblasts in bone marrow (Bottomley, May et al., 1995).  X-linked 
sideroblastic anemia, an inherited form of sideroblastic anemia, is due to any number of 
mutations in the erythroid-specific ALAS2 gene located on the X-chromosome (May and 
Bishop, 1998).  In addition to the symptoms associated with anemia, patients also exhibit 
iron overload resulting from increased intestinal absorption of dietary iron and result in 
the major complications of this disorder (Bottomley, 1982; Propper and Nathan, 1982).  
The increased iron delivery to the tissues ultimately leads iron overload and secondary 
hemochromatosis which can result in diabetes, liver and heart failure without treatment 
(Bottomley, 1991; May and Bishop, 1998).   
Porphyrias are a group of diseases associated with the accumulation of porphyrin 
intermediates of heme biosynthesis.  Porphyrias are classified as hepatic or erythropoietic 
and neurovisceral or photocutaneous, according to the site of expression and the 
associated symptoms, although some overlap, Table 1.4.  A wide array of neurovisceral 
and/or photocutaneous symptoms is associated with porphyrias.  In addition to porphyrin 
neurotoxicity, the neurovisceral symptoms are also thought to be associated with the 
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build up of ALA or PBG, which also have a role neurotoxicity (Ryter and Tyrrell, 2000; 
Dombeck, T. A. and Satonik, R. C. , 2005).   Furthermore, ALA may act as a GABA 
analog and interact with neural GABA receptors (Dombeck, T. A. and Satonik, R. C. , 
2005).  Photocutaneous symptoms are caused by porphyrin activation with long wave UV 
light and the subsequent generation of oxygen radicals that damages the skin (Dombeck, 
T. A. and Satonik, R. C. , 2005).   
There are 8 types of porphyrias which are associated with the 8 enzymes involved 
in heme biosynthesis.  The recently characterized X-linked-dominant protoporphyria 
results from gain-of-function mutations in the rate-limiting ALAS2 (Whatley, Ducamp et 
al., 2008).  The increased ALA production is propagated down the pathway resulting in 
an overproduction of protoporphyrin, which ultimately results in a disparity between the 
protoporphyrin and heme production.  This porphyria results in photosensitivity 
indistinguishable from erythropoietic protoporphyria which is associated with impaired 
ferrochelatase activity, with almost one-fifth of the cases exhibiting liver disease 
(Whatley, Ducamp et al., 2008). 
ALA dehydratase porphyria (AD-P) is the rarest, with only four confirmed cases 
(Sassa and Kappas, 2000).  As the name suggests, this porphyria is attributed to a 
deficiency in ALA dehydratase.  AD-P is autosomal recessive and is classified as an 
acute hepatic porphyria (Sassa and Kappas, 2000).  A major characteristic found in 
patients is a marked increase in the urinary excretion of ALA (Sassa and Kappas, 2000). 
Acute intermittent porphyria (AIP) is an autosomal dominant hepatic porphyria 
that is the most significant with respect to its incidence and clinical severity (Sassa and 
Kappas, 2000; Thunell, S. , 2000).  AIP results from a deficiency in porphobilinogen 
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deaminase in which the porphobilinogen deaminase activity is reduced by approximately 
50% (Sassa and Kappas, 2000).  The majority of those with AIP are clinically latent and 
only around one-half will experience an attack during their life span.  The acute attacks 
occur in about 1-2 individuals per 100,000 in the US and in certain populations, such as 
Lapland, Sweeden, the rate may be as high as 1/1000 (Dombeck, T. A. and Satonik, R. C. 
, 2005).  Acute attacks may be life threatening and are often precipitated by various 
factors such as drugs, hormones, starvation, and infection (Dombeck, T. A. and Satonik, 
R. C., 2005).  These factors induce heme synthesis by either depleting heme stores or via 
more direct mechanisms of ALAS induction.  This results in an increase in porphyrin 
intermediates in the heme pathway.  Patients exhibit a variety of visceral and peripheral 
symptoms from the involvement of the autonomic and central nervous system during an 
attack (Thunell, S. , 2000; Dombeck, T. A. and Satonik, R. C., 2005).  Extreme 
abdominal pain, tachycardia, nausea and various other neuropsychiatric symptoms are 
common indicator, with abdominal pain and tachycardia occurring in 90% and 80% of 
attacks, respectively (Dombeck, T. A. and Satonik, R. C., 2005).  
Congenital erythroblastic porphyria (CEP) is an autosomal recessive 
photosensitive porphyria characterized by an uroporphyrinogen III synthase deficiency.  
Only about 100-200 cases of the relatively rare disorder has been reported (Sassa and 
Kappas, 2000).  The porphyrin intermediates that accumulate in CEP lead to cutaneous 
photosensitivity, hemolytic anemia and fragile bones (Sassa and Kappas, 2000) . 
Porphyria cutanea tarda is the most common porphyria and can be inherited or 
acquired.  Congenital PCT results from decrease uroporphyrinogen III decarboxylase 
activity and occurs in 1-2 individuals per 100,000.  Acquired PCT represents 80-90% of 
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all cases and among these 80-90% is hepatic with normal erythrocytes.  Iron overload is 
central to the pathogenesis of both acquired and congenital versions.  The symptoms can 
be both neuoroviseral and photocutaneous and include other neuropsychiatric conditions, 
abdominal pain, and chronic blistering lesions of sunlight-exposed skin. 
Hereditary coproporphyria is an autosomal dominant acute hepatic porphyria 
disorder caused by a deficiency in coproporphyrinogen oxidase (Sassa and Kappas, 
2000).  Like AIP, factors that are associated the induction of heme biosynthesis can 
induce an attack in which neurological symptoms predominate, although symptoms are 
usually milder than those displayed with AIP (Dombeck, T. A. and Satonik, R. C., 2005).   
Mild photosensitivity also occurs in 30% of patients (Dombeck, T. A. and Satonik, R. C., 
2005).                
Variegate porphyria is autosomal dominant hepatic porphyria and due to a 
deficiency in protoporphyrinogen oxidase activity (Sassa and Kappas, 2000).  It is 
relatively uncommon except in South Africa where the disorder is prevalent in the white 
population (Sassa and Kappas, 2000). The clinical symptoms and precipitating factors 
also resemble those seen with AIP, with the addition of skin photosensitivity symptoms 
including blisters and superficial ulcers (Dombeck, T. A. and Satonik, R. C., 2005).   
Erythropoietic protoporphyria (EPP) is due to a partial deficiency of 
ferrochelatase activity and is an autosomal dominant disorder (Dombeck, T. A. and 
Satonik, R. C., 2005).  EPP is usually characterized by moderate skin photosensitivity 
and high concentrations of protoporphyrin IX in the erythrocytes, plasma, and bone 
marrow (Sassa and Kappas, 2000).   Sun exposure is the major contributing factor and 
symptoms usually occur within minutes of exposure.  The phototoxic reactions results in 
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burns causing intense pain, edema and vesicle formation with repeated insults often 
leading to “velvet knuckles,” attributed to thick hyperkeratonic skin with deep skin 
markings over the dorsum the hands (Dombeck, T. A. and Satonik, R. C., 2005).   
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General Roles Examples
Oxygen carrier Erythrocyte
hemoglobin (HbA, HbF, HBA 2 , HbA 1 )
Cardiac and skeletal muscle
myoglobin
Central and peripherial nervous system
neuroglobin
Brain 
cytoglobin
Electron transport Mitachondrial electron transport chain
Cytochorme a, a 3 , b, c
Electron carrier and Oxidation/Reduction Fatty Acid Metabolism (Fatty acids, Prostaglandins, Eicosanoids)
(cytochrome P450 mediated) 5-lipoxygenase
Metabolism of steroids and related compounds (i e. vitamin D, bile acids)
cholesterol 24-hydroxylase
vitamin D 3  25-hydroxylase
retinoic acid hydroxylase
7-a-hydroxylase
Drug and xenobiotic oxidation
cyrochrome p450 mono-oxogenase
Antioxidant Reduction of hydrogen perixide
catalase peroxidase
glutathione peroxidase
Tryptophan degredation tryptophan pyrrolase
Sensors (NO, CO,O2 and CO2) NO sensor
nitric oxide sensitive guanylate cyclase
         
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1.3: The role of some hemoproteins in biological processes 
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Table 1.4: Classification of porphyrias 
Classification    Deficient enzyme Manifestations Inheritance 
Erythropoietic    
Congenital 
erythropoietic porphyria  
Uroporphyrinogen III 
synthase  
Photosensitivity  Autosomal recessive 
Erythropoietic 
protoporphyria  
Ferrochelatase  Photosensitivity  Autosomal 
dominant/recessive 
X-linked dominant 
protoporphyria 
Erythroid 
aminolevulinate 
synthase  
Acute Photosensitivity        
(hepatic in 20% of patients) 
Autosomal 
dominant 
Hepatic    
ALA dehydratase 
deficiency porphyria 
ALA dehydratase  Chronic neurological 
symptoms  
Autosomal recessive 
Acute intermittent 
porphyria 
 Porphobilinogen 
deaminase  
Acute neurological 
symptoms often severe 
Autosomal 
dominant 
Hereditary 
coproporphyria 
Coproporphyrinogen 
oxidase  
Acute neurological 
symptoms    
Autosomal 
dominant 
Variegate porphyria  Protoporphyrinogen 
oxidase  
Acute photosensitivity and/or 
neurological symptoms 
Autosomal 
dominant 
Porphyria cutanea tarda  Uroporphyrinogen 
decarboxylase  
Acute photosensitivity and 
neurological symptoms 
Autosomal 
dominant and 
sporadic 
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The medical significance of other α-oxoamine synthases  
The α-oxoamine subfamily of the fold-type I, α-family of PLP-dependent 
enzymes has 4 members, two of which are involved in the synthesis of protein prosthetic 
groups which are essential for optimal health, biotin and heme.  The two other members 
of this small family, 2-amino-3-ketobutyrate ligase (KBL) and serine 
palmitoyltransferase (SPT), are involved in threonine degradation and the synthesis of 
sphingosine the precursor for spingolipids.  While no disease has been associated with 
KBL, missense mutations in SPT have been associated with hereditary sensory 
neuropathy I (Bejaoui, Uchida et al., 2002).   
SPT catalyzes the decarboxylative condensation reaction of L-serine with 
palmitoyl-CoA to generate 3-ketodihydrosphingosine which is the first and rate-limiting 
step in sphingosine biosynthesis.  SPT is expressed in many species ranging from bacteria 
to man.  The bacterial enzyme, like most fold-type 1 α-family members, is a water 
soluble homodimer.  However, in mammals SPT is a heterodimer between the SPTLC1 
subunit and either SPTLC2 or SPTLC3 and the heterodimer is anchored to the 
endoplasmic reticulum.  Homozygous SPTLC1 and SPTLC2 mice are embryonic lethal 
(Hojjati, Li et al., 2005).  Myriocin, a potent selective SPT inhibitor (Chen, Lane et al., 
1999), is an immunosuppressant between 10-100 fold more potent than cyclosporin A 
(Fujita, Inoue et al., 1994), indicating that sphingolipids have a key role or roles in 
immunity.    
 Sphingolipids are a class of lipids derived from the aliphatic amino alcohol 
sphingosine and include glycosphingolipids and sphingomyelins.  These compounds are 
known to play important roles in signal transduction and cell recognition (Merrill, 2002).  
 42
De novo synthesis and turnover of sphingolipids are involved in cell regulation including 
sphingolipid mediated cell death (Merrill, 2002).  Spingolipids are exploited during 
infection by some bacteria and viruses and have key roles in the toxic action of some 
exotoxins and endotoxins from a number of microorganisms (Heung, Luberto et al., 
2006).  Disruption of sphingolipid turnover results in sphingolipidoses, a group of 
lysosomal storage diseases in which the accummulation of spingolipids in the central 
nervous system results in neural degeneration (Jeyakumar, Butters et al., 2002).  The 
roles of this group of lipids are varied and scientists still have much work to do to 
understand all the mechanisms by which sphingolipds are used to mediate cellular 
processes.   
 
Research Aims  
 PLP is the active form of vitamin B6 and is an essential cofactor for enzymes involved 
a wide array of reactions that are essential for life and the maintenance of health.  The 
small fold-type I subfamily of α-oxoamine synthases, composed of just 4 enzymes, 
exemplifies this in that they play roles in the biosynthesis of biotin, heme and 
sphingolipids, biomolecules that are involved in a wide array of cellular processes 
essential for the maintenance of health.  The aim of the research described in the 
following chapters is to better understand the relationships among this group of enzymes.  
Understanding the similarities and differences between these enzymes will provide 
insight into features that provide them with a shared catalytic mechanism, as well as at 
mechanisms by which these enzymes enforce selectivity.   
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The studies in the following chapter examine the phylogenic relationships and the 
remarkable structural plasticity of the a-oxoamine synthases, as well as the significance 
of a conserved active site histidine.   Chapter 2 explains how sequence and phylogenetic 
analysis of the α-oxoamine synthases were used to identify amino acids that may be 
significant in regulating the distinctive substrates specificity of each enzyme.  Chapter 3 
describes how single chain ALAS dimers and chimeras between ALAS and AONS 
generated by engineering a single polypeptide chain linking two ALAS polypeptides or 
the ALAS and AONS polypeptides are used to explore the remarkable structural 
plasticity exhibited by this group of enzymes.  Finally, in chapter 4 the role of an active 
site histidine that is conserved among the α-oxoamine synthases is explored with the 
characterization of an ALAS variant in which the histidine is replaced with an alanine. 
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Chapter Two 
Sequence and phylogenetic analysis of PLP-dependent α-oxoamine synthases and 
their role in identifying residues regulating enzyme specificity  
Introduction 
Pyridoxal 5’-phosphate (PLP) is a versatile cofactor, which exhibits a non-
enzymatic ability to catalyze a variety of reactions involving amino acids, including 
transaminations, racemizations, and α, β eliminations (Snell and Guirard, 1943; Metzler 
and Snell, 1952; Olivard, Metzler et al., 1952; Longenecker, Ikawa et al., 1957).  PLP-
dependent enzymes exploit the diverse catalytic repertoire of the PLP-cofactor, as is 
evident from the fact that this group of enzymes belong to five of six total Enzyme 
Commission enzyme reaction classes (Mehta and Christen, 2000).  PLP-catalyzed 
reactions utilize the electron withdrawing property of the  positively charged heterocyclic 
nitrogen acting as an “electron sink” which allows for the stabilization of a variety of 
carbanion intermediates and subsequent labilization of an amino acid α-carbon bond 
(Christen and Metzler, 1985).   
Scrutiny of evolutionary pedigrees in a number of enzyme families has provided 
significant insight helping to deduce how functional specialization developed.  
Examination of the evolutionary relationships between the α-family of PLP-dependent 
enzymes revealed that specialization of the catalytic apparatus for reaction specificity 
generally requires more extensive adaptations than specialization for a specific substrate 
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(Alexander, Sandmeier et al., 1994; Mehta and Christen, 2000; Schneider, Kack et al., 
2000).   This clear pattern found in the α-family temporal sequence leading to functional 
specialization prompted the proposal that primitive regio-specific enzymes first diverged 
into reaction specific protoenzymes, which later acquired substrate specificity and 
ultimately, phylogenetic diversity (Mehta and Christen, 2000; Christen and Mehta, 2001).   
PLP-dependent enzymes are represented by four evolutionary distinct structural 
groups, with the α-family being the largest and most functionally diverse (Jansonius, 
1998; Schneider, Kack et al., 2000; Christen and Mehta, 2001; Eliot and Kirsch, 2004).  
The CoA-dependent aclytransferases, or α-oxoamine synthases, constitute a small but 
widespread reaction specific subfamily within the α-family of PLP-dependent enzymes.   
The α-oxoamine synthase subfamily is comprised of 8-amino-7-oxononanoate synthase 
(AONS), 5-aminolevulinate synthase (ALAS), serine palmitoyltransferase (SPT), and 2-
amino-3-ketobutyrate-CoA ligase (KBL) (Alexeev, Alexeeva et al., 1998; Schneider, 
Kack et al., 2000; Schmidt, Sivaraman et al., 2001; Astner, Schulze et al., 2005; Yard, 
Carter et al., 2007), which catalyze Claisen condensations between amino acids and 
carboxylic acid CoA thioesters (Ferreira, 1999; Bhor, Dev et al., 2006).  At the amino 
acid level, these enzymes share about 12% identity, with the identity between any pair 
around 30% (Alexeev, Alexeeva et al., 1998).  Sequence alignments among members of 
the α-oxoamine synthase subfamily have been instrumental in the identification of 
conserved amino acids, while crystallographic and kinetic studies have increased our 
understanding of the structural and functional significance of these residues.  However, 
the low sequence identities have made it challenging to distinguish residues that 
differentiate substrate specificity among this group of enzymes.   
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The recent surge of sequence database submissions resulting from advances in 
sequencing speed and reliability has generated a reservoir of data that can be used to 
provide a better understanding of the phylogenetic relationships between the members of 
the α-oxoamine synthases.  A more thorough understanding of the evolutionary 
progression of α-oxoamine synthases could add insight into the mechanism by which 
functional specialization developed and provide valuable knowledge for re-engineering 
substrate specificity.   
Because of the diverse catalytic potential of the PLP-cofactor, selectivity of 
reaction type and substrate specificity also requires PLP-dependent enzymes to 
significantly diminish or abolish superfluous side reactions and utilization of undesired 
substrates.  Hence, PLP-dependent enzymes commonly demonstrate activity to more than 
one substrate or reaction (Percudani and Peracchi, 2003).  While enzyme promiscuity 
may seem incompatible with the evolutionary specialization of enzymes, it is often 
regarded as the origin for the divergent evolution of new specificities and functions (Hult 
and Berglund, 2007).  Engineering substrate promiscuity and/or new substrate specificity 
in the α-oxoamine synthase family would facilitate a better understanding of the 
mechanisms by which these enzymes enforce selectivity.   
The identification of key residues that distinguish between substrates is a 
challenge for the protein engineer that also may be overcome using directed evolution. 
Directed evolution, also known as evolutionary engineering, has emerged as a practical 
approach because it does not rely on extensive structural information or an understanding 
of the protein structure, function, or catalytic mechanism (Moore, Jin et al., 1997; Zhao 
and Arnold, 1997).  Directed evolution involves repeated cycles of random mutagenesis 
 53
(and/or gene recombination), functional expression, and finally, selection of variants 
acquiring new features (or exhibiting improvements in the targeted property) (Kuchner 
and Arnold, 1997).  The number of amino acid changes between the parent and the 
laboratory evolved progeny is significantly smaller than that observed in naturally 
evolved enzymes.  Thus, sequential changes in the in vitro evolved variants may provide 
insight into residues or positions regulating substrate preference. Incorporating the 
phylogenetic relationships of both natural and laboratory evolved enzymes with structural 
data may help identify amino acids key for enzyme selectivity. 
AONS and ALAS catalyze decarboxylative condensations leading to the 
formation of a 2-aminoketone product (Scheme 2.1) (Alexeev, Alexeeva et al., 1998). 
The sequence, kinetic, and structural similarities between these two enzymes have led to 
the proposal of a shared kinetic mechanism (Alexeev, Alexeeva et al., 1998; Webster, 
Campopiano et al., 1998).  The relatively short evolutionary space required for 
developing substrate specificity in the α-family fold–type I PLP-dependent enzymes 
suggests that alteration of substrate specificity is a practical target for directed evolution.  
While directed evolution has been used successfully to enhance specificity for minor 
substrates and relieve product inhibition in other members of the α-family of PLP-
dependent enzymes (Yano, Oue et al., 1998; Chow, McElroy et al., 2004; Rothman, 
Voorhies et al., 2004), there are no records of the use of either approach to redesign α-
oxoamine synthases.  Reengineering AONS to utilize ALAS substrates would enhance 
our knowledge of the mechanism by which these enzymes enforce substrate selectivity by 
identifying residues with key roles in determining substrate specificity.  
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An enhanced understanding of the phylogenetic relationships among the α-
oxoamine synthases is desirable to help identify amino acids that may be relevant for 
substrate specificity in evolved variants.  Therefore, an examination of the relationships 
among α-oxoamine synthase sequences representing a broad taxonomic and phylogenetic 
spectrum was performed to help identify residues that may regulate substrate specificity 
in ALAS, AONS and other α-oxoamine synthases.  The reengineering of ALAS to 
acquire AONS function using directed evolution requires an efficient selection system to 
identify enzymes exhibiting AONS activity.  Thus, one goal of this study is to develop a 
selection system to identify AONS function in which the growth of biotin-auxotrophic 
Escherichia coli may be rescued by evolved ALAS variants acquiring activity for AONS 
substrates.    
 
Experimental Details 
Sequence search, alignments and phylogenetic analysis 
A series of alignments using AONS, ALAS, KBL, and/or SPT amino acid 
sequences were performed with MAFFT using mafftE, which incorporates a Ruby script 
to align input sequences with up to 100 additional homologues from NCBI-BLAST or 
SwissProt to improve accuracy in the alignment (Katoh, Kuma et al., 2005).  Sequences 
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from the additional homologues aligned using mafftE were selected and added to input 
sequence sets to obtain a broad phylogenetic distribution of the α-oxoamine synthase 
family members.  To obtain the final sequence set, additional sequences were added to 
reflect the taxonomic distributions of AONS, ALAS, KBL, and SPT and the final 
alignments were performed with ClustalW using blssm (blocks amino acid substitution 
matrices), open gap penalty 10, and gap extension penalty 0.05 (Thompson, Higgins et 
al., 1994).  The ClustalW alignment scores were generated using the 
SLOW/ACCURATE alignment parameters.  The number of amino acid substitutions per 
site determined from averaging overall sequence pairs is based on the pairwise 
sequences.  Analyses were conducted using the Dayhoff matrix based method in MEGA4 
(Schwartz and Dayhoff, 1979; Tamura, Dudley et al., 2007). 
The evolutionary history was inferred using the neighbor-joining (NJ), the 
maximum parsimony (MP), and the minimum evolution (ME) methods (Eck and 
Dayhoff, 1966; Saitou and Nei, 1987; Rzhetsky and Nei, 1992).  Phylogenetic analyses 
were conducted in MEGA4 (Tamura, Dudley et al., 2007).  All positions containing gaps 
and missing data were eliminated from the dataset.  There were a total of 257 positions in 
the final dataset.  
The sum of the length branch in the NJ tree is =16.425 and.  The sum of the 
branch length in the ME tree is 16.330 and the. The ME tree was searched using the 
close-neighbor-interchange algorithm at a search level of 3 (Tamura, Dudley et al., 2007). 
The evolutionary distances for the NJ and ME trees were computed using the Poisson 
correction method. The MP tree was obtained using the close-neighbor-interchange 
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algorithm with search level 3 in which the initial trees were obtained with the random 
addition of sequences (100 replicates) (Felsenstein, 1985 ; Nei and Kumar, 2000).  
Construction of ALAS random library  
Random mutagenesis of mature ALAS cDNAs by error-prone PCR was 
performed under conditions similar to those previously described (Shafikhani, Siegel et 
al., 1997; Zhao, Giver et al., 1998).  In error-prone PCR, the MgCl2 concentration is 
increased, MnCl2 is added and the dNTP concentration is increased to decrease the 
fidelity of the Taq polymerase during DNA synthesis (Cadwell and Joyce, 1992).   The 
pGF23 plasmid containing the ALAS cDNA sequence flanked by a 5’ SalI and a 3’ 
BamHI restrictions site was used as the template (Ferreira and Dailey, 1993).  The 5’ 
primer (TTCG TCT TCA AGT CTT CTC ATG TTT G) was designed to anneal upstream 
of the SalI restriction site and the 3’ primer (TAC AGA TGT ACA AAA GTT CAG 
ATA CTG GCG ATC ATC CGC CAC) was designed to anneal with the sequence of the 
vector backbone, downstream of BamHI site.  The PCR was performed in 100 μl 
containing 50 mM KCl, 10 mM Tris (pH 8.3), 7 mM MgCl2, 0.15 mM MnCl2, 0.2 mM 
dGTP and dATP, 1 mM dCTP and dTTP, 0.1 μM primer and 5 to 10 ng template and 5 
units Taq polymerase (Roche, Indianapolis, IN)  using a MJ Research MiniCycler.   The 
times and temperatures for annealing, extension, and denaturation were 1 min at 94oC, 1 
minute at 50oC and 1 minute at 72oC, respectively.  This sequence was repeated for 30 
cycles. Subsequently, the PCR product was purified using QIAquick spin columns 
(QIAGEN, Valencia, CA).   
The “megaprimer PCR of whole plasmid”, MEGAWHOP, cloning method was 
used to subclone the mutant library using the error-prone PCR products as megaprimers 
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(Miyazaki and Takenouchi, 2002).  PCR was performed in 100 μl reactions containing 50 
mM KCl, 10 mM Tris (pH 8.3), 1 mM MgCl2 and 2.5 units of Taq polymerase, 0.2 mM 
each dNTP, 0.5 to 1.0 μg megaprimers and 50-100 ng of pGF23 using an MJ Research 
MiniCycler. The times and temperatures for annealing, extension, and denaturation were 
30 seconds at 94oC, 1 minute at 50oC and 7 minutes at 72oC, respectively.  This sequence 
was repeated for 30 cycles. After the PCR, 10 units of DpnI were added directly to the 
reaction mixture and incubated at 37oC for 30 minutes.   The DpnI digestion was 
terminated by incubating the reaction at 80oC for 10 minutes. The amplified and DpnI-
treated DNA was purified using QiaQuick spin columns (QIAGEN, Valencia, CA).  
Competent Escherichia coli DH5α cells were transformed with the Dpn I-treated 
MEGAWHOP library and grown on Luria-Bertani medium (Bertani, 1951) containing 50 
mg/ml ampicillin for 16 hours at 37oC.  After incubation, the cells were scraped from the 
plate and resuspended in sterile buffer P1 (QIAGEN, Valencia, CA).  Plasmid DNA from 
the library of ALAS variants was purified using Q-10 mini columns according to the 
manufacturers’ protocol (QIAGEN, Valencia, CA).   
 
Selection and bioassay for AONS activity 
E. coli strain R872 (Del Campillo-Campbell, Kayajanian et al., 1967), which can 
only grow on a medium containing AON, biotin or when harboring a plasmid expressing 
functional AONS, were used to screen for AONS function. Competent R872 E. coli cells 
were transformed with the variant ALAS plasmid library and plated on M-9 minimal 
medium supplemented with 0.1 % vitamin-free casamino acids and containing 1.5% agar, 
0.1 mM CaCl2, 50 mg/ml ampicillin and 5 to 10 pg/ml biotin. The M9 medium contains 
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43 mM Na2HPO4-7H2O, 22 mM KH2PO4, 8.5 mM NaCl, and 18 mM NH4Cl, 2 mM 
MgSO4, and 0.4 % glucose (Smith and Levine, 1964).  The plates were incubated at 37oC 
for 20 hours, followed by 16 hours at room temperature.   
The plates were examined for apparent colonies.  R872 E. coli colonies 
expressing ALAS variants were selected and used to inoculate 0.3 ml of LB medium and 
then grown at 37oC while shaking at 115 rpm.  Subsequently, 5 ml of M9 minimal 
medium supplemented with 0.1 % vitamin-free casamino acids, 0.1 mM CaCl2, 50 mg/ml 
ampicillin and 100 pg/ml biotin was inoculated with 20 μl of the ALAS library 
expressing-R872 culture. The bacterial cells were incubated for 20 hours at 37o C while 
shaking at 200 rpm.  The cell culture was centrifuged at 4000 x g for 15 minutes and the 
supernatant was discarded.   The cells were washed twice with M-9 minimal medium.  To 
wash the cells, 1.5 ml of M-9 minimal medium was added, the cells were centrifuged at 
4000 x g for 15 minutes and the supernatant removed.  The washed pellet was 
resuspended in 150 μl of M-9 minimal medium and 20 μl of the bacterial cell suspension 
was used to inoculate 1.5 ml of M-9 minimal medium supplemented with 0.1 % vitamin-
free casamino acid and various biotin concentrations in a 24-well plate.  Plates were 
incubated for 24 hours at 37oC while shaking at 115 rpm and the OD at 600 nm was read 
at various time intervals between 20 and 50 hours. 
 
Results 
Sequence selection and alignment  
A total of 44 amino acid sequences were selected to equitably represent the 
phylogenetic and taxonomic distribution of each member of the α-oxoamine synthase 
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subfamily of PLP-dependent enzymes.  Hence, 13 AONS, 10 ALAS, 11 KBL, and 10 
SPT sequences were selected.  The taxon and species of these sequences are given in 
Table 2.1.  Both AONS and SPT sequences were found in four of the 5 kingdoms, with 
AONS being the most broadly distributed member of the α-oxoamine synthase family.  
While all known AONSs, KBLs, ALASs and prokaryotic SPTs are homodimers, 
eukaryotic SPTs function as heterodimers composed of dissimilar subunits, LCB1 and 
LCB2, and possess a single PLP-binding moiety, which is attributed to LCB2 (Han, 
Gable et al., 2006).  In this study, SPT1 and SPT2 refer to LCB1 and LCB2 sequences, 
respectively, and SPT refers to the prokaryotic sequences.  Mammals and other 
vertebrates express genetically distinct housekeeping and erythroid ALAS genes for two 
distinct isoforms, ALAS1 and ALAS2, respectively (Bishop, 1990; Ferreira and Gong, 
1995).   
After the removal of the non-homologous terminal residues, the ClustalW aligned 
sequences ranged from 361 to 409 amino acids.  A selected subset of ALAS, KBL and 
AONS aligned sequences is shown in Figure 2.1 and pairwise alignment scores of all 
sequences, given in percent identity, are given in Table 2.2.  The average evolutionary 
divergence, deduced by determining the number of amino acid substitutions per site, was 
1.5 among all 44 sequences and the AONS sequence set, 0.7 for both the ALAS sequence 
set and the KBL sequence set, and 0.8 for the SPT2 sequence set.  
The sequence alignment of ALAS, AONS, KBL, SPT2 and SPT indicated that 
nine positions are occupied with completely conserved residues, Gly88, H142, Ser189, 
Asp214, H217, Lys248, Gly254, Arg356, and Pro364 (Figure 2.1).  As inferred from the 
ALAS and AONS crystal structures (Alexeev, Alexeeva et al., 1998; Webster, Alexeev et 
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al., 2000; Astner, Schulze et al., 2005), six of the nine conserved residues, Ser189, 
Asp214, Lys248 and Gly254, correspond to residues interacting with the PLP cofactor.  
Gly88 and Pro364 appear to bind succinyl-CoA, while Arg356 appears to bind the amino 
acid carboxylate group, as deduced from the crystal structures of R. capsulatus ALAS 
bound to either glycine or succinyl-CoA substrates (Astner, Schulze et al., 2005).  
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 TABLE 2.1 
 
 
Aligned Sequences   
Taxon Species (Abbreviation) Protein Accession No. 
Monera Actinobacteria  Mycobacterium tuberculosis (MyTu) AONS  NP_336073 
 Actinobacteria  Streptomyces avermitilis (StAv) KBL  NP_822803.1 
 Alpha  Rhizobium etli (RhEt) ALAS  YP_473106.1 
 Alpha  Rhizobium etli  KBL   YP_470446 
 Alpha  Rickettsia bellii (RiBe) ALAS  YP_53807 
 Alpha  Rhodobacter capsulatus (RhCa) ALAS   P18079 
 Alpha  Sphingomonas paucumobilis (SpPa) SPT  2JGT_B 
 Alpha  Sphingomonas sp SKA38 (SPSk) AONS  ZP_01304166 
 Alpha  Sphingomonas sp SKA38  SPT   ZP_01303842 
 Alpha  Sphingomonas sp SKA38  ALAS ZP_01304166 
 Aquifex  Aquifex aeolicus (AqAe) AONS  NP_213435 
 Bacteroidetes  Gramella forsetii (GrFo) KBL  YP_863382.1 
 Delta/Epsilon  Helicopacter pylori J99 (HePy) AONS   NP_223263 
 Firmicutes  Bacillus cereus (BaCe) AONS   NP_833835 
 Firmicutes  Bacillus cereus  KBL  NP_830437 
 Firmicutes  Bacillus subtilis (BaSu) AONS    NP_390900 
 Firmicutes  Bacillus subtilis  KBL  NP_389582 
 Firmicutes  Staphphylococcus aureus (StAu) AONS   NP_372948 
 Firmicutes  Staphphylococcus aureus  KBL  YP_040004 1 
 Gamma  Escherichia coli (EsCo) AONS   1DJ9A 
 Gamma  Escherichia coli  KBL  ZP_00736622 
 Gamma  Haemophilus infllenzae (HaIn) AONS   NP_439702 
 Euryarchaeota  Thermococcus kodakarensis (ThKo) AONS   YP_184630.1 
Animalia Arthopoda  Drosphilia melanogaster (DeMe) ALAS  AAL89936 
 Arthopoda  Drosphilia melanogaster KBL   NP_648509.1 
 Chordata  Mus musculus (MuMu) SPT1  NP_033295 
 Chordata  Mus musculus  SPT2   NP_035609 
 Chordata  Mus musculus  ALAS1   NP_65584 
 Chordata  Mus musculus  ALAS2  NP_033783 
 Chordata  Mus musculus  KBL  O88986 
Fungi Ascomycota  Aspergillus fumigatus (AsFu) SPT1  XP_751117 1 
 Ascomycota  Aspergillus fumigatus  SPT2   XP_752555.1 
 Ascomycota  Aspergillus fumigatus  ALAS  XP_754006.1 
 Ascomycota  Saccharomyces cerevisiae (SaCe) SPT1  NP_014025 
 Ascomycota  Saccharomyces cerevisiae  SPT2  NP_010347 
 Ascomycota  Saccharomyces cerevisiae  ALAS  NP010518 
 Ascomycota  Aspergillus niger (AsNi) AONS  Q58FL7 
Plantae Magnoliophyta  Arabidopsis thalia (ArTh) AONS    NP 974731 
 Magnoliophyta  Arabidopsis thalia SPT1   NP_568005 
 Magnoliophyta  Arabidopsis thalia SPT2  NP_197756 
Protist Alveolates  Plasmodium falciparum (PiFa) ALAS    XP_001350846 
 Alveolates  Tetrahymena  thermophilia (TeTh) AONS  Q224308 
  Euglenozoa  Trypanosoma brucei (TrBr) KBL  XP_847436.1 
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FIGURE 2.1  
Alignment of representative sequences of ALAS and KBL with closest   AONS 
sequences. The abbreviations are explained in Table 2.1.  Amino acid shading in black 
and grey represent residues with homology greater than 50% identity or similarity, 
respectively. Residues in red or blue indicate positions that are conserved (or non- 
conserved) in ALAS or KBL sequences, respectively.  (Numbering used in figure one is 
based on R. capsulatus ALAS crystal structure (Astner, Schulze et al., 2005).) (Con’t on 
next page.) 
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Phylogenetic analysis of the α-oxoamine synthase family of PLP-dependent enzymes 
The neighbor-joining (NJ), maximum parsimony (MP) and minimum evolution 
(ME) methods were used to infer the evolutionary history of the α-oxoamine synthase 
family of PLP-dependent enzymes (Eck and Dayhoff, 1966; Saitou and Nei, 1987; 
Rzhetsky and Nei, 1992; Tamura, Dudley et al., 2007).  Analyses were conducted using 
the MEGA4 software package (Figure 2.2) (Tamura, Dudley et al., 2007). The three 
methods differ in the way the trees are constructed.  Both the NJ and ME are distance 
matrix methods utilizing pairwise distances for phylogenetic reconstruction. The ME 
criterion incorporates a tree-search protocol and accepts the tree with the shortest sum of 
branch lengths, and thus minimizes the total amount of evolution assumed (Rzhetsky and 
Nei, 1992).  The NJ method analyzes only a small number of trees and employs a “greedy 
search” based on locally optimized choices (Saitou and Nei, 1987). In the MP method, 
the preferred phylogenetic tree is the tree that requires the least number of evolutionary 
changes.  The MP criterion incorporates a tree search protocol in which trees are scored 
based on how many evolutionary transitions are required to explain the distribution of 
each character(Eck and Dayhoff, 1966).  The bootstrap method of Felsenstein was used 
to evaluate the level of confidence associated with the phylogenetic trees; bootstrap 
values between 70% and 100% indicate significant support for a branch (Felsenstein, 
1985 ; Soltis and Soltis, 2003).   
The overall topologies of the three trees have significant congruencies.  Each tree 
contained two main branches, one formed by SPT1s and SPT2s and the second formed 
by AONSs, ALASs, SPTs and KBLs (Figure 2.2).   In all three trees, ALASs were 
isolated within a single cluster and all KBLs appeared together in a single cluster, which 
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also included B. cereus and T. kodakarensis AONSs. The distribution of SPTs and 
AONSs deviated between the three trees. The bootstrap probability values were generally 
>50% among the branches containing ALASs, KBLs, SPT1s and SPT2s, whereas the 
branches containing AONSs generally exhibited <50% scores.  This suggests that larger 
evolutionary distances separate representative AONS sequences, relative to the 
evolutionary distance between either ALAS or KBL sequences.   
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Strategy for selection of evolved ALAS variants with AONS activity   
 The isolation of ALAS variants evolved to acquire AONS activity relied on the 
development of a biological selection system.  The bioF mutant E. coli R872 cells have 
no AONS function and thus are biotin-auxotrophic.  When grown on a minimal plate, 
R872 cells cannot grow without biotin supplementation (>100 pg/ml).  Thus the 
biological system involved the reversion of the biotin auxotrophy by transformation of 
the E. coli R872 cells with ALAS variants exhibiting AONS activity.  It should be noted 
that when transformed with a plasmid expressing E. coli AONS, the growth of R872 cells 
in a medium without biotin was rescued, while transformation of R872 cells with an 
ALAS expression plasmid did not rescue their growth in a medium without biotin (data 
not shown). 
To increase the probability of selecting ALAS variants which would confer R872 
cells the ability to synthesize biotin, the initial round of screening was performed in a 
medium containing 5 pg/ml biotin, while biotin was omitted in the subsequent rounds of 
screening to the medium.  Thus, a simple and efficient bioassay was developed to further 
confirm and compare AONS function in ALAS variants selected in the initial screen.  
The bioassay also took advantage of the bioF mutant E. coli R872 strain. The assay was 
based on previous studies by Hwang et. al. , who described that the growth of an E. coli 
bioF deletion strain in minimal medium was dependent on the addition of biotin, in the  0 
- 10 ng/ml concentration range (Hwang, Su et al., 1999).  The bioassay was modified to 
follow growth of R872 cells in 24-well plates (2. 3).   Using the modified assay, AONS 
function in multiple ALAS variants can be efficiently screened by following the growth 
of R872 cells. 
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FIGURE 2.3  
Growth of R872 cells in minimal media. Growth of bacterial R872 cells as function of 
biotin concentration.  Cell growth was monitoring by determining the absorbance at 600 
nm (OD600 nm) following 24 hours of incubation in minimal medium or minimal medium 
supplemented with biotin. (Inset: Linear plot following R872 cell growth with increasing 
concentrations of biotin.) 
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Directed Evolution of ALAS and screening for AONS function 
 Error-prone PCR was used to create an ALAS cDNA library with a low 
mutation rate and thus reduce the number of simultaneous, hindering amino acid 
mutations and simplify the analysis of ALAS variants exhibiting AONS function (Zhao, 
Giver et al., 1998).  The library was initially transformed into DH5α E. coli, because high 
efficiency transformations of the ALAS libraries could not be attained with E. coli R872.  
Plasmids isolated from approximately 364,000 DH5α transformants were subsequently 
transformed into R872 cells.  Approximately 1.5 x106 R872 transformants were plated on 
minimal plates supplemented with 5 pg/ml biotin to screen for variants exhibiting AONS 
function.  A total of 21 variants were selected for screening using the bioassay.  
Of the 21 selected variants screened using the AONS bioassay, one variant (B2) 
exhibited significantly higher cell density after 24 hours in medium supplemented with 5 
and 10 pg/ml of biotin and two (E5 and E6) exhibited increased cell density at a single 
biotin concentration when compared to R872 cells transformed with an “empty” vector 
(i.e., containing neither the AONS- nor the ALAS-encoding DNA) (Figure 2.4). To 
ensure that the increased growth resulted from the transformation with evolved ALAS 
variants and not reversion of the R872 strain cells, plasmids expressing the ALAS 
variants were obtained from the cells exhibiting increased growth rates and transformed 
into new batches of freshly made competent R872 cells. (Plasmid encoding the E6 variant 
could not be obtained.)  
 
The bioassay was repeated using both the progeny of the screened R872 cells 
harboring plasmids encoding ALAS variants and R872 cells freshly transformed with the 
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isolated plasmids.  When cell growth was monitored between 20 and 50 hours, growth 
observed with the freshly transformed cells was comparable to that of bacterial cells 
transformed with the “empty” vector controls in medium supplemented with 1, 5 or 10 
pg/ml of biotin, while the progeny of cells isolated during screening continued to exhibit 
growth over negative controls at all biotin concentrations (Figure 2.5).  This indicated 
that cells were not rescued by the expression of the ALAS variants selected upon 
screening for AONS function.   
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FIGURE 2.4 
Growth of R872 cells expressing ALAS variants.  Comparison of cell growth as 
measured by OD at 600 nm for R872 cells expression ALAS variants and the “empty” 
vector (Cass3) at 24 hours at 5 (white) and 10 (grey) pg/ml of biotin.  
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FIGURE 2.5  
Comparison of cell growth of freshly transformed R872 cells.  R872 cells expressing 
selected ALAS variants in minimal medium with (A) 10, (B) 5 or (C) 1 pg/ml of biotin.  
Cell growth was monitored by measuring the OD600 nm of the cell cultures.  Red lines 
indicate growth for R872 cells expressing AONS, blue lines indicate growth for cells 
transformed with the “empty” vector, solid black lines indicate freshly transformed cells 
and dashed black indicates progeny from initial transformation of selected variants.  
Symbols indicates ALAS variants expressed in R872 cells, ?=B2 variant, ?=E5 variant 
and ?=E3 variant. 
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The bioassay was repeated using both the progeny of the screened R872 cells 
harboring plasmids encoding ALAS variants and R872 cells freshly transformed with the 
isolated plasmids.  When cell growth was monitored between 20 and 50 hours, growth 
observed with the freshly transformed cells was comparable to that of bacterial cells 
transformed with the “empty” vector controls in medium supplemented with 1, 5, or 10 
pg/ml of biotin, while the progeny of cells isolated during screening continued to exhibit 
growth over negative controls at all biotin concentrations (Figure 2.5).  This indicated 
that cells were not rescued by the expression of the ALAS variants selected upon 
screening for AONS function.   
Identification of residues that potentially regulate α-oxoamine synthase specificity 
 Given that no evolved ALAS variants were generated to identify residues with an 
ability to influence substrate specificity in the α-oxoamine synthase family, we 
proceeded to scrutinize the primary structure and search for residues potentially involved 
in the regulation of specificity in ALAS and KBL.  Residues were identified that may 
have a role in controlling specificity by taking advantage of an improved understanding 
of the evolutionary relationships among this group of enzymes.   
The evolutionary space between AONS and ALAS or KBL sequences varied 
widely, 10-36% or 17-53% identity between AONS and ALAS or AONS and KBL 
sequences, respectively.  Because of this large variation, we reasoned that AONS 
sequences closest to those of ALAS or KBL were likely to be most similar to a shared 
ancestor sequence.  Therefore, the AONS sequences closest to ALAS and KBL were 
used to help us suggest residue variations that may have influenced changes in enzyme 
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specificity.  The phylogenetic trees and % identity scores were used to select AONS 
sequences most similar to ALAS and KBL sequences.  AqAe, BaCe, BaSu, and ThKo 
AONS sequences were most similar to both ALAS and KBL sequence sets.  (Table 2.2). 
(Species abbreviations defined in Table 2.1.) 
 In order to identify residues that may play a role in determining enzyme specificity, 
the ClustalW-aligned ALAS and KBL sequences were compared to the 4 selected AONS 
sequences (Figure 2.1).  The 37 residues identified and their structural position relative to 
the ALAS crystal structure are summarized in Table 2.2.  Figures 2.6 and 2.7 illustrate 
the residues positioned near the SCoA- and glycine-binding pockets, with the majority of 
the identified residues being located at or adjacent to the active site.  
 
Discussion 
Phylogenetic Analysis 
The evolutionary distances among all 44 α-oxoamine synthase sequences and the 
13 AONS sequences, as determined by the number of amino acid substitutions, is 
equivalent and twice that observed among ALAS, KBL or SPT2 sequences.  Moreover, 
the clustering of ALASs, KBLs and SPTs in single branches and the bootstrap probability 
scores below 50% contrast with the relatively broad distribution of AONSs in all three 
evolutionary trees.  Together these data are consistent with the proposition of the 
appearance of AONS function early in the evolutionary time line of the α-oxoamine 
synthases and the subsequent development of ALAS, KBL, SPT and SPT1/2 function. 
The α-family of PLP-dependent enzymes consists of enzymes essential for amino 
acid metabolism as well as synthesis of the vital protein cofactors heme and biotin (Ploux 
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and Marquet, 1992; Ferreira and Gong, 1995).  AONS and 7,8 diaminopelargonic acid 
aminotransferase catalyze the first two common reactions in the biosynthesis of biotin 
(Schneider, G. and Lindqvist, Y. , 2001) and are two of only six members of the α-family 
of PLP dependent enzymes for which sequences have been found in all biological 
kingdoms (Mehta and Christen, 1998), suggesting that the biotin biosynthesis pathway 
was likely developed in the universal ancestor cell.   Considering that biotin is essential 
for all organisms and there are no naturally occurring alternative pathways known for 
biotin biosynthesis, the assertion of an early evolutionary appearance of AONS is 
plausible.   
Strategy for selection of evolved ALAS variants 
 The selection system developed is based on the auxotrophy of the bioF mutant E. coli 
R872 strain, which does not exhibit AONS function.  The R872 strain of E. coli was 
obtained for this project on the premise that BioF gene, encoding AONS, was knocked 
out.  Late into the first round screening for AONS function, it was discovered that this 
auxotrophic strain was a mutant and not a knockout strain (Del Campillo-Campbell, 
Kayajanian et al., 1967).   
Utilizing a mutant BioF strain instead of a BioF knockout strain, could permit 
BioF reversions that restore AONS function and eliminate biotin dependency.  Therefore, 
ALAS variants-encoding plasmids, isolated during the initial screening for AONS 
function, were retransformed into new batches of R872 cells in order to verify whether 
the growth observed during selection was not attributed to the reversion of the BioF 
mutant.  Unfortunately, the freshly transformed cells could not grow in a medium 
supplemented with biotin concentrations used during selection.  This almost certainly 
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indicates that the growth observed during the selection of the ALAS variants resulted 
from the reversion of the R872 BioF gene and is not attributed to the ALAS variants.  
This conclusion is further supported by the DNA sequencing data of the expression 
plasmid for the variant B2, which indicated the absence of amino acid substitutions in the 
B2 variant-encoding cDNA, albeit the apparent ability of R872 cells harboring the B2 
variant to grow in minimal medium or minimal medium supplement with a limited biotin 
concentration (Figure 2.4).   
For directed evolution of AONS function to be feasible, an efficient selection is 
required.  While a biotin auxotrouph encoding a mutant BioF gene can effectively select 
for AONS function, the efficiency is compromised with the screening of large libraries 
when reversions result in the selection of false positives.  The flawed selection strategy 
prevented the continuation of this project.   
Identification of residues that potentially regulate specificity in α-oxoamine synthase  
While no ALAS variants with altered substrate specificity were identified using 
directed evolution, the enhanced understanding of the evolutionary relationships among 
the α-oxoamine synthases allowed for the identification of residues which potentially 
influence specificity.  The large evolutionary distance among AONS sequences resulting 
from an early evolutionary appearance of AONS presents the possibility that significant 
diversity was present in the α-oxoamine synthases prior to the appearance of ALAS and 
KBL function.  Thus, the ALAS and KBL precursor sequences were likely most similar 
to AONS sequences with the closest identity to the ALAS and KBL sequence sets.   
By comparing the ALAS and KBL primary structures with the closest AONS 
relatives we identified the sequential position of residues that may function to regulate 
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enzyme specificity (Table 2.3).  The ALAS crystal structure from R. capsulatus provided 
insight into the role of various positions identified. The majority of the 37 sequential 
positions were clustered near the active site (Figure 2.6 and 2.7); in fact, only 4 positions 
were distal to the active site.  Interestingly, nine of the identified active site positions 
were occupied with residues that interact with either a substrate or the PLP cofactor in the 
ALAS crystal structure. 
In the R. capsulatus ALAS crystal structure seven of the identified residues are 
involved in succinyl-CoA recognition.  Gly82, Thr83, Asn85 and Ile86 are located in a 
glycine-rich stretch directly involved in positioning the carboxylate group of succinyl-
CoA (Astner, Schulze et al., 2005).  The carboxylate is positioned through a van der 
Waals interaction with Ile86 and hydrogen bonds between the two carboxylate O and 
Thr83 and Asn85.    Lys156 and Ile149 also have a role in succinyl-CoA recognition 
through a hydrogen bond between the O3’ of the succinyl-CoA ribose moiety and 
Lys156-Nξ and a hydrophobic interaction between the adenine moiety and Ile149 
(Astner, Schulze et al., 2005).   Asn362 in the R. capsulatus ALAS is equivalent to 
Arg349 in the E. coli AONS crystal structures.  Both ALAS Asn362 and AONS Arg349 
are hydrogen-bonded to an N-terminal arginine in the holoenzyme (ALAS or AONS) and 
respective SCoA- or AON-bound structures.  This arginine forms a hydrogen bond with 
the SCoA or AON carboxylate in the ALAS or AONS structure, respectively, and likely 
has a role coordinating the C-terminal transition upon SCoA or AON binding (Webster, 
Alexeev et al., 2000; Astner, Schulze et al., 2005).  
The crystal structures of α-oxoamine synthases also reveal an active site loop, 
which upon the transition of the enzyme from the open to closed conformation, closes 
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over the active site (Webster, Alexeev et al., 2000; Astner, Schulze et al., 2005).  In 
ALAS, the closure of this loop, comprised of residues 358-374, over the active site is 
important for the proper orientation of succinyl-CoA for catalysis (Astner, Schulze et al., 
2005).  Three residues identified, Gln359, and Glu379 along with the previously 
mentioned Asn362, are at positions located on this active site loop in R. capsulatus 
ALAS (Astner, Schulze et al., 2005).    
The three above identified residues appear to be involved in positioning the PLP 
cofactor in the R. capsulatus ALAS crystal structure.  Tyr116 and Ser277 form two of six 
hydrogen bonds with the phosphate group (Astner, Schulze et al., 2005).  At position 216 
of the amino acid alignment, a Val residue is conserved among all ALAS sequences, 
while Ala is conserved among all AONS, SPT and SPT2 sequences (Figure 2.1).  The 
corresponding residue in the ALAS and AONS crystal structures (Val216 and Ala206, 
respectively) forms hydrophobic contacts with PLP and functions to stabilize the 
pyridinium ring from underneath (Alexeev, Alexeeva et al., 1998; Astner, Schulze et al., 
2005).  Equivalent residues in aspartate aminotransferase and 1-aminocyclopropane-1-
carboxylate were mutated to isoleucine, i.e., Ala224Ile and Ile232Ala, respectively, 
resulting in a 4-10 fold decrease in kcat/Km and altered pKa values for the internal aldimine 
in both enzymes (Eliot and Kirsch, 2002).   
Hereditary sideroblastic anemia or XLSA is attributed to point mutations in 
ALAS2 (Bottomley, May et al., 1995) .  Five of the residues identified in the R. 
capsulatus ALAS structures are associated with mutations observed in XLAS patients 
(Astner, Schulze et al., 2005).  Mutations at four of these residues, including those 
previously cited, Lys156 as well as Phy23, Gly273 and Leu133, disrupt the binding of the 
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succinyl-CoA substrate (Astner, Schulze et al., 2005). XLSA mutations impacting PLP 
affinity also occur at positions that were identified; these residues are equivalent to Lys30 
and the abovementioned Gly273 (Astner, Schulze et al., 2005). 
While the significance of the residues occupying the positions identified as 
determining in substrate selectivity and/or discrimination can not be completely 
understood with the crystal structures alone, the location of the majority of these residues 
at or near the active site does not contradict the proposition that they may be important in 
regulating substrate specificity in ALAS, KBL and AONS.  In fact, one third of the 
positions identified using the alignment are equivalent to ALAS residues that are either 
involved in direct interactions with succinyl-CoA or PLP, associated with XLSA, or 
located on an active site loop that functions to position succinyl CoA.  This indicates that 
many of the residues located at the identified positions do have a role in enzyme function 
and determining function specificity.  Furthermore, enzyme-dependent residue variation 
at each of the positions also suggests that the significance of each position for ALAS, 
AONS and KBL function is different.  
 In summary, sequences were selected to represent the broad taxonomic and 
phylogenetic distribution of each member of the α-oxoamine synthase subfamily of PLP-
dependent enzymes and to better comprehend their evolutionary relationships.  The 
enhanced understanding of these relationships may have helped to provide insight into 
the significance of the primary structure differences in laboratory evolved variants.  
While no evolved variants were identified, the knowledge gained by the phylogenetic 
analysis did aid in the identification of sequential positions at which amino acid residues 
varied according to enzyme function.  Furthermore, one third of the identified amino 
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acids occupied relevant active site positions in the ALAS crystal structure and/or were 
previously recognized to be mutated in XLSA. 
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# ALAS AONS KBL Role in ALAS Crystal Structure
3 Y X X Remote
23 F R,L,I I,E
Adjacent to active site (ALAS mutation disrupts SCoA 
binding and N- and C-terminal interactionsa)
30 A,K(N) E,P,Q Q(N)
Adjacent to active site (ALAS mutation disrupts PLP 
binding and enzyme stabilitya) 
50 V(M) D,N(L,V) N(Q) Adjacent to residue involved in glycine binding
55 D N,D N 
Adjacent to active site N54 which forms hydrogen bond 
with the carboxylate of glycine
82 G A,G S Glycine rich stretch that positions terminal carboxylate of SCoA 
83 T S V
Forms hydrogen bond with SCoA carboxylate O  (In 
AONS, S has key role in governing enzyme specifityb) 
85 N L(T, H) F,T Glycine rich stretch that positions terminal carboxylate of SCoA
86 I V, L(T, A) I Glycine rich stretch that positions terminal carboxylate of SCoA
103 L F,W(L,R) F Remote
104 H X X Remote
106 K X X Remote
113 S(T) X X Adjacent
116 Y,F F,Y F Forms hydrogen bond with phosphate O 
117 I,V X D(T) Adjacent
127 A,G(R) X L,M Adjacent to active site  and surface loop 130-134  
130-
132
M,L(F)-   
P(N,K) -X
X-      
D,E(S,C)-X
E(N) -   
D-A(I) Surface loop adjacent to active site
133-
134
C,L(I) -
E,I,V Deleted Deleted
Surface loop adjacent to active site (ALAS 133 mutation 
disrupts SCoA adenine binding pocket reducing SCoA 
affinitya)  
147 X D D Adjacent to active site
149 I V,C,M V,C,M Bottom of hydrophobic pocket for SCoA adenine moity
156 K X K, R
Forms hydrogen bond with SCoA ribose moity ALAS 
(ALAS mutation reduces SCOA affinitya) 
159 F(Y,W) F,Y(T,A,V) Y(V) Adjacent to active site
184 F T(S) T Adjacent to active site
185 E D D
Forms hydrogen bond with H142 which positions PLP 
from above 
216 V A A,C,S ALAS and AONS supports the PLP ring from belowa,b
270 Y,F(L,S) X K,R 270-272 LOOP between α9 and α10 PLP binding
271 A(S) A(M) S,G 270-272 LOOP between α9 and α10 PLP binding
272 P,A,S R(K,T) R, I 270-272 LOOP between α9 and α10 PLP binding
273 G(H) X P ALAS mutation disrupts residues involved in both SCoA  and PLP binding 
277 T(S) S, T, Q S Shares hydrogn bond with Phophate O
359 Q Q,I,P X Loop of C terminal loop that moves to widen the active site channel in open and closed conformation
362 N R(M,E,V) V, S, F Loop of C terminal loop the moves to narrow the active site channel in open and closed conformation
371 E X  A (G) Loop of C terminal loop the moves to narrow the active site channel in open and closed conformation
379 P A, S, L A Remote-Possible role in intersubunit interaction
TABLE 2.3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
X = none conserved      Italic = Occurs in single sequence 
 a(Astner, Schulze et al., 2005)b(Alexeev, Alexeeva et al., 1998) 
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FIGURE 2.6 
Succinyl-CoA binding pocket of R. capsulatus ALAS. Ribbon structure of the ALAS 
homodimer (PDB code:2BWO) active site in which one subunit is depicted in blue with 
the active site loop in green and the adjacent subunit is in grey. (A) and (B) Cartoon 
representation of active site residues with the succinyl-CoA substrate (red) depicted in 
ball and stick representation (carbon in green, oxygen in red, nitrogen in blue).  Variable 
residues according to enzyme function within the α-oxoamine synthase family, which 
interact with or lie adjacent to succinyl-CoA, are in yellow and residues that lie adjacent 
to active site loop are green.  Images were generated with Deep View (Guex and Peitsch, 
1997; Kaplan and Littlejohn, 2001). 
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FIGURE 2.7 
Active site interactions with PLP cofactor and glycine substrate in R. capsulatus ALAS 
(A) Ribbon structure of the ALAS homodimer active site (PDB code: 2BWP) in which 
one subunit is depicted in blue and the adjacent subunit is in grey. Cartoon representation 
of active site residues with the PLP-bound glycine substrate (red) depicted in ball and 
stick representation (carbon in green, oxygen in red, nitrogen in blue).  Variable residues 
according to enzyme function within the a-oxoamine synthase family, which interact with 
or lie adjacent to PLP or glycine, are in green. (B) Ball and stick representation with 
ribbon structure removed for clarity.  (Guex and Peitsch, 1997; Kaplan and Littlejohn, 
2001) 
 
Y270
P272
N117                                                 A271
Y116 G273
S277
V216
D55
 A 
 
 
 
 
 
 
 
 
 
 
 
B 
 85
References 
 
Alexander, F. W., E. Sandmeier, et al. (1994). "Evolutionary relationships among 
pyridoxal-5'-phosphate-dependent enzymes. Regio-specific alpha, beta and 
gamma families." Eur. J. Biochem 219(3): 953-960. 
 
Alexeev, D., M. Alexeeva, et al. (1998). "The crystal structure of 8-amino-7-
oxononanoate synthase: a bacterial PLP-dependent, acyl-CoA-condensing 
enzyme." J. Mol. Biol. 284(2): 401-419. 
 
Astner, I., J. O. Schulze, et al. (2005). "Crystal structure of 5-aminolevulinate synthase, 
the first enzyme of heme biosynthesis, and its link to XLSA in humans." Embo. J. 
24(18): 3166-3177. 
 
Bertani, G. (1951). "Studies on lysogenesis. I. The mode of phage liberation by lysogenic 
Escherichia coli." J Bacteriol 62(3): 293-300. 
 
Bhor, V. M., S. Dev, et al. (2006). "Broad substrate stereospecificity of the 
Mycobacterium tuberculosis 7-keto-8-aminopelargonic acid synthase: 
Spectroscopic and kinetic studies." J. Biol. Chem. 281(35): 25076-25088. 
 
Bishop, D. F. (1990). "Two different genes encode delta-aminolevulinate synthase in 
humans: nucleotide sequences of cDNAs for the housekeeping and erythroid 
genes." Nucleic Acids Res. 18(23): 7187-7188. 
 
Bottomley, S. S., B. K. May, et al. (1995). "Molecular defects of erythroid 5-
aminolevulinate synthase in X-linked sideroblastic anemia." J. Bioenerg. 
Biomembr. 27(2): 161-168. 
 
Cadwell, R. C. and G. F. Joyce (1992). "Randomization of genes by PCR mutagenesis." 
PCR Methods Appl 2(1): 28-33. 
 
Chow, M. A., K. E. McElroy, et al. (2004). "Narrowing substrate specificity in a directly 
evolved enzyme: the A293D mutant of aspartate aminotransferase." Biochemistry 
43(40): 12780-12787. 
 
Christen, P. and P. K. Mehta (2001). "From cofactor to enzymes. The molecular 
evolution of pyridoxal-5'-phosphate-dependent enzymes." Chem. Rec. 1(6): 436-
447. 
 
Christen, P. and D. E. Metzler (1985). Transaminases. New York, Wiley. 
 
Del Campillo-Campbell, A., G. Kayajanian, et al. (1967). "Biotin-requiring mutants of 
Escherichia coli K-12." J. Bacteriol. 94(6): 2065-2066. 
 
 86
Eck, R. and M. Dayhoff (1966). Atlas of Protein Sequence and Structure. Silver Springs, 
Maryland, National Biomedical Research Foundation. 
 
Eliot, A. C. and J. F. Kirsch (2002). "Modulation of the internal aldimine pK(a)'s of 1-
aminocyclopropane-1-carboxylate synthase and aspartate aminotransferase by 
specific active site residues." Biochemistry 41(11): 3836-3842. 
 
Eliot, A. C. and J. F. Kirsch (2004). "Pyridoxal phosphate enzymes: mechanistic, 
structural, and evolutionary considerations." Annu. Rev. Biochem. 73: 383-415. 
 
Felsenstein, J. (1985 ). "Confidence limits on phylogenies: An approach using the 
bootstrap." Evolution 39: 783-791. 
 
Ferreira, G. C. (1999). Iron Metabolism.  Inorganic Biochemistry and Regulatory 
Weinheim, Germany, Wiley-VCH. 
 
Ferreira, G. C. and H. A. Dailey (1993). "Expression of mammalian 5-aminolevulinate 
synthase in Escherichia coli. Overproduction, purification, and characterization." 
J. Biol. Chem. 268(1): 584-590. 
 
Gong, J. and G. C. Ferreira (1995). "Aminolevulinate synthase: functionally important 
residues at a glycine loop, a putative pyridoxal phosphate cofactor-binding site." 
Biochemistry 34(5): 1678-1685. 
 
Guex, N. and M. C. Peitsch (1997). "SWISS-MODEL and the Swiss-PdbViewer: an 
environment for comparative protein modeling." Electrophoresis 18(15): 2714-
2723. 
 
Han, G., K. Gable, et al. (2006). "Expression of a novel marine viral single-chain serine 
palmitoyltransferase and construction of yeast and mammalian single-chain 
chimera." J. Biol. Chem. 281(52): 39935-39942. 
 
Hult, K. and P. Berglund (2007). "Enzyme promiscuity: mechanism and applications." 
Trends Biotechnol. 25(5): 231-238. 
 
Hwang, S. Y., V. Su, et al. (1999). "Bioassay of biotin concentration with a Escherichia 
coli bio deletion mutant." J Biochem Biophys Methods 39(1-2): 111-114. 
 
Jansonius, J. N. (1998). "Structure, evolution and action of vitamin B6-dependent 
enzymes." Curr. Opin. Struct. Biol. 8(6): 759-769. 
 
Kaplan, W. and T. G. Littlejohn (2001). "Swiss-PDB Viewer (Deep View)." Brief 
Bioinform 2(2): 195-197. 
 
 87
Katoh, K., K. Kuma, et al. (2005). "MAFFT version 5: improvement in accuracy of 
multiple sequence alignment." Nucleic Acids Res. 33(2): 511-518. 
 
Kuchner, O. and F. H. Arnold (1997). "Directed evolution of enzyme catalysts." Trends 
Biotechnol 15(12): 523-530. 
 
Longenecker, J. B., M. Ikawa, et al. (1957). "The cleavage of alpha-methylserine and 
alpha-methylolserine by pyridoxal and metal ions." J. Biol. Chem. 226(2): 663-
666. 
 
Mehta, P. K. and P. Christen (1998). "The Molecular Evolution of Pyridoxal 5-Phosphate 
Dependent Enzymes." Adv. Enzymol. Relat. Areas Mol. Biol. 74: 129-185. 
 
Mehta, P. K. and P. Christen (2000). "The molecular evolution of pyridoxal-5'-
phosphate-dependent enzymes." Adv. Enzymol Relat. Areas Mol. Biol. 74: 129-
184. 
 
Metzler, D. E. and E. E. Snell (1952). "Deamination of serine. I. Catalytic deamination of 
serine and cysteine by pyridoxal and metal salts." J. Biol. Chem. 198(1): 353-361. 
 
Miyazaki, K. and M. Takenouchi (2002). "Creating random mutagenesis libraries using 
megaprimer PCR of whole plasmid." Biotechniques 33(5): 1033-1034, 1036-
1038. 
 
Moore, J. C., H. M. Jin, et al. (1997). "Strategies for the in vitro evolution of protein 
function: enzyme evolution by random recombination of improved sequences." J 
Mol Biol 272(3): 336-347. 
 
Nei, M. and S. Kumar (2000). Molecular Evolution and Phylogenetics. New York, 
Oxford University Press. 
 
Olivard, J., D. E. Metzler, et al. (1952). "Catalytic racemization of amino acids by 
pyridoxal and metal salts." J. Biol. Chem. 199(2): 669-674. 
 
Percudani, R. and A. Peracchi (2003). "A genomic overview of pyridoxal-phosphate-
dependent enzymes." EMBO Rep. 4(9): 850-854. 
 
Ploux, O. and A. Marquet (1992). "The 8-amino-7-oxopelargonate synthase from 
Bacillus sphaericus. Purification and preliminary characterization of the cloned 
enzyme overproduced in Escherichia coli." Biochem J. 283 ( Pt 2): 327-331. 
 
Rothman, S. C., M. Voorhies, et al. (2004). "Directed evolution relieves product 
inhibition and confers in vivo function to a rationally designed tyrosine 
aminotransferase." Protein Sci. 13(3): 763-772. 
 
 88
Rzhetsky, A. and M. Nei (1992). "A simple method for estimating and testing minimum 
evolution trees." Molecular Biology and Evolution 9: 945-967. 
 
Rzhetsky, A. and M. Nei (1992). "A simple method for estimating and testing minimum 
evolution trees." Molecular Biology and Evolution 9: 945-967. 
 
Saitou, N. and M. Nei (1987). "The neighbor-joining method: a new method for 
reconstructing phylogenetic trees." Mol. Biol. Evol. 4(4): 406-425. 
 
Schmidt, A., J. Sivaraman, et al. (2001). "Three-dimensional structure of 2-amino-3-
ketobutyrate CoA ligase from Escherichia coli complexed with a PLP-substrate 
intermediate: inferred reaction mechanism." Biochemistry 40(17): 5151-5160. 
 
Schneider, G., H. Kack, et al. (2000). "The manifold of vitamin B6 dependent enzymes." 
Structure 8(1): R1-R6. 
 
Schneider, G., H. Kack, et al. (2000). "The manifold of vitamin B6 dependent enzymes." 
Structure 8(1): R1-6. 
 
Schneider, G. and Y. Lindqvist (2001). "Structural enzymology of biotin biosynthesis." 
FEBS Lett. 495(1-2): 7-11. 
 
Schwartz, R. M. and M. O. Dayhoff (1979). "Protein and Nucleic Acid Sequence Data 
and Phylogeny." Science 205(4410): 1038-1039. 
 
Shafikhani, S., R. A. Siegel, et al. (1997). "Generation of large libraries of random 
mutants in Bacillus subtilis by PCR-based plasmid multimerization." 
Biotechniques 23(2): 304-310. 
 
Smith, H. O. and M. Levine (1964). "Two Sequential Repressions of DNA Synthesis in 
the Establishment of Lysogeny by Phage P22 and Its Mutants." Proc. Natl. Acad. 
Sci. U S A 52: 356-363. 
 
Snell, E. E. and B. M. Guirard (1943). "Some Interrelationships of Pyridoxine, Alanine 
and Glycine in Their Effect on Certain Lactic Acid Bacteria." Proc. Natl. Acad. 
Sci. U S A 29(2): 66-73. 
 
Soltis, D. E. and P. S. Soltis (2003). "The role of phylogenetics in comparative genetics." 
Plant Physiol 132(4): 1790-1800. 
 
Tamura, K., J. Dudley, et al. (2007). "MEGA4: Molecular Evolutionary Genetics 
Analysis (MEGA) Software Version 4.0." Mol. Biol. Evol. 24(8): 1596-1599. 
 
Thompson, J. D., D. G. Higgins, et al. (1994). "CLUSTAL W: improving the sensitivity 
of progressive multiple sequence alignment through sequence weighting, 
 89
position-specific gap penalties and weight matrix choice." Nucleic Acids Res. 
22(22): 4673-4680. 
 
Webster, S. P., D. Alexeev, et al. (2000). "Mechanism of 8-amino-7-oxononanoate 
synthase: spectroscopic, kinetic, and crystallographic studies." Biochemistry 
39(3): 516-528. 
 
Webster, S. P., D. J. Campopiano, et al. (1998). "Characterisation of 8-amino-7-
oxononanoate synthase: a bacterial PLP-dependent, acyl CoA condensing 
enzyme." Biochem. Soc. Trans. 26(3): S268. 
 
Yano, T., S. Oue, et al. (1998). "Directed evolution of an aspartate aminotransferase with 
new substrate specificities." Proc. Natl. Acad. Sci. U.S.A. 95(10): 5511-5515. 
 
Yard, B. A., L. G. Carter, et al. (2007). "The structure of serine palmitoyltransferase; 
gateway to sphingolipid biosynthesis." J. Mol. Biol. 370(5): 870-886. 
 
Zhao, H. and F. H. Arnold (1997). "Combinatorial protein design: strategies for screening 
protein libraries." Curr Opin Struct Biol 7(4): 480-485. 
 
Zhao, H., L. Giver, et al. (1998). "Molecular evolution by staggered extension process 
(StEP) in vitro recombination." Nat. Biotechnol. 16(3): 258-261. 
 
 
 
 90
 
 
 
 
 
Chapter Three 
 
Functional asymmetry for active sites of single chain homo- and chimeric dimers of 
5-aminolevulinate synthase and 8-amino-7-oxononanoate synthase 
Abstract 
5-Aminolevulinate synthase (ALAS) and 8-amino-7-oxononanoate synthase 
(AONS) are homodimeric members of the α-oxoamine synthase family of pyridoxal 5’-
phosphate (PLP)-dependent enzymes.  Previously, linking two ALAS subunits into a 
single polypeptide chain dimer resulted in an enzyme (ALAS/ALAS) with a significantly 
greater turnover number than that of wild-type ALAS.  To examine the contribution of 
each active site to the enzymatic activity of ALAS/ALAS, the conserved lysine, which 
covalently binds the PLP cofactor, was substituted with alanine yielding single chain 
dimeric ALAS variants with one of the two active sites having no measurable enzymatic 
activity.  Albeit the amount of ALA produced during the first turnover was identical in 
both active sites of ALAS/ALAS, the kcat values of the variants varied significantly (4.4 ± 
0.2 min-1 vs. 21.6 ± 0.7 min-1) depending on which active site harbored the mutation.  
Chimeric ALAS/AONS proteins exhibited a distinct oligomeric state from that of 
ALAS/ALAS, with two sites having ALAS activity and two AONS activity.  
Remarkably, while the steady-state rates for the ALAS and AONS activities were lower 
than in the parent enzymes, the reactivity of the ALAS sites in ALAS/AONS was similar 
to that of wild-type ALAS.  We propose that the different contribution of each active site 
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to the steady-state activity of ALAS/ALAS and the reduced steady-state activities of the 
ALAS/AONS chimera, compared to the parent enzymes, relate to different extents of 
protein conformational changes associated with product release due to the strain caused 
with the linking the two ALAS (or ALAS and AONS) subunits. 
 
Introduction  
Pyridoxal 5’-phosphate (PLP) is a necessary cofactor for a catalytically versatile 
class of enzymes (Ferreira and Gong, 1995).  PLP-dependent enzymes that catalyze 
reactions involving amino acids share the common mechanism of using the electron 
withdrawing properties of the PLP cofactor to labilize bonds to the substrate α-carbon 
(Christen and Mehta, 2001).   
PLP-dependent enzymes have been classified according to fold types inferred 
from three-dimensional structures and reaction specificity (Christen and Mehta, 2001; 
Eliot and Kirsch, 2004).  The largest and most diverse group is the aspartate 
aminotransferase superfamily or fold-type I, α−family (Paiardini, Bossa et al., 2004).  
The α-oxoamine synthases constitute a small but widespread subfamily within fold-type I 
PLP-dependent enzymes, comprising 8-amino-7-oxononanoate synthase (AONS), 5-
aminolevulinate synthase (ALAS), serine palmitoyltransferase (SPT), and 2-amino-3-
oxobutyrate CoA ligase (Alexeev, Alexeeva et al., 1998; Schneider, Kack et al., 2000; 
Schmidt, Sivaraman et al., 2001; Astner, Schulze et al., 2005; Yard, Carter et al., 2007).  
These four members of the α-oxoamine family share about 12% identity at the amino 
acid level, while the amino acid sequence identity between any pair is around 30% 
(Alexeev, Alexeeva et al., 1998).  The three-dimensional structures for all four α-
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oxoamine synthases are highly conserved, as demonstrated by the Cα root-mean-square 
deviation values for SPT of 1.4-1.6 Å relative to the other three members (Yard, Carter et 
al., 2007). 
AONS and ALAS catalyze Claisen condensations between amino acids and acyl-
CoA thioesters with concomitant decarboxylation of the amino acid leading to the 
formation of a 2-aminoketone product, CoA and carbon dioxide (Ferreira and Gong, 
1995; Alexeev, Alexeeva et al., 1998).  AONS catalyzes the reaction between alanine and 
pimeloyl-CoA to give 8-amino-7-oxononanoate (AON), whereas ALAS catalyzes the 
reaction between glycine and succinyl-CoA to give 5-aminolevulinic acid (ALA) 
(Scheme 3.1).  Both AON and ALA are essential metabolic compounds: the first is an 
intermediate in biotin synthesis (Ploux and Marquet, 1992) and the second is an 
intermediate in the tetrapyrrole biosynthetic pathway (Ferreira and Gong, 1995; Tan and 
Ferreira, 1996). 
 
 
 
 
 
SCHEME 3.1  Reaction catalyzed by ALAS and AONS 
 
 
 
ALAS and AONS function as homodimers (Tan and Ferreira, 1996; Alexeev, 
Alexeeva et al., 1998; Astner, Schulze et al., 2005).  The active site is located at the 
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subunit interface, where the PLP cofactor is covalently bound to an active site lysine 
through a Schiff base linkage (Ferreira, Neame et al., 1993; Alexeev, Alexeeva et al., 
1998; Astner, Schulze et al., 2005) .  Each monomer consists of three domains, a short N-
terminal domain (~50 residues), a central catalytic core (~250 residues), and a C-terminal 
domain (~100 residues).  Although all three domains participate in dimerization, the 
catalytic domain contributes the most to the dimeric interface (Alexeev, Alexeeva et al., 
1998; Astner, Schulze et al., 2005; Yard, Carter et al., 2007). 
 Despite the highly conserved tertiary structure of the α-oxoamine synthases, the 
plasticity of the PLP-binding and active site is quite remarkable, as demonstrated with 
circularly permuted murine erythroid ALAS variants (Cheltsov, Barber et al., 2001; 
Cheltsov, Guida et al., 2003).  Circular permutation of ALAS, which changed the primary 
sequence without altering the amino acid composition, did not prevent folding of the 
polypeptide chain into a structure compatible with binding of the PLP cofactor and 
assembly of the two subunits into a functional enzyme (Cheltsov, Barber et al., 2001; 
Cheltsov, Guida et al., 2003).  In fact, the circularly permuted ALAS variants were able 
to form tertiary structures similar to wild-type (WT) ALAS that retained enzymatic 
function in spite of the rearrangement of the secondary structural elements (Cheltsov, 
Barber et al., 2001).  Cheltsov et al. (Ferreira and Cheltsov, 2002) argued that a PLP fold 
and enzymatic activity are achievable as long as the polypeptide chain of ALAS (and 
presumably of other α-oxoamine synthases) folds to allow binding of the cofactor and 
correct positioning of the catalytic residues. 
Structural plasticity in the α-oxoamine synthase family has also been 
substantiated with the creation of a “single chain dimeric” ALAS (Cheltsov, Barber et al., 
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2001; Cheltsov, Guida et al., 2003; Zhang, Cheltsov et al., 2005), the discovery of a 
marine viral single-chain SPT and construction of yeast and mammalian single-chain 
SPT chimeras (Han, Gable et al., 2006).  The “single chain, dimeric” ALAS (i.e., 
ALAS/ALAS), created by linking two ALAS polypeptide chains, exhibited distinct 
spectroscopic properties and substantially greater enzymatic activity than WT ALAS 
(Zhang, Cheltsov et al., 2005).  Single-chain chimeras formed from either the two yeast 
or mammalian SPT subunits, LCB1 and LCB2, displayed novel substrate specificity 
(Han, Gable et al., 2006).  As a matter of fact, similarly to the marine viral single-chain 
SPT and in contrast to the naturally occurring eukaryotic, heterodimeric SPTs, the yeast 
and mammalian single-chain SPT chimeras prefer myristoyl-CoA rather than palmitoyl-
CoA as substrate (Han, Gable et al., 2006).  Essentially, these findings indicate that 
significant flexibility is present in the architecture and formation of the PLP-binding and 
active sites of α-oxoamine synthases.  
To address whether 1) each of the two active sites in the “single chain dimeric” 
ALAS contributes equally to the overall enzymatic activity and 2) the structural plasticity 
and flexibility in active site formation can be extended to chimeras between different 
members of the α-oxoamine synthase family, we characterized “single chain dimeric” 
ALAS variants, in which one of the two active sites had no measurable enzymatic 
activity, and single-chain chimeras between WT or mutated ALAS and AONS.  We 
report that each of the two active sites in ALAS/ALAS contributes differently to the 
steady-state activity of the enzyme, even though the amount of ALA produced during the 
first turnover is identical in both active sites.  Further, while the chimeric ALAS/AONS 
proteins tolerate a high degree of structural plasticity, the oligomeric state and the active 
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site arrangement of the chimeric proteins differ from those of proteins generated from the 
fusion of identical polypeptide chains (e.g., ALAS/ALAS). 
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Material and Methods  
Materials  
The following reagents were purchased from Sigma-Aldrich Chemical Company: 
DEAE-Sephacel, Ultrogel AcA-44, β-mercaptoethanol, PLP, succinyl-CoA, ALA-
hydrochloride, α-ketoglutaric acid, α-ketoglutarate dehydrogenase, pyruvate 
dehydrogenase, HEPES-free acid, MOPS, tricine, thiamin pyrophosphate, NAD+, pyruvic 
acid, the gel filtration molecular weight markers kit (cytochrome c, carbonic anhydrase, 
bovine serum albumin, alcohol dehydrogenase, β-amylase), and the bicinchoninic acid 
protein determination kit.  Glycerol, alanine, glycine, disodium ethylenediamine 
tetraacetic acid dihydrate, ammonium sulfate, magnesium chloride hexahydrate, 
perchloric acid, and potassium hydroxide were acquired from Fisher Scientific.  Sodium 
dodecyl sulfate polyacrylamide gel electrophoresis reagents were acquired from Bio-Rad.  
All resctriction enzymes, Vent DNA polymerase, and T4 DNA ligase were from New 
England Biolabs.  Superdex 200 gel filtration resin was from Amersham Biosciences-GE 
Healthcare and DNA oligonucleotides were from Integrated DNA Technologies.    
Escherichia coli R872 strain and pET6HAONS were generous gifts from Dr. Dominic 
Campopiano (University of Edinburg).  E. coli HU227 strain was a generous gift from 
Dr. Charlotte S. Russell (City University of New York). 
 
Construction of ALAS/ALAS and ALAS/AONS chimeric expression plasmids 
Chimeras between murine, mature erythroid ALAS and E. coli AONS or between 
mutated forms of either ALAS or AONS and the WT enzymes were engineered using 
pGF23 as the expression vector (Figure 3.1, Table 3.1).  The pGF23 plasmid contains the 
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sequence for murine, mature erythroid ALAS under the control of the alkaline 
phosphatase promoter (Ferreira and Dailey, 1993).  pTDT1, an expression plasmid for 
6x-histidine-tagged E. coli AONS, was constructed by PCR-amplification of the E. coli 
bioF gene, which encodes the AONS protein, and subcloning of the PCR product into 
pGF23, such that the bioF gene replaced the ALAS-encoding fragment (see Supporting 
Information for Experimental Details).   
 The pTDT5 and pTDT4 expression plasmids (Table 3.1) were constructed to yield 
chimeric proteins between ALAS and AONS (Figure 3.1).  Using the 5’ to 3’ convention 
for the “chimeric gene” under the control of the alkaline phosphatase promoter, pTDT5 
contains the cDNA coding for ALAS linked to the following bioF gene for AONS 
through a Mfe I site, whereas in pTDT4, the bioF gene precedes the ALAS cDNA (Figure 
3.1).  These constructs were based on the pAC1 plasmid (Cheltsov, Barber et al., 2001; 
Cheltsov, Guida et al., 2003; Zhang, Cheltsov et al., 2005) (Figure 3.1), which contains 
two tandem ALAS cDNA sequences separated by an MfeI cloning site (see Supporting 
Information for Experimental Details).  
 The pTDT12 and pTDT17 expression plasmids (Table 3.1) were constructed 
using the pGF27 expression plasmid for the ALASK313A variant (Ferreira, Vajapey et al., 
1995) as the starting material for a DNA piece coding for the ALASK313A mutation.  The 
pGF27 plasmid was digested with Kpn I and Xba I and the ALASK313A-encoding 
fragment was ligated into pTDT4 and pTDT5 digested with the same enzymes.   
 The pTDT8 plasmid (Table 3.1) was designed to encode a full-length ALAS with 
phenylalanine-341 mutated to alanine.  To introduce the F341A encoding mutation into 
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ALAS cDNA, the method previously described by Gong et al. was followed (Gong, 
Hunter et al., 1998) (see Supporting Information for Experimental Details).  
 The pTDT14 and pTDT15 expression plasmids (Table 3.1) were constructed 
using pTDT8 as the source plasmid for the ALASF341A-encoding fragment.  The pTDT8 
plasmid was digested with Kpn I and Xba I and the fragment containing the ALASF341A 
mutation was isolated and subcloned into pTDT5 and pTDT4 to generate pTDT14 and 
pTDT15, respectively. 
The pTDT7 expression plasmid encodes the ALAS/AONS chimera in which the 
AONS active-site lysine involved in the Schiff base linkage with the PLP cofactor, K236, 
is mutated to an alanine (Table 3.1; Figure 3.1).  The method described by Gong et al. 
(11) was used to introduce the K236A-encoding mutation in the bioF gene harbored in 
pTDT5 (see Supporting Information for Experimental Details).   
  The pCA1 and pMG1 expression plasmids, encoding ALASK313A/ALAS and 
ALAS/ALASK313A, respectively, were constructed using the pAC1 and pGF27 plasmids 
(Table 3.1; Figure 3.1) (see Supporting Information for Experimental Details).   
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Table 3.1: Nomenclature defining the plasmids and enzymes described in this report 
Plasmid Proteina Description Massb Reference 
pGF23 ALAS ALAS homodimer 56 kD  (Ferreira and Dailey, 1993) 
pTDT1 AONS AONS homodimer 40 kD This study 
pGF27 ALASK313A ALAS homodimer harboring the K313A mutation 56 kD 
(Ferreira, Vajapey et al., 
1995; Hunter and Ferreira, 
1999) 
pTDT8 ALASF341A ALAS homodimer harboring the F341A mutation 56 kD This study 
pAC1 ALAS/ALAS Single polypeptide ALAS homodimer 112 kD (Zhang, Cheltsov et al., 2005) 
pCA1 ALASK313A /ALAS Chimera of ALASK313A and ALAS 112 kD This study 
pMG1 ALAS/ALASK313A Chimera of ALAS and ALASK313A 112 kD This study 
pTDT5 ALAS/AONS Chimera of ALAS and AONS 96 kD This study 
pTDT4 AONS/ALAS Chimera of AONS and ALAS 96 kD This study 
pTDT12 ALASK313A /AONS Chimera of ALASK313A and AONS 96 kD This study 
pTDT17 AONS/ALASK313A Chimera of AONS and ALASK313A 96 kD This study 
pTDT14 ALASF341A /AONS Chimera of ALASF341A and AONS 96 kD This study 
pTDT15 AONS/ALASF341A Chimera of AONS and ALASF341A 96 kD This study 
pTDT7 ALAS /AONSK236A Chimera of ALAS and AONSK236A 96 kD This study 
aIn the linked proteins the first abbreviation refers to the N-terminal enzyme. bMonomeric molecular 
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FIGURE 3.1   
Ribbon representation ALAS and AONS homodimers and schematic representation of 
expression plasmids (A-B) ALAS and AONS homodimers in ribbon representation with 
one subunit shown in yellow and the central catalytic core, N-terminal domain, and C-
terminal domain of the second subunit rendered in dark, medium and light blue, 
respectively.  (A) ALAS homodimer from R. capsulatus (PDB code: 2BWN).  The PLP 
cofactor (red), the active site lysine (green) involved in the Schiff base linkage with PLP 
(K248 in R. capsulatus ALAS and K313 in murine erythroid ALAS) and F276 (purple; 
F341 in murine erythroid ALAS) are depicted in ball-and-stick representation. (B) AONS 
homodimer from E. coli (PDB code: 1BS0).  The PLP cofactor (red) and the active site 
lysine (green) involved in the Schiff base linkage with PLP (K236) are depicted in ball-
and-stick representation.  (C) Schematic representation of the expression plasmids for 
mutated ALAS, AONS, ALAS/ALAS variants, and single-chain chimeras between, 
ALAS (WT or mutated) and AONS (WT or mutated).  Each of the expression plasmids 
contains a DNA fragment, encoding either a single protein or a chimeric protein, under 
the control of the phoA promoter (Ferreira and Dailey, 1993) and possesses an ampicillin 
resistance selectable marker.  (See “Experimental Procedures” for details).  Ampr, 
ampicillin resistance gene; Bam HI, Mfe I and Sal I, cloning sites.   
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Biological screening for ALAS and AONS function.   
 HemA- E. coli strain HU227 can only grow in a medium containing ALA, hemin 
or when harboring an expression plasmid for ALAS or a functional ALAS variant 
(Sasarman, Surdeanu et al., 1968; Li, Brathwaite et al., 1989).  BioF- E. coli R872 strain 
can only grow in a medium containing AON, biotin or when harboring an expression 
plasmid for AONS or a functional AONS variant (Del Campillo-Campbell, Kayajanian et 
al., 1967). Competent E. coli HU227 and R872 cells were transformed by electroporation 
with expression plasmids containing the ALAS and AONS chimeric constructs. To 
screen for ALAS function, transformed HU227 cells were plated on Luria-Bertani 
medium (0.5% yeast extract, 1% tryptone, 1.0% NaCl and 1.5% agar) containing 50 
mg/ml ampicillin.  To screen for AONS function, transformed R872 cells were plated on 
M9 minimal medium containing 50 mg/ml ampicillin.  M9 medium contains 1X M9-salts 
(12.8 g Na2HPO4-7H2O, 3.0 g KH2PO4, 0.5g NaCl, and 1.0g NH4Cl per 1 L ), 2 mM 
MgSO4, 0.1 mM CaCl2, 0.4 % glucose, 0.1 % vitamin-free casamino acids and 1.5% 
agar. 
Purification of ALAS, AONS, ALAS/ALAS, ALASK313A/ALAS, ALAS/ALASK313A and 
ALAS/AONS.   
The purification of ALAS from E. coli DH5α cells harboring pGF23 was as 
described by Ferreira and Dailey (Ferreira and Dailey, 1993). Recombinant E. coli AONS 
and chimeric ALAS/AONS were purified from E. coli DH5α cells harboring pTDT1 and 
pTDT5, respectively.  Tandem ALAS variants (i.e., ALAS/ALAS, ALASK313A/ALAS 
and ALAS/ALASK313A) were purified from E. coli strain BL21(DE3) overproducing cells 
harboring pAC1, pCA1 or pMG1. E. coli cells harboring any of the six expression 
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plasmids were grown in MOPS medium containing ampicillin and harvested as 
previously described (Ferreira and Dailey, 1993).  The cell pellet was resuspended in 
buffer A (20 mM potassium phosphate buffer, pH 7.5, containing 10% glycerol, 1 mM 
EDTA, 20 mM PLP and 5 mM β-mercaptoethanol) with protease inhibitors (1 μg/ml 
aprotinin, 1 μg/ml leupeptine, 1 μg/ml pepstatin and 1 mg/ml PMSF) as previously 
described (Ferreira and Dailey, 1993).  The steps following cell lysis and centrifugation 
were essentially as described in (Ferreira and Dailey, 1993) with slight modifications.  
Specifically, for both AONS and ALAS/AONS, the initial ammonium sulfate 
fractionation step was 20%.  After stirring for 20 min at 4 0C, the solution was 
centrifuged at 27,000xg for 30 min at 4 oC, and the supernatant was further fractionated 
with ammonium sulfate to a final concentration of 40%. 
For the purification of AONS, the protein pellet was resuspended in buffer A and 
loaded onto an Ultrogel ACA-44 gel filtration column equilibrated with buffer A. The 
protein solution was adjusted to 20% (w/v) ammonium sulfate and the subsequent 
chromatographic steps using Phenyl-Sepharose and Q-Sepharose anion exchange 
columns were as previously described (Webster, Alexeev et al., 2000).   
The purification of ALAS/ALAS from bacterial cells harboring the pAC1 
expression plasmid (Table 3.1) was according to a previously published method 
(Cheltsov, Barber et al., 2001; Cheltsov, Guida et al., 2003; Zhang, Cheltsov et al., 2005).  
For the tandem ALAS variants, ALASK313A/ALAS and ALASK313A/ALAS encoded by 
pCA1 and pMG1, respectively (Table 3.1), the protein pellet was resuspended in buffer A 
and loaded onto a Superdex 200 column equilibrated with buffer A. The fractions 
containing protein were pooled and loaded onto a DEAE-sephacel resin equilibrated with 
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buffer A.  The resin was washed with buffer A, and the protein was eluted with buffer A 
containing 70 mM KCl.  For the purification of ALAS/AONS, the protein pellet obtained 
after 40% ammonium sulfate fractionation was resuspended in buffer A, pH 7.9, and 
loaded onto an Ultrogel ACA-44 column equilibrated with the same buffer.  The fractions 
containing protein were pooled and loaded onto a Q-Sepharose column equilibrated with 
buffer A, pH 7.9.  The Q-Sepharose resin was washed with buffer A, pH 7.9, containing 
25 mM KCl, until Abs280 of the “washed proteins” was lower than 0.1; ALAS/AONS was 
eluted from the Q-Sepharose resin with a 100 mM to 150 mM KCl gradient in buffer A, 
pH 7.5.  The protein purity was assessed using SDS-PAGE. When the final product did 
not meet our purity criteria (i.e., over 95% homogeneity as judged by SDS-PAGE), size 
exclusion chromatography with Sephadex 200 resin was used to eliminate protein 
contaminants.  Protein-containing fractions were pooled and concentrated in an Amicon 
8050 stirred cell with an YM30 membrane.  The purified and concentrated enzyme (WT 
ALAS, AONS, ALAS/ALAS, ALASK313A/ALAS, ALAS/ALASK313A or ALAS/AONS) 
was stored in liquid nitrogen. 
Protein concentrations were determined with the bicinchoninic acid method using 
bovine serum albumin as the standard (Smith, Krohn et al., 1985).  ALAS/AONS 
concentrations are reported on the basis of a subunit molecular mass of 96 kD, while 
ALAS/ALASK313A and ALASK313A/ALAS concentrations are reported on the basis of a 
subunit molecular mass of 112 kD.  (ALAS  and AONS have monomeric molecular 
masses of 56 kD and 40 kD, respectively (Ferreira and Dailey, 1993; Alexeev, Alexeeva 
et al., 1998)).  
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Molecular mass determination by gel filtration chromatography.  
 The native molecular mass of ALAS/AONS was determined using gel filtration 
chromatography as previously described by Cheltsov et al. (Cheltsov, Barber et al., 
2001).   
Pimeloyl-CoA synthesis.  
Pimeloyl-CoA was synthesized as previously described by Ploux and Marquet 
(Ploux and Marquet, 1992). Purity was assessed by reverse-phase HPLC and 
concentration was determined by measuring the absorbance at 260 nm and using an ε260nm 
= 16800 M-1cm-1. 
Spectroscopic measurements.  
 Absorption spectra were acquired at ambient temperature using a Shimadzu UV 
2100 dual beam spectrophotometer, with a reference containing all components except 
the purified enzyme. Fluorescence spectra were collected on a Shimadzu RE-5301 PC 
spectrofluorophotometer using protein concentrations of 2-4 μM. Fluorescence blank 
spectra were collected from samples containing all components except enzyme 
immediately prior to the measurement of samples containing enzyme. The blank spectra 
were subtracted from the spectra of samples containing enzyme.   
Steady-state kinetic characterization of ALAS/AONS, ALASK313A/ALAS, and 
ALAS/ALASK313A.   
 ALAS steady-state activity of the ALAS/AONS chimera, ALASK313A/ALAS and 
ALAS/ALASK313A was determined at 30°C using a continuous spectrophotometric assay 
as described previously for WT ALAS (Hunter and Ferreira, 1995).  AONS steady-state 
activity of the of the ALAS/AONS chimera was determined at 30oC using a coupled 
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enzymatic spectrophotometric assay for AONS (Webster, Campopiano et al., 1998), 
which is similar to that developed for determination of ALAS activity (Hunter and 
Ferreira, 1995).  Briefly, in the latter assay, α-ketoglutarate dehydrogenase was replaced 
by pyruvate dehydrogenase as the coupling enzyme, and the reactions contained 20 mM 
HEPES, pH 7.5, 3 mM MgCl2, 1 mM pyruvic acid, 1 mM NAD+ and 0.25 to 1 μM 
enzyme. Data were acquired using a Shimadzu UV 2100 dual-beam spectrophotometer.  
Enzymatic activity data were plotted vs. substrate concentration in which one of the 
substrate concentrations varied, while the second was kept constant.  The steady-state 
kinetic parameters (i.e., GlymK , 
SCoA
mK , and kcat of the ALAS/AONS chimera, 
ALASK313A/ALAS and ALAS/ALASK313A and AlaninemK , 
PCoA
mK , and kcat of the 
ALAS/AONS chimera) were determined by fitting the data to the Michaelis-Menten 
equation using non-linear regression analysis software.   
Rapid chemical quenched-flow experiments and data analysis.  
 Rapid chemical quenched-flow experiments were performed using a SFM-400/Q 
mode quenched-flow apparatus (BioLogic Science Instruments, France), equipped with a 
circulating water bath to control the temperature of the reactants as described in Zhang 
and Ferreira (Zhang and Ferreira, 2002). ALA concentration in the quenched samples 
was also determined as previously described (Zhang and Ferreira, 2002). ALA produced 
at different reaction times were plotted against time and fitted to equation 1 (Yard, Carter 
et al., 2007), using the nonlinear least-squares regression analysis program SigmaPlot, 
where Pt represents the product concentration at an aging time t, A is the amplitude of the 
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burst phase, kb is the burst rate constant, kss is the steady-state rate constant, and E0 is the 
total enzyme concentration (Zhang and Ferreira, 2002). 
 
 
Pt = A(1 − e−kbt) + kssE0t Equation 1 
 
 
Results 
In vivo activity screen of ALASK313A/ALAS and ALAS/ALASK313A.   
To rapidly verify if ALASK313A/ALAS and ALAS/ALASK313A, which harbor the 
K313A mutation in either of the two linked ALAS subunits, exhibited ALAS activity, 
positive genetic complementation of hemA- E. coli HU227 cells was employed.  Since 
HU227 cells can only grow in a medium supplemented with ALA (Li, Brathwaite et al., 
1989) or when transformed with functional ALAS expression plasmids (Gong and 
Ferreira, 1995; Tan and Ferreira, 1996) the rescue of HU227 cells in a non-ALA 
supplemented medium indicates the production of a variant with ALAS activity.  Indeed, 
while HU227 cells harboring the ALAS homodimer or the single chain dimeric 
ALAS/ALAS can grow in a medium without ALA (Gong and Ferreira, 1995; Tan and 
Ferreira, 1996), HU227 cells overproducing the K313A homodimer cannot (Tan and 
Ferreira, 1996) (Table 3.2).  Both ALASK313A/ALAS and ALAS/ALASK313A variants 
retained function as indicated by the ability of transformed HU227 cells to grow when 
harboring either variant (Table 3.2).   
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Spectroscopic characterization of ALASK313A/ALAS and ALAS/ALASK313A.   
Although, as previously reported (Zhang, Cheltsov et al., 2005), the UV/visible 
absorbance spectra for both ALAS and the single chain dimeric ALAS/ALAS exhibited 
the characteristic maxima for PLP-dependent enzymes at ~330 and ~420 nm, the 
prominence of these absorbance bands varied between the spectra of the two proteins 
(Figure 3.2).  The absorbance band at ~420 nm was more prominent in the spectrum of 
ALAS/ALAS than that of ALAS, whereas the absorbance band at 330 nm was less 
distinct in ALAS/ALAS.  Indeed, at pH 7.5, the ratio of the 420 nm to 330 nm 
absorbance changed from 0.44 for ALAS to 0.67 for ALAS/ALAS (Figure 3.2).  
Similarly, the UV/visible absorbance spectra of the ALASK313A/ALAS and 
ALAS/ALASK313A variants retained the characteristic maxima at ~330 and ~420 nm 
while the prominence of the two absorbance bands varied, resulting in a 420 to 330 nm 
absorption ratio of 0.35 and 0.58 at pH 7.5 for ALASK313A/ALAS and ALAS/ALASK313A, 
respectively. The ~330 and ~420 nm maxima were previously attributed to the substituted 
aldimine and ketoenamine forms of the internal aldimine  between PLP and the ε-amino 
group of K313, respectively (Zhang, Cheltsov et al., 2005). Clearly, the mutation of the 
lysine residue in either of the two active sites of ALAS/ALAS has unique affects on the 
environment of the PLP cofactor of each site.  These results indicate that each active site 
makes distinctive contributions to the UV/visible spectrum of the single chain dimeric 
ALAS/ALAS and that the linking of the two subunits of WT ALAS produces 
asymmetrical cofactor-binding sites in the single chain dimeric ALAS/ALAS. 
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Table 3.2: Growth of transformed E. coli strains on selective media 
 E. coli HU227 E. coli R872 
Plasmid Protein LB/Amp/ALA LB/Amp LB/Amp Biotin- minimal 
pGF23 ALAS + + + - 
pTDT1 AONS + - + + 
pGF27 ALASK313A + - + - 
pTDT8 ALASF341A + - + - 
pAC1 ALAS/ALAS + + + - 
pCA1 ALASK313A /ALAS + + + - 
pMG1 ALAS/ALASK313A + + + - 
pTDT5 ALAS/AONS + + + + 
pTDT4 AONS/ALAS + + + + 
pTDT12 ALASK313A /AONS + - + + 
pTDT17 AONS/ALASK313A + - + + 
pTDT14 ALASF341A /AONS + - + + 
pTDT15 AONS/ALASF341A + - + + 
pTDT7 ALAS /AONSK236A + + + - 
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FIGURE 3.2 
Absorption spectra of ALAS, ALAS/ALAS, ALASK313A/ALAS and ALAS/ALASK313A. 
The inset includes the region from 300–500 nm. Protein concentrations were adjusted to 
30 μM for ALAS/ALAS, ALASK313A/ALAS and ALAS/ALASK313A or 20 μM for ALAS 
in 20 mM Hepes, pH 7.5.  ALAS/ALASK313A (—), ALASK313A/ALAS (· · · ), 
ALAS/ALAS(--), and  ALAS (– · –). 
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Kinetic characterization of the ALASK313A/ALAS and ALAS/ALASK313A variants and 
determination of the dissociation constants for the binding of ALA.   
The steady-state kinetics of the ALASK313A/ALAS and the ALAS/ALASK313A 
reactions were examined, and the results are presented in Table 3.3.  Previously, it was 
reported that linking the two ALAS subunits into the single chain dimeric ALAS/ALAS 
resulted in over 5-fold and 28-fold increases in the kcat and SCoAcat m/k K values, respectively 
(Zhang, Cheltsov et al., 2005).  In addition, mutagenesis of K313, the active site residue 
involved in the Schiff base linkage with the PLP cofactor (Ferreira, Neame et al., 1993) 
and in catalysis (Hunter and Ferreira, 1999), to alanine rendered the “natural” ALAS 
homodimer into a variant of the enzyme (K313A) with no measurable ALAS activity 
(Ferreira, Vajapey et al., 1995; Hunter and Ferreira, 1999).  To determine the individual 
contribution of the two active sites to the overall steady-state activity of ALAS/ALAS, 
the steady-state kinetic parameters of the ALASK313A/ALAS and ALAS/ALASK313A 
variants, in which the K313A mutation was independently introduced in each of the two 
active sites, were determined (Table 3.3).  While the K313A mutation in 
ALASK313A/ALAS decreased the kcat 2.5-fold, the same mutation in ALAS/ALASK313A 
resulted in a 12.6-fold decrease of the kcat value.  Similarly, the catalytic efficiencies of 
ALASK313A/ALAS for glycine and succinyl-CoA were decreased approximately 2.9- and 
1.8-fold, respectively, whereas those of ALAS/ALASK313A were reduced approximately 
9- and 51-fold for glycine and succinyl-CoA, respectively.  If both active sites were to 
contribute equally to the steady-state activity of ALAS/ALAS, then a 50% reduction of 
the turnover number would be expected for the single chain dimer in which the enzymatic 
activity of one of the two active sites was impaired.  This seems to be the case for 
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ALASK313A/ALAS but not for the ALAS/ALASK313A variant.  These findings suggest that 
linking the N-terminus of one subunit to the C- terminus of the other subunit in 
ALAS/ALAS may have created strain that hindered the steady-state enzymatic activity of 
one of the active sites, and, consequently, produced a single chain dimer with unequal 
participation of the two active sites. 
 
 
 
 
Table 3.3: Summary of steady-state kinetic parameters for ALAS, 
ALAS/ALAS, ALAS/ALASK313A and ALASK313A/ALAS 
 catk  (min-1) 
Gly
mK  
(mM) 
Gly
cat m/k K  
(min-1mM-1)
SCoA
mK  
(μM) 
SCoA
cat m/k K  
(min-1μM-1) 
ALA
dK  
(μM) 
ALAS 10 ± 1a 23 ± 1a 0.43 ± 0.06a 2.3 ± 0.1a 4.3 ± 0.2a 25 ± 3a
ALAS/ALAS 55.4 ± 16.7 ± 0.2b 3.32 ± 0.04b 0.45 ± 0.03b 123 ± 8b 1.46 ± 0.01
ALAS/ALASK313A 4.4 ± 0.2 11.8 ± 2.8 0.37 ± 0.09 1.8 ± 0.3 2.4 ± 0.4 6.8 ± 1.1 
ALASK313A/ALAS 21.6 ± 0.7 14.8 ± 11.7 1.46 ± 0.17 0.32 ± 0.05 67.5 ± 10.8 2.3 ± 0.8 
a Data from ref (Gong, Hunter et al., 1998).  b Data from ref (Zhang, Cheltsov et al., 2005). 
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Pre-steady-state burst experiments for ALASK313A/ALAS and ALAS/ALASK313A.   
Similarly to the ALAS-catalyzed reaction, the rate-limiting step for the single chain 
dimeric ALAS occurs after catalysis and is proposed to be associated with a protein 
conformational change associated with ALA release (Zhang, Cheltsov et al., 2005).  To 
determine if the rate-limiting step of the reactions catalyzed by the K313A single chain 
dimeric variants occurs after the chemical step and to compare the amount of ALA 
produced in the first turnover of the ALASK313A/ALAS and ALAS/ALASK313A reactions 
with that generated in the ALAS/ALAS first turnover, pre-steady-state burst experiments 
using chemical quenched-flow were performed (Figure 3.3).  The reaction of 
ALASK313A/ALAS with saturating glycine and succinyl-CoA occurred with a burst in 
ALA production at a rate of 30.6 ± 4.2 s-1, whereas the first turnover of the 
ALAS/ALASK313A reaction was at a rate of 45.1 ± 6.1 s-1.  These burst rates are similar to 
the burst rate previously reported for the ALAS/ALAS reaction, 48.6 ± 6.1 s-1 (Zhang, 
Cheltsov et al., 2005).  Another important piece of information provided by the burst 
experiments shown in Figure 3.3 relates to the burst amplitudes, representing the 
concentration of ALAS active sites for the reactions.  The burst amplitudes were 
0.25/active site and 0.21/active site for ALASK313A/ALAS and ALAS/ALASK313A, 
respectively, nearly 50% less than the burst amplitude previously determined for 
ALAS/ALAS, 0.49/active site (Zhang, Cheltsov et al., 2005).  These results are consistent 
with ALASK313A/ALAS and ALAS/ALASK313A possessing half-sites of the ALAS/ALAS 
reactivity.  Further, given that the number of the active sites of either ALASK313A/ALAS 
or ALAS/ALASK313A is roughly 50% of that of ALAS/ALAS, the results also indicate 
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that the different contributions of each of the two active sites of ALAS/ALAS to its 
steady-state activity emanate from a step occurring after chemistry. 
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FIGURE 3.3 
 Kinetics of a pre-steady-state burst of ALA product in the ALAS/ALASK313A and 
ALASK313A/ALAS reactions.  ALAS/ALASK313A (square) or ALASK313A/ALAS (triangle) 
(15 μM) preincubated with glycine (200 mM) was quickly reacted with succinyl-CoA 
(150 μM) at 20°C.   The concentrations shown in parentheses are final concentrations 
after mixing.  The reactions were quenched with 0.14 M perchloric acid at various aging 
times, and the ALA concentration was determined.  The inset illustrates the first 0.3 
seconds of the the reaction time course.  The curves represents the best fits to equation 1 
with a burst amplitude of 6.27 ± 0.36 μM and a burst rate of 45.1 ± 6.1 s−1 for 
ALAS/ALASK313A and a burst amplitude of 7.50 ± 0.31 μM and a burst rate of 30.6 ± 4.2 
s−1 for ALASK313A/ALAS.    
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Biological screening for ALAS and AONS function.   
The determination of the crystallographic structures of ALAS (Astner, Schulze et 
al., 2005) and AONS (Alexeev, Alexeeva et al., 1998) confirmed the prediction drawn 
from the high degree of sequence similarity between ALAS and AONS (37%) that these 
two α-oxoamine synthases have similar 3D fold and active site architecture.  To extend 
our studies on the plasticity of the PLP-binding and active site of ALAS to other 
members of the α-oxoamine synthase family, chimeras of ALAS and AONS and 
chimeras of singly-mutated ALAS variants and AONS were constructed (Table 3.1 and 
Figure 3.1).  The two major objectives were 1) to determine whether the chimeras retain 
ALAS and AONS activities and 2) to examine the active site arrangement in the 
ALAS/AONS chimera. Both ALAS/AONS and AONS/ALAS exhibited ALAS and 
AONS activities as assessed by the positive genetic complementation of hemA- HU227 
and bioF- R872 cells, which are ALA/heme (Sasarman, Surdeanu et al., 1968; Li, 
Brathwaite et al., 1989) and biotin auxotrophes (Del Campillo-Campbell, Kayajanian et 
al., 1967), respectively (Table 3.2).  From these in vivo activity assays, ALAS/AONS and 
AONS/ALAS appear to be bifunctional enzymes (i.e. ALAS and AONS activities).  
 To start addressing the question related to the active site arrangement of ALAS/AONS 
chimera, directed-mutagenesis of critical residues in ALAS and AONS had to be 
established.  K236 of E. coli AONS, the conserved active site lysine involved in PLP 
binding and catalysis (Webster, Campopiano et al., 1998), corresponds to K313 of murine 
ALAS (Ferreira, Vajapey et al., 1995; Hunter and Ferreira, 1999). Thus, when the K236A 
mutation was introduced in the AONS homodimer, bioF- R872 cells did not grow in a 
medium without biotin (data not shown), similar to the absence of growth of hemA- 
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HU227 cells overproducing ALASK313A when plated onto a medium lacking ALA (Table 
3.2).  The crystal structure of the R. capsulatus ALAS homodimer revealed that amino 
acids of the two polypeptide chains contribute to the same active site, which is located at 
the dimer interface (Astner, Schulze et al., 2005).  For example, F276 (R. capsulatus 
ALAS numbering or F341 in the equivalent murine erythroid ALAS numbering), a 
phenylalanine crucial for interaction with the pantetheine moiety of CoA, and the lysine 
involved in the Schiff base linkage participate in the architecture of the same active site 
but reside in different polypeptide chains.  Of significance to this study, F341 is critical to 
ALAS function, as the F341A mutation abolished the production of ALA necessary to 
sustain growth of HU227 cells on a selective medium (Table 3.2).  Thus, while K313 and 
F341 are critical for function of the murine erythroid ALAS homodimer, of the 
corresponding K236 and Y264 (Alexeev, Alexeeva et al., 1998), only K236 is essential 
for function in the E. coli AONS homodimer.   
 The three possible arrangements for the active sites of ALAS/AONS chimera are 1) 
formation of two active sites with the contribution of amino acids from one ALAS and 
one AONS polypeptide chains to each active site (Figure 3.4B) in an analogous 
arrangement to that of single chain dimeric ALAS/ALAS (Figure 3.4A); 2) formation of 
four active sites with the contribution of amino acids from one ALAS and one AONS 
polypeptide chains to each active site (Figure 3.4C); 3) formation of four active sites with 
two of the active sites being formed with only ALAS amino acids and the other two of 
the active sites with only AONS amino acids (Figure 3.4D), such that they represent WT 
ALAS- and AONS-like active sites.  While the first active site arrangement would result 
from one single, chimeric polypeptide chain (Figure 3.4B), the latter two active site 
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arrangements would arise from two chimeric polypeptide chains (Figures 3.4C and 3.4D).  
The determined molecular mass of ~182 KDa for the chimeric ALAS/AONS (see below 
and Figure 3.5) ruled against a single chain, dimeric ALAS/AONS and the active site 
arrangement depicted in Figure 3.4B.  To distinguish between the other two possibilities 
for the active site arrangement of the ALAS/AONS chimera (Figures 3.4C and 3.4D), an 
experimental approach involving the use of specific amino acid mutations targeted to 
abolish either ALAS or AONS function and biological selection systems (E. coli HU227 
and E. coli R872) was followed.  If the active site arrangement in Figure 3.4C were 
correct the K313A mutation would eliminate ALAS function in two of the four active 
sites, and the AONS residues in one or two of the remaining sites would have to  
complement the ALAS residues, yielding a chimeric protein with ALAS and AONS 
activities.  In contrast, with the active site arrangement presented in Figure 4D, the ALAS 
and AONS activities arise from WT ALAS- and AONS-like active sites, and thus a 
deleterious mutation of a critical active site residue in ALAS or AONS would produce a 
chimeric enzyme with impaired ALAS or AONS activity.  HU227 cells transformed with 
either pTDT12 or pTDT17 [i.e., expression plasmids for the ALAS/AONS chimera 
harboring the K313A mutation in ALAS (i.e., Table 3.1)] did not support the growth of 
these cells in an ALA-depleted medium (Table 3.2).  However, R872 cells harboring 
either of these two plasmids could grow in a medium without biotin.  A similar situation 
was observed with the chimeras ALASF341A/AONS and AONS/ALASF341A, in which the 
phenylalanine at position 341 of murine erythroid ALAS was substituted with an alanine 
(Table 3.2).  When the ALAS sequence was maintained intact and a mutation of the 
Schiff base linkage-lysine residue was introduced into AONS (i.e., K236A), the 
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generated chimeric proteins, AONSK236A/ALAS or ALAS/AONSK236A, could rescue the 
growth of HU227 cells in a medium without ALA but not of R872 cells in a non-biotin 
supplemented medium (Table 3.2).  Taken together, these findings are consistent with the 
active site arrangement for ALAS/AONS depicted in Figure 3.4D, in which the active 
sites responsible for ALAS activity are built with ALAS residues, while those 
with AONS activity are made of AONS residues.  
Oligomeric state of the ALAS/AONS chimera.   
Although ALAS/AONS and AONS/ALAS could be overproduced as active 
chimeric enzymes in E. coli DH5α cells (data not shown), only ALAS/AONS could be 
purified.  Poor solubility and low stability were among the factors preventing the 
purification of AONS/ALAS.   
The molecular mass of each subunit of the WT ALAS and WT AONS 
homodimers is ~56 and ~40 kD, respectively.  Thus a single chimeric subunit, derived 
from the fusion of an ALAS and AONS polypeptide, is expected to be ~96 kD.  This is in 
agreement with the molecular mass estimated by SDS-PAGE (Figure 3.5, inset).  The 
molecular mass of the native ALAS/AONS chimera was determined to be ~182 kD 
(Figure 3.5), consistent of a “homodimer” of ~96 kD subunits.  Further, coupled enzyme 
assays confirmed that the 182-kD protein exhibits both ALAS and AONS activities, 
indicating that the ALAS/AONS chimera is bifunctional as a homodimer of two ~96 kD 
chimeric polypeptide subunits. 
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FIGURE 3.4   
Schematic representation illustrating the active site active site arrangement for 
ALAS/ALAS and possible active site arrangements for ALAS/AONS.  Red bars 
represent ALAS polypeptide chains, with the essential active site residues K313 and 
F341 from one single polypeptide chain contributing to separate active sites.  Green bars 
represent AONS polypeptide chains, with the essential active site residues K236 and 
Y264 from one single polypeptide chain contributing to separate active sites.  In (A) and 
(B), there are two active sites per single chain dimer, whereas in (C) and (D), there are 
four active sites per chimeric ALAS/AONS dimer.  (A) Active site arrangement of the 
ALAS/ALAS “single chain dimer”.  (B) - (D) Possible active site arrangements for 
ALAS/AONS.  (B) ALAS/AONS single chain dimer.  (C) ALAS/AONS chimeric dimer 
with “hybrid” active sites comprised of both ALAS and AONS residues.  (D) 
ALAS/AONS chimeric dimer with two of the active sites containing only ALAS residues 
and the other two active sites containing only AONS residues.  
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Spectroscopic characterization of AONS and ALAS/AONS.  
 At pH 7.5, absorbance maxima at ~330 and ~420 nm were also observed in the 
ALAS/AONS chimera (Figure 6A).   Because the UV-visible spectra of both ALAS and 
AONS exhibited maxima at 330 nm and 420 nm, their fluorescence spectra were 
examined for distinctive features among ALAS, AONS and ALAS/AONS.  With 
excitation at 420 nm, the PLP cofactor of either ALAS or AONS exhibited a fluorescence 
emission maximum at 510 nm for ALAS and AONS (Figure 6B), albeit the magnitude of 
the 510 nm fluorescence emission maximum was more than three times greater for the 
AONS cofactor than  that of ALAS.  Similar to AONS and ALAS, the PLP cofactor of 
the ALAS/AONS chimera exhibited a fluorescence emission maximum at 510 nm upon 
excitation at 420 nm, and the magnitude of this fluorescence emission maximum fell 
between the values observed for the PLP cofactor of ALAS and AONS (Figure 6B).  
Upon excitation at 330 nm, the fluorescence emission spectra of ALAS and AONS 
exhibited maxima at 385 nm and 430 nm, respectively, while the fluorescence emission 
spectrum of the ALAS/AONS chimera displayed a broad emission band between 385 nm 
and 430 nm (Figure 6C).    
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FIGURE 3.5  
Determination of the molecular mass of the ALAS/AONS chimera by gel filtration 
chromatography.  ALAS/AONS (5 mg) was applied to a Pharmacia Sephadex 200 
filtration column and eluted with 20 mM potassium phosphate buffer containing 10% 
glycerol at 4 0C and pH 7.5 (flow rate 1.0 mL/min).  The molecular mass calibration 
curve for the Superdex 200 column using cytochrome c (12.4 kDa), carbonic anhydrase 
(29.0 kDa), ovalbumin (45 kDa), bovine serum albumin (66.0 kDa), alcohol 
dehydrogenase (150.0 kDa), and β-amylase (200.0 kDa) as protein standards (indicated 
by circles).  The ALAS/AONS chimera is indicated by a triangle. (Inset) 12.5% SDS-
PAGE of the purified ALAS, AONS and ALAS/AONS chimera, which as were detected 
using Coomassie Brilliant Blue staining.  Approximately 5 μg of each protein sample was 
loaded per lane. 
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FIGURE 3.6  
Absorption and fluorescence spectra of ALAS, AONS and ALAS/AONS.  (A) UV-
visible absorption spectra.  The inset includes the region from 300–510 nm.    
Fluorescence emission spectra upon excitation at (B) 420 nm and (C) 330 nm and 
fluorescence excitation spectra upon emission at 510 nm (inset B) and 385 nm (inset C).  
For absorption spectra, protein concentrations were adjusted to 15 μM (AONS and 
ALAS) or 7.5 μM (ALAS/AONS) and for fluorescence spectra, protein concentrations 
were adjusted to 4 μM (AONS and ALAS) or 2 μM (ALAS/AONS) in 20 mM Hepes, pH 
7.5 containing 10% glycerol.  For (A) – (C), AONS (--), ALAS (—), and ALAS/AONS (– 
· –).    
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Steady-state and transient kinetics of ALAS/AONS.  
 To examine the ALAS and AONS activities of the ALAS/AONS chimera, the 
steady-state kinetic parameters of the chimeric protein associated with both activities 
were determined using substrates for ALAS and AONS (Tables 3.4 and 3.5).  Regarding 
the ALAS activity, the kcat decreased almost 40%, the catalytic efficiency for glycine 
increased ~1.4-fold, and the catalytic efficiency for succinyl-CoA remained virtually the 
same relative to ALAS (Table 3.4).  With respect to the AONS activity, while the value 
for kcat decreased approximately 50%, the catalytic efficiencies towards alanine and 
pimeloyl-CoA of the ALAS/AONS chimera were similar to those of AONS (Table 3.5).       
 Using chemical quenched-flow, pre-steady-state experiments of the ALAS 
reaction were performed to examine the extent of ALA production by ALAS/AONS and 
ascertain the reactivity of the ALAS active sites in the ALAS/AONS chimera (Figure 
3.7).  The time course associated with ALA formation was biphasic and is described by a 
burst phase with a rate of 13.2 ± 2.6 s-1 and a steady-state rate of 0.015 s-1.  While the 
values for the burst and the steady-state rates were approximately 70% and 50% of those 
previously determined for the ALAS-catalyzed reaction (Zhang, Cheltsov et al., 2005), 
the burst amplitude of 0.10/active site was similar to that formerly observed with ALAS 
(Zhang, Cheltsov et al., 2005).  Significantly, the ~50% decrease in the value of the 
steady-state rate agrees with that inferred from the experiments performed under steady-
state conditions (above).  Thus, the reactivity of the ALAS sites in ALAS/AONS is 
similar to that of ALAS, and the diminished steady-state ALAS activity of the 
ALAS/AONS chimera in relation to that of ALAS must arise from a step occurring after 
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the reaction chemistry, presumably a strained protein conformational change associated 
with product release.       
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Table 3.4:  ALAS activity: Summary of steady-state kinetic parameters for ALAS 
and ALAS/AONS chimera 
 cat
k  
(min-1) 
Gly
mK  
(mM) 
Gly
cat m/k K  
(min-1mM-1) 
SCoA
mK  
(μM) 
SCoA
cat m/k K  
(min-1μM-1) 
ALASa 10 ± 1 23 ± 1 0.43 ± 0.02 2.3 ± 0.1 4.3 ± 0.2
ALAS/AONS 6.2 ± 0.8 5.5 ± 0.8 1.1 ± 0.2 1.5 ± 0.2 4.1 ± 0.7
a Data from ref (Gong, Hunter et al., 1998) 
Table 3.5: AONS activity: Summary of steady-state kinetic parameters for AONS 
and ALAS/AONS chimera 
 catk  
(min-1) 
Alanine
mK  
(mM) 
Alanine
cat m/k K  
(min-1mM-1) 
PCoA
mK  
(μM) 
PCoA
cat m/k K  
(min-1μM-1) 
AONSa 3.6 ± 0.6 0.5 ± 0.4 7.2 ± 1.3 25 ± 2 0.14 ± 0.03 
ALAS/AONS 1.7 ± 0.3 0.25 ± 0.05 6.8 ± 1.8 10 ± 1 0.16 ± 0.03 
a Data from ref (Webster, Alexeev et al., 2000)   
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Figure 3.7  
Kinetics of a pre-steady-state burst of ALA product in the ALAS/AONS reaction.  
ALAS/AONS (50 μM) preincubated with glycine (140 mM) was quickly reacted with 
succinyl-CoA (150 μM) at 20°C.  The concentrations shown in parentheses are final 
concentrations after mixing.  The reactions were quenched with perchloric acid (0.14 M) 
at various aging times, and the ALA concentration was determined.  The inset illustrates 
the reaction time course, while the first 0.7 seconds of the reaction are shown in a larger 
plot.   The first 0.7 s of the time course is expanded while in the inset the time course is 
extended to 3.0 s.  The curve represents the best fit to equation 1 with a burst amplitude 
of 4.7 ± 0.4 μM and a burst rate of 13.2 ± 2.6 s−1.  
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Discussion 
ALAS and other fold-type I PLP-dependent enzymes function as homodimers 
with two active sites per dimer; each active site is created at the interface between the two 
monomeric subunits (Christen and Mehta, 2001; Eliot and Kirsch, 2004).  The crystal 
structure of the R. capsulatus ALAS holoenzyme revealed that the enzyme symmetrically 
binds two PLP molecules, one at each active site (Astner, Schulze et al., 2005).  
Previously, we demonstrated that linking the two subunits of ALAS into a single 
polypeptide chain yielded a more-active enzyme that functioned as a single-chain dimer 
(Zhang, Cheltsov et al., 2005).  Although linking the N-terminus of one subunit and the 
C-terminus of the adjacent subunit without the introduction of a polypeptide linker did 
not affect the global conformation, changes in the environment of the PLP cofactor 
altered the predominant tautomeric form of the internal aldimine, which contributed to 
the greater activity of the single-chain dimer (Zhang, Cheltsov et al., 2005).  However, it 
was not clear if these changes affected the enzymatic activity of each active site to a 
similar extent.  To determine whether the two active sites in ALAS/ALAS contribute 
equally to enzymatic activity, we characterized variants in which one of the two active 
sites had no measurable enzymatic activity due to a mutation of the conserved K313 
residue that binds to the cofactor.  
Spectral characterization of and ALAS/ALASK313A and ALASK313A/ALAS 
revealed asymmetric cofactor environments in the two active sites, which was reflected in 
the disproportionate kinetic behavior of the two sites.  In contrast to ALAS/ALAS and 
ALASK313A/ALAS, in which the steady-state rates increased 5-fold and 2-fold, 
respectively, relative to the values for WT ALAS, the steady-state rate decreased 
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approximately 50% for ALAS/ALASK313A.  The concentration of catalytically active sites 
in ALAS/ALASK313A and ALASK313A/ALAS was half that of the ALAS/ALAS but, 
unlike the variations observed in the steady-state rates, the chemical rates were similar in 
all three forms.  As with ALAS/ALAS and WT ALAS (Zhang and Ferreira, 2002; Zhang, 
Cheltsov et al., 2005), the pre-steady-state burst results for the two K313A variants were 
consistent with the rate-limiting step occurring after the reaction chemistry. 
In ALAS, the rate-limiting step has been ascribed to the opening of an active site 
loop that allows ALA release; the rate of this assigned loop opening closely corresponds 
to the steady-state rate (Zhang and Ferreira, 2002; Hunter, Zhang et al., 2007).  Thus, the 
variations observed in the steady-state kinetic parameters are likely to be due to 
alterations in the energy barrier for this conformational change required for ALA release.  
The ALAS crystal structure indicates that the N-terminus of one subunit and the C-
terminus of the adjacent subunit are located near the surface on opposite faces of the 
holoenzyme (Astner, Schulze et al., 2005).  The strain resulting from linking the remote 
N- and C-termini of two ALAS subunits in ALAS/ALAS appears to increase the barrier 
for product release at one site while decreasing the barrier at the other; that is, the steady-
state enzymatic activity is enhanced at one active site and hindered at the other. 
Consequently, the active sites contribute asymmetrically to enzyme function.  
Generally, the active sites in fold type I PLP-dependent enzymes are equivalent 
and independent (Eliot and Kirsch, 2004), although some examples of kinetic asymmetry 
have been documented. In glutamate-1-semialdehyde aminomutase (GSAM), allosteric 
interactions between active sites lead to inactivation of the site in one subunit by the 
activation of the site in the other subunit (Stetefeld, Jenny et al., 2006).  In aspartate 
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aminotransferase (AAT), dissimilar lattice contact in the crystalline enzyme contributes 
to kinetic asymmetry in the active sites, although the active sites display kinetic 
equivalence in solution (Kirsten, Gehring et al., 1983).  In addition, heterodimeric 
variants created for a number of complementation studies have contained asymmetric 
active sites (Onuffer and Kirsch, 1994; Tan and Ferreira, 1996; Tan, Harrison et al., 
1998; Tarun and Theologis, 1998), but the creation of ALAS/ALAS is the first example 
of engineered active site asymmetry without the introduction of active site mutations in 
fold-type I PLP-dependent enzymes.  
Despite the unequal steady-state rates in the functioning active sites of 
ALAS/ALASK313A and ALASK313A/ALAS, we would expect the total activity of the two 
variants to be similar to ALAS/ALAS, in which both sites contribute to enzyme function.  
Clearly, this was not the case.  The total steady-state activities for the two K313A 
variants was only about 50% of the activity observed in the non-mutated single-chain 
dimer, suggesting that the enzymatic activity of at least one active site is impaired by the 
elimination of the Schiff base linkage between K313 and the PLP cofactor at the adjacent 
site.  Conversely, studies in the unlinked ALASK313A and ALASR149A heterodimer,  
containing one nonactive site with both K313A and R149A mutations and one WT 
catalytically active site, show that the variant heterodimer retained approximately 50% of 
the activity observed in the ALAS homodimer (Tan and Ferreira, 1996); that is, the WT 
active site was not significantly affected by mutations at the adjacent site.  Thus, linking 
the termini of the two ALAS subunits likely altered the intermolecular dynamics such 
that movement at one site can be transmitted to the adjacent site.   
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Because the single-chain ALAS dimer showed structural plasticity and had 
increased activity, we wondered whether the structural plasticity would extend to single-
chain chimeras constructed from two members of the α-oxoamine synthase family, 
ALAS and AONS.  We also hypothesized that it might be possible to generate an enzyme 
with novel activity by creating hybrid ALAS/AONS active sites.  In vivo assays indicated 
that the ALAS/AONS and AONS/ALAS chimeras possessed both ALAS and AONS 
activities.  Thus, the chimeric protein had sufficient structural plasticity to achieve the 
conformations necessary to produce both enzymatic activities.  The linking of two ALAS 
subunits did not significantly affect the dimeric interface or the folding of the core in the 
individual subunits, and the dissociation of the dimeric interface of ALAS and the 
ALAS/ALAS single-chain dimer exhibited similar free energies and resulted in stable 
intermediates that retained a substantial amount of their secondary and tertiary structure 
(Cheltsov, Barber et al., 2001; Cheltsov, Guida et al., 2003).  Similarly, we would not 
expect the linking of ALAS and AONS to strongly affect the folding core or subunit 
interface of the two domains, and it is not surprising that the two domains retained their 
overall structural character given that the entire ALAS and AONS polypeptides were 
used in the creation of the chimeras.  
Despite our initial hypothesis that the chimeric protein would create chimeric 
active sites with potentially novel enzymatic activities, both ALAS/AONS and 
AONS/ALAS appeared to function as chimeric homodimers with functionally 
independent ALAS and AONS modules.  In these modules, two active sites exhibiting 
ALAS activity were built exclusively with ALAS residues, and two active sites 
with AONS activity were built with AONS residues (Figure 3.4D).  Nonetheless, the 
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dimerization of two chimeric polypeptides into a bifunctional homodimer with 
functionally independent ALAS and AONS modules suggests that the structural plasticity 
observed in ALAS can be extended to other members of the α-oxoamine synthase family.  
It is possible that creating a chimera from individual domains of each protein (for 
example, the N-terminal domain of ALAS and the catalytic and C-terminal domains of 
AONS) would produce a functional hybrid, but this remains to be tested.  
Although we succeeded in expressing both the ALAS/AONS and AONS/ALAS 
chimeras as active enzymes, we were only able to purify the ALAS/AONS chimera.  The 
molecular mass of the native ALAS/AONS chimera was consistent with that of a 
homodimer containing two chimeric polypeptide subunits.  The fluorescence spectra 
exhibited by the ALAS/AONS chimera were distinct from those of ALAS and AONS 
and were consistent with an enzyme exhibiting a mixture of ALAS and AONS 
spectroscopic characteristics.  The ALAS and AONS steady-state kinetic activities were 
diminished by roughly one-half in the chimera, and the catalytic efficiencies were not 
impaired.  The pre-steady-state kinetic analysis for the ALAS reaction demonstrated that 
the reactivity of the ALAS sites in ALAS/AONS was similar to that of ALAS, with the 
rate-limiting step occurring after catalysis.   
The linking of two proteins or functional domains in natural and de novo fusion 
proteins generally involves a peptide linker (Gokhale and Khosla, 2000; Arai, Ueda et al., 
2001; Wriggers, Chakravarty et al., 2005).  A primary goal of linker engineering is to 
effectively separate the two functional domains to avoid intermolecular strain and prevent 
unwanted interactions between the two modules (Carlsson, Ljung et al., 1996; Seo, Koo 
et al., 2000; Arai, Ueda et al., 2001; Arai, Wriggers et al., 2004; Wriggers, Chakravarty et 
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al., 2005).  Because our objective was to facilitate interaction between the subunits of 
ALAS/ALAS and the AONS and ALAS chimeras, only two amino acids (Glu-Leu), 
which were introduced with the construction of a restriction site between the cDNAs, link 
the two subunits.  Like both ALAS single-chain dimeric variants, the linking of the 
ALAS and AONS subunits appeared to change the energy barrier associated with the 
structural rearrangement that occurs upon ALA formation to allow product release.  It is 
likely that the use of the short dipeptide to link the ALAS C-terminus with the N-
terminus of either ALAS or AONS introduced intermolecular strain which altered 
conformational flexibility.  
 Remarkably, the strain introduced with the short linker did not significantly 
impair the catalytic efficiencies in the any of the fusion proteins.  In fact, the catalytic 
efficiency for succinyl-CoA increased roughly 15- and 30-fold in ALASK313A/ALAS and 
ALAS/ALAS, respectively (Table 3.3).  The short linker also appears to have facilitated 
interdomain communication in the single-chain dimeric variants, allowing changes at one 
site to be propagated to the adjacent site.  Generally, efforts are made to avoid the 
introduction of strain when engineering hybrid proteins; however, with the increased use 
of high-throughput protein engineering, the introduction of intermolecular strain through 
linker domains may be a reasonable approach to creating new proteins with enhanced or 
novel functions.   
In summary, we have shown that the two active sites in the ALAS/ALAS single-
chain dimer make asymmetrical steady-state contributions to the activity of the enzyme.  
This and the reduced steady-state activity of the single-chain chimeras of ALAS and 
AONS relative to the parent enzymes are likely to be caused by differences in 
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conformational changes at product release, which in turn are due to the strain introduced 
by joining the two subunits without a linker region.  Although the chimeric ALAS/AONS 
and AONS/ALAS proteins did not form hybrid active sites, they were able to form 
dimers with separate regions of ALAS and AONS activity.  Thus, the extensive structural 
plasticity seen in ALAS extends to another member of the α-oxoamine family, AONS. 
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Chapter Four 
 
Histidine-282 in 5-Aminolevulinate Synthase Affects Substrate Binding and 
Catalysis 
 
Abstract 
5-Aminolevulinate synthase (ALAS), the first enzyme of the heme biosynthetic 
pathway in mammalian cells, is member of the α-oxoamine synthase family of pyridoxal 
5’-phosphate (PLP)-dependent enzymes.  In all structures of the enzymes of the α-
oxoamine synthase family, a conserved histidine hydrogen bonds with the phenolic 
oxygen of the PLP cofactor and may be significant for substrate-binding, PLP-
positioning, and maintaining the pKa of the imine nitrogen.  In ALAS, replacing the 
equivalent histidine, H282, with alanine reduces the catalytic efficiency for glycine 450-
fold.  The slow phase rate for glycine binding is decreased 60%, while the overall Kd 
increased 4.5 fold.  The distribution of the absorbing 420 and 330 nm species was altered 
with an increased A420/A330 ratio from 0.45 to 1.05.  This shift in species distribution 
was mirrored in the cofactor fluorescence and 300 to 500 nm circular dichroic spectra and 
likely reflects variation in the tautomer distribution of the holoenzyme.  The 300 to 500 
nm circular dichroic spectra of ALAS and H282A diverged in the presence of either 
glycine or aminolevulinate indicating that the reorientation of the PLP cofactor upon 
external aldimine formation is impeded in H282A.  Alterations were also observed in the 
Gly
dK  value and spectroscopic and kinetic properties, while the 
PLP
dK  increased 9-fold.    
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Altogether, the results imply that H282 coordinates the movement of the pyridine ring 
with the reorganization of the active-site hydrogen bond network and acts as a hydrogen 
bond donor to the phenolic oxygen to maintain the protonated Schiff base and enhance 
the electron sink function of the PLP cofactor.  
 
Introduction 
Heme is an essential tetrapyrrole in nearly all living cells, and all tetrapyrroles are 
biosynthesized from the same precursor, 5-aminolevulinic acid (ALA). In mammals, 5-
aminolevulinate synthase (ALAS, EC 2.3.1.37) catalyzes the condensation of glycine and 
succinyl-CoA to form ALA, CoA, and carbon dioxide, in the first and regulatory step of 
heme biosynthesis. Mammals express genetically distinct erythroid and housekeeping 
ALAS isoforms, and mutations in the erythroid specific ALAS have been implicated in 
X-linked sideroblastic anemia, a disease characterized by inadequate formation of heme 
and the accumulation of iron in the erythroblast mitochondria (May and Bishop, 1998).   
ALAS belongs to a catalytically versatile class of enzymes that require pyridoxal 
5’-phosphate (PLP) as a cofactor (Ferreira and Gong, 1995).  PLP-dependent enzymes 
that catalyze reactions involving amino acids share common mechanistic characteristics 
based on utilization of the electron withdrawing properties of the cofactor to labilize 
bonds to the substrate α-carbon (Christen and Mehta, 2001).  Specifically, the PLP 
cofactor covalently binds to the ε-amino group of an active site lysine via a Schiff base 
linkage to form the “internal aldimine.”  The incoming amino acid substrate replaces the 
lysine amino group to form an “external aldimine” via a gem-diamine intermediate, in a 
reaction often referred to as transaldimination.  Subsequently, the cleavage of one of the 
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substrate α-carbon bonds leads to a resonance-stabilized quinonoid intermediate in which 
the coenzyme acts an electron sink, storing electrons from the cleaved bond through the 
conjugated system of the Schiff base and pyridinium ring.  Ultimately, the electrons are 
dispensed back for the formation of new linkages to the Cα (Christen and Mehta, 2001). 
PLP-dependent enzymes have been classified according to reaction specificity 
relative to the Cα (Mehta and Christen, 1994) and fold-types derived from three-
dimensional structures (Alexander, Sandmeier et al., 1994; Eliot and Kirsch, 2004). 
ALAS is classified within the α-oxoamine synthase sub-family of the α- within class II 
of fold type I of PLP-dependent enzyme superfamilies (Schneider, Kack et al., 2000).  In 
all known structures of fold-type I, the pyridine ring of the PLP cofactor superimposes 
very well (Kack, Sandmark et al., 1999). The pyridoxal moiety interacts with the enzyme 
in a common motif, which includes the previously mentioned Schiff base linkage with an 
active site lysine, a salt-bridge between the pyridinium ring nitrogen and an aspartate, and 
a hydrogen bond with the phenolic oxygen which occurs through a variety of amino acids 
(Kack, Sandmark et al., 1999).  
In ALAS and other α-oxoamine synthase enzymes, the hydrogen bond of the 
phenolic oxygen involves a conserved histidine (Alexeev, Alexeeva et al., 1998; Schmidt, 
Sivaraman et al., 2001; Astner, Schulze et al., 2005) , which corresponds to H282 in 
murine erythroid ALAS (4.1).  No studies have examined the role of this residue in any 
α-oxoamine synthase family member, although based on structural data alone it has been 
suggested that it may function as an acid catalyst during transaldimination (Webster, 
Alexeev et al., 2000; Zhang, Cheltsov et al., 2005), play a key role in positioning the PLP 
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aromatic ring (Schmidt, Sivaraman et al., 2001), or influence the pKa of the imine 
nitrogen (Webster, Alexeev et al., 2000).   
Studies in other α-family enzymes indicate that the significance of interaction 
between the protein and the phenolic oxygen of PLP may vary according to the 
requirements of the enzyme.  In aspartate aminotransferase and 1-aminocyclopropane-1-
carboxylate synthase, the phenolic oxygen interacts with a tyrosine residue (Goldberg, 
Swanson et al., 1991; White, Vasquez et al., 1994). The deletion of the hydrogen bond 
through the replacement of the active site tyrosine with phenylalanine reveals a different 
function in the kinetic properties of each enzyme.  In aspartate aminotransferase, the 
tyrosine stabilizes the reactive form of the internal aldimine at physiological pH and 
increases the kcat value (Goldberg, Swanson et al., 1991; White, Vasquez et al., 1994). 
Similar studies of 1-aminocyclopropane-1-carboxylate synthase reveal that the tyrosine 
decreases the Km, but has no affect on kcat (White, Vasquez et al., 1994).  
In murine erythroid ALAS, H282 is tethered between PLP and Y121 through 
hydrogen bonds between the imidazole Nε2 and Nδ1, respectively (Figure 4.1).  Previous 
studies have demonstrated that the H-bond between the Y121 hydroxyl group and H282 
Nδ1 is important for efficient cofactor and substrate binding (Tan, Barber et al., 1998), 
providing evidence for a probable role for H282 in these interactions. The ordered ALAS 
catalytic pathway is comprised of the following steps (Scheme 4.1): the association of 
glycine with the enzyme forming the Michaelis complex (I); the transaldimination 
reaction between glycine and the active site lysine (K313) to generate the external 
aldimine (II); the removal of the pro-R proton to generate a transient quinonoid 
intermediate (III); the condensation of succinyl-CoA (IV); the removal of Co-A and the 
 142
formation α-amino-β-ketoadipate (V); decarboxylation of the α-amino-β-
ketoadipate(VI); the protonation of the second quinonoid intermediate (VII) and finally 
the releases of ALA (VII) (Zhang and Ferreira, 2002),(Hunter and Ferreira, 1999).  In 
order to characterize the role of the conserved histidine in murine erythroid ALAS 
function, a series of H282 variants were constructed.  The results provide evidence that 
H282 impacts a variety of ALAS functions including substrate and PLP binding and 
catalysis. 
Materials and Methods 
Materials 
The following reagents were purchased from Sigma-Aldrich Chemical Company: DEAE-
Sephacel, Ultrogel AcA-44, β-mercaptoethanol, PLP, bovine serum albumin, succinyl-
CoA, ALA-hydrochloride, α-ketoglutaric acid, α-ketoglutarate dehydrogenase, Bis-Tris, 
HEPES-free acid, AMPSO-free acid, MOPS, tricine, thiamin pyrophosphate, NAD+, and 
the bicinchoninic acid protein determination kit.  Glycerol, glycine, disodium 
ethylenediamine tetraacetic acid dihydrate, ammonium sulfate, magnesium chloride 
hexahydrate, perchloric acid, and potassium hydroxide were acquired from Fisher 
Scientific.  Sodium dodecyl sulfate polyacrylamide gel electrophoresis reagents were 
acquired from Bio-Rad.  Phenylhydrazine was from by Eastman Kodak. PD-10 columns 
were from Amersham Biosciences. Chameleon mutagenesis kit was from Stratagene. 
Xho I and Xba I restriction enzymes were from New England Biolabs. 
Methods 
Mutagenesis.  
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The pGF23 plasmid encoded the full-length sequence for the murine, mature 
erythroid ALAS.  Site-directed mutagenesis for the H282Y and H282F mouse ALAS 
mutant was performed on the single-stranded pGF23 using the chameleon mutagenesis 
kit from Stratagene.  The mutagenic oligonucleotides for H282Y and H282F were GAT 
GAA GTC TAT GCT TAT GCT GTA GGA CTG TAT GGA and GAT GAA GTC TTT 
GCT TAT GCT GTA GGA CTG TAT GGA, respectively, with the introduced codon 
substitutions underlined.  The H282A mutant was generated using the method previously 
described by Gong (1998).  Briefly, two rounds of PCR were performed to obtained DNA 
fragments with the desired mutation flanked by unique restriction sites.  The mutagenic 
primers used to generate the H282A mutation were 5’-GTA GAT GAA GTC GCT GCT 
GTA GGA CTG or 5’-GAG TCC TAC AGC AGC GAC TTC ATC TAC with the 
introduced codon substitution underlined.  The two fragments containing the mutation 
were used as megaprimers and amplified by a third round of PCR.  The product was then 
digested with Xba I and Xho I and subcloned into pGF23 vector.  Clones obtained after 
mutagenesis procedures were confirmed by sequencing.   
Protein purification, SDS-PAGE, protein determination and steady-state analysis    
  Recombinant murine erythroid ALAS and the H282A variant were purified from 
DH5α Escherichia coli bacterial cells containing the overexpressed protein as previously 
described (Hunter and Ferreira 1995).  Sufficient expression of H282Y and H282F 
variants could not be obtained.  Purity was determined by SDS-PAGE (Laemmli, 1970) 
and protein concentration determined by the bicinchoninic acid method using BSA as the 
standard (Smith, Krohn et al., 1985).  All protein concentrations are reported on the basis 
of a subunit molecular weight of 56,000 kD.  Enzymatic activity was determined by a 
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continuous spectrometric assay at 30oC (Hunter and Ferreira, 1995).  To evaluate the pH 
dependence of the kinetic parameters, assays were performed in 20 mM MOPS for pH 
6.7, HEPES for pH 7-8 or AMPSO for pH 8.2-9.5.  The pH dependences of log kcat and 
log kcat/Km were fit to equation 1, while the pH dependence of log 1/Km was fit to 
equation 2.  
 
Equation 1 
Equation 2 
 
Spectroscopic measurements.  
Prior to spectroscopic measurement, enzyme was dialyzed in 20 mM HEPES, pH 
7.5 with 10% glycerol to remove free PLP. Absorption spectra were acquired at ambient 
temperature using a Shimadzu UV 2100 dual beam spectrophotometer, with a reference 
containing all components except the purified enzyme.  Circular dichroism (CD) spectra 
were obtained using an AVIV CD spectrometer calibrated for both wavelength maxima 
and signal intensity with an aqueous solution of D-10 camphorsulfonic acid (Chen, 
1977).  Protein concentrations were 10-11 μM and 100 μM for the near and far CD 
spectra, respectively, in 20 mM Bis-Tris, pH 7.5 containing 10% glycerol.  Spectra were 
recorded in triplicate and averaged, using a 0.1 cm path length cuvette with a total 
volume of 300 μl.  Fluorescence spectra were collected on a Shimadzu RE-5301 PC 
spectrofluorophotometer using protein concentrations of 2-4 μM.  The pH was adjusted 
with 20 mM MOPS (pH range 6.7-7.0), 20 mM HEPES (pH range 7- 8.2), or 20 mM 
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AMPSO, (pH range 8.3-9.5).  10% glycerol was also included in the buffers.  CD and 
fluorescence blank spectra were collected from samples containing all components except 
protein immediately prior to the measurement of samples.  The blank spectra were 
subtracted from spectra of sample containing enzyme.  The pH dependence of the 510 
nm-fluorescence emission upon 420 nm-excitation was fit to equation 3. 
 
 
Equation 3              
                
Stopped-flow spectroscopy.  
Rapid scanning stopped-flow measurements were conducted using a model RSM-
100 stopped-flow spectrophotometer (OLIS Inc.  This instrument has a dead-time of 
approximately 2-ms and an observation chamber path length of 4 mm.  Scan spectra 
covering a wavelength range of 300-510 nm were collected at a rate of 1000 scans/s and 
then averaged to 62 scans/s to reduce data files to a manageable level.  The temperature 
of the syringes and the stopped-flow cell compartment was maintained at 30oC by an 
external water bath.  The concentration of glycine was always at least 10-fold greater 
than the enzyme concentration to ensure pseudo-first order kinetic were observed.  
For each experimental condition, three replicate experiments were performed. The 
ΔAbsorbance 420 nm were globally fit using the simulation software Dynafit to the 
binding models described in scheme 4.2 and 4.3  (Kuzmic, 1996).   
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Determination of dissociation constants of glycine and ALA.    
Dissociation constants were determined spectroscopically by monitoring spectral 
changes upon the binding of glycine and ALA (Gong, Hunter et al., 1998).  The Kd values 
for glycine from pH 6.7-9.5 were determined at 30 oC for ALAS and the H282A variant 
by monitoring the increase in cofactor absorbance at 420 nm upon glycine binding.  The 
pH was adjusted with 20 mM MOPS (pH range 6.7-7.0), 20 mM HEPES (pH range 7- 
8.2), or 20 mM AMPSO, (pH range 8.3-9.5).  10% glycerol was also included in the 
buffers.  Glycine was prepared as 2 M stocks adjusted to the same pH as the 
corresponding buffers.  Kd is defined by equation 4 where [Gly] and [Enz] are the 
concentrations of free glycine and free enzyme, respectively, and [Gly-Enz] represents 
the concentration of glycine-bound ALAS. 
 
Equation 4 
 
The changes in absorbance at 420 nm were plotted as a function of glycine 
concentration and the data were fit to equation 5 to determine Kd, where ΔAbs is the 
absorbance increase at 420, Absmax is the maximum increase in absorbance, and [Gly] is 
             k1                            k2 
E   ?   E G*   ?   E-G 
          k-1                         k-2
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the total glycine concentration. The pH dependence of Kd for ALAS was fit to equation 3 
and for H282A equation 6.  
 
Equation 5 
 
 
Equation 6 
 
 
    
The ALA Kd for the H282A variant was determined by monitoring the decrease in 
absorbance at 420 nm at 30oC in 20 mM HEPES, pH 7.5 and 10% glycerol.  Enzyme (25-
30 μM) solution was titrated with small aliquots of concentrated ALA solution, and the 
change in absorbance measured.  Data were analyzed by non-linear regression fitting to 
equation 7, where A is the observed absorbance, and Ai and Af are the fitted values of the 
initial and final absorbance, respectively.  [L] is the ligand concentration, and [E] is the 
enzyme concentration.  Determinations were made in duplicate and the reported values 
represent the mean and standard error of measurement. 
 
 
Equation 7 
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 Preparation of apoenzyme and determination of the PLP dissociation constant.  
To obtain H282A apoenzyme, 1 mg/ml enzyme in 20 mM HEPES pH 7.5, 
containing 20% glycerol was treated with 150 mM phenylhydrazine for 1.5 hours at 4oC, 
following which phenylhydrazine was removed by running the solution through a PD-10 
column.  The phenylhydrazine treatment was then repeated to ensure all PLP was 
removed. 
  The PLP Kd for the H282A variant was determined at 25oC by monitoring the 
PLP-dependent increase in 510 nm fluorescence emission upon excitation at 420 nm, in a 
buffer composed of 20 mM HEPES, pH 7.5 and 10% glycerol. To determine Kd, data 
were analyzed by non-linear regression fitting to equation 7, where A is the observed 
fluorescence, and Ai and Af are the fitted values of the initial and final fluorescence, 
respectively.   
 pH titration of quinonoid intermediate formation for H282A variant.  
The pH dependence of quinonoid intermediate formation was investigated with 
ALA saturated enzymes as described previously  (Gong, Hunter et al., 1998).  Equation 8 
was used to fit the quinonoid intermediate titration curves where Y is the observed 
absorbance at 510 nm, Ymax and Ymin are the theoretical maximal and minimal absorbance 
values at 510 nm, and pKa is the equivalence point for quinonoid intermediate formation. 
 
 
Equation 8                
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Results 
Spectroscopic properties of the H282A variant.   
At pH 7.4, three absorbance maxima at approximately 278, 330 and 420 nm are 
observed in both ALAS and the H282A variant (Figure 4.2A). The absorbance at 278 nm 
is primarily due to the protein, while the 330 nm and 420 nm maxima are common in 
PLP-dependent enzymes and are typically attributed to deprotonated and protonated 
aldimine species, respectively (Metzler and Metzler, 1987).  A similar assignment for 
ALAS is ambiguous because the spectrum is unchanged in the pH range 6.5-9.51.  The 
mutation had no discernable effect on the protein absorption band centered at 278 nm, but 
the cofactor absorption peaks were significantly altered.  The ratio of the 420 nm to 330 
nm absorbance was increased from 0.45 in the wild-type enzyme to 1.05 in the variant.   
 The changes in the absorption spectra were reflected in the fluorescence spectra 
(Figure 4.2B and C). Upon excitation at 330 nm ALAS exhibits only one maximum at 
385 nm, while in H282A the 385 nm fluorescence emission maximum is shifted to 410 
nm with a 6-fold decrease and a second maximum is observed at 510 nm.  With 
excitation at 420 nm, the cofactor exhibits fluorescence emission maximum at 510 nm for 
both enzymes; however the magnitude of the 510 nm emission was ~7 times greater in 
the H282A.  The pH titration of the species emitting at 510 nm upon excitation at 420 nm 
demonstrated that this species diminished as a result of loss of a single proton for both 
enzymes (Figure 4.3).  A fit of the data to equation 3 yield a pKa of 8.05 ± 0.043 and 9.02 
± 0.07 for ALAS and H282A, respectively.   
                                                 
1 G.C. Ferreira and G.A. Hunter, unpublished results 
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Kinetic characterization of the H282A variant.  
The steady-state kinetic parameters of the H282A variant were determined and 
the results are summarized in Table 4.1.  The mutation resulted in a kcat of 1.4% of the 
wild-type ALAS value.   The Km for glycine was increased 5-fold relative to ALAS, 
while the Km for succinyl-CoA was not significantly affected.  The overall catalytic 
efficiency for glycine and succinyl-CoA decreased 450-fold and 87-fold respectively as 
compared to ALAS values.  
If H282 acts as a hydrogen bond donor to the phenolic oxygen of the cofactor, 
then the H282A mutation may lower the pKa for the imine nitrogen.  To investigate this 
possibility the pH dependence of the steady-state kinetic parameters was studied, with the 
results summarized in Table 4.2 and Figure 4.4.  The log kcat vs. pH profile for H282A 
decreased on both the acidic and basic sides, and the best fit of the data to equation 1 
generated a pKa of 7.2 ± 0.1 for a residue in the enzyme-substrate complex that must be 
protonated for optimal catalysis.  A second pKa of 8.6 ± 0.1 for a residue that is 
deprotonated during catalysis was also observed for H282A, which shifted from the 
previously reported pKa of 9.1 ± 0.03 in ALAS (Zhang, Cheltsov et al., 2005).  The 
possibility of an acidic limb pKa, below 7.0, in the wild-type enzyme could not be 
investigated due to instability at pH values below 6.5-7.0 (Zhang, Cheltsov et al., 2005), 
but the available data do suggest that the H282A mutation results in a substantial increase 
to the pKa of an important enzyme-substrate complex ionization.  This ionization might 
be assigned directly to H282, or it could be assigned to the imine nitrogen that 
presumably shares a proton with the phenolic oxygen atom.  
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The log kcat/Km pH profile for the mutant was similar to that of the wild-type 
enzyme, decreasing on both the acidic and basic limbs.  Nonlinear regression of the data 
using equation 1 yielded a pKa for the acidic and basic limb of 8.00 ± 0.14 and 8.50 ± 
0.14 for H282A, which reflects a shift in the acidic limb from the at 8.60 ± 0.11 pKa 
value previously reported in ALAS (Zhang, Cheltsov et al., 2005).  The pH variation of 
the log 1/KmGly decreased with increasing pH for both enzymes.  The data were fit to 
equation 2 to generate a pKa of 8.36 ± 0.1 for ALAS and 7.76 ± 0.16 for the H282A 
variant.  The log kcat and log Glymcat /Kk  profiles limiting slopes of approximately 1 or -1 
indicate the ionization of a single group for acidic and basic limbs.  Given that glycine is 
not a sticky substrate and does not ionize over the pH range studied, the pKa observed for 
1/KmGly and the acidic limb of the log Glymcat /Kk  likely represents group(s) in the free 
enzyme.    
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aData from (Gong, 1998)
14 
(±4)
40 
(±4)
0.05 
(±0.002)
2.75 
(±0.07)
49 
(±5)
9.5 x10-4
(±0.06x10-4)
144 
(±7.7)
0.137 
(±0.003)H282A
1.6 
(±1)
25 
(±3)
4.35 
(±0.62)
2.3 
(±0.1)
22 
(±2)
0.4 
(±0.06)
23 
(±1)
10 
(±1)ALAS
a
(μM)(μM)(min-1μM-1)(μM)(mM)(min-1mM-1)(mM)(min-1)  Protein
Table  Summary of steady-state kinetic parameters and dissociation constants
Gly
mK
Gly
mcat Kk
Gly
dK
SCoA
mK
ALA
dK
PLP
dKcatk
SCoA
mcat Kk
 
 
 
 
 
Table 4.2: Summary of pK values obtained from the pH 
dependence of kinetic parameters 
   ALAS  H282A 
   pKa  pKa 
   1 2  1 2 
Log catk   nda (<6.7) 9.1±0.03  7.2±0.09 8.6 ±0.09
Log Gly
mK
1  8.4±0.10   7.8±0.16  
Log Gly
m
cat
K
k  8.6±0.11a 8.75±0.13b 8.0±0.14 8.5 ±0.14
Log GlydK   nd (<7)   7.4±0.2 8.1±0.2 
aData from  (12)   bData from (21)   
nd, not determined      
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Reaction of glycine with H282A variant.   
The reaction of 60 μM H282A variant with glycine resulted in an increased 
absorbance at 420 nm (Figure 4.5a).  The data best fit to the two step model described by 
scheme 4.2 (Figure 4.5b-c). A fit of the data yielded values for k1 of 0.001654 ± 3.8 x 10-
5 s-1, k-1 of 0.14 ± 0.0064 s-1,  k2 of 0.022 ± 0.0025 s-1, and k-2 of 0.0455 ±0.0016.  
Dissociation constants for the binding of glycine and ALA.   
To elucidate a potential role of H282 in substrate binding, the enzymes were 
titrated with glycine and ALA to determine the dissociation constants for formations of 
the external aldimine with the substrate and product.  At pH 7.5 the Kd for ALA and 
glycine increase 8.5-fold and 5-fold, respectively, relative to ALAS (Table 4.1).  To 
establish if the ionization of groups reflected in the kcat profiles are involved in substrate 
binding or catalysis, the pH dependence of Kd for glycine was determined.  The loss of 
the PLP-O3-H282 interaction also had a marked effect on the pH profile for the GlydK  
values.  For ALAS, the GlydK  decreases with increasing pH and, when fitted to equation 1, 
yielded a pKa value at the boundary of the pH range tested, therefore a pKa  < 7 was 
assumed.  In contrast, the KdGly for the H282A variant fit to a bell curve with pKa values 
at 7.4 ± 0.2 and 8.1 ± 0.2 (Figure 4.6).  The data indicate that the H282 mutation results 
in a substantial modification to the pKa of an enzyme-glycine complex ionization. 
pH titration of quinonoid intermediate formation for H282A variant.  
When ALAS is saturated with ALA, the external aldimine is converted to a 
quinonoid intermediate in a pH-dependent manner; the extent of this reaction can be 
monitored by following the absorbance of the quinonoid intermediate at 510 nm.  
Formation of the ALA-bound quinonoid intermediate in ALAS has been reported to 
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occur with an apparent pKa of 8.1 ± 0.1 (Gong, Hunter et al., 1998), and involves 
participation of the active site K313, which acts as a general base catalyst for the reaction 
by abstracting a proton from the ALA-aldimine to form the quinonoid intermediate 
(Hunter and Ferreira, 1999).  The ALA-bound quinonoid intermediate was observed to 
increase with pH for H282A as was observed previously in ALAS (Hunter and Ferreira, 
1999), although the amplitude of the absorption of the quinonoid intermediate was 
markedly diminished by the mutation at all pH values tested (Figure 4.7A).  pH titration 
of the H282A quinonoid intermediate absorbance demonstrated that the intermediate was 
formed as a result of loss of a single proton with an equivalence point at 8.8 ± 0.1 (4.7B).  
The higher pKa value in the variant indicates that one function of H282 is to lower the 
apparent pKa for quinonoid intermediate formation such that the PLP cofactor functions 
more effectively as an electron sink at physiological pH.  The observation that disruption 
of a hydrogen bond to the phenolic oxygen of the cofactor has a significant effect on 
quinonoid intermediate formation indicates that the equivalence point of 8.1 ± 0.1 
observed with ALAS is a complex function of the electronic interaction of the active site 
lysine with the ALA-PLP aldimine and its active site environment, and not simply 
reflective of an ionization constant for the active site lysine. 
CD spectroscopy.  The disruption of the H-bond between the phenolic oxygen and 
the enzyme could potentially alter the time-averaged orientation of the PLP cofactor in 
the active site. The circular dichroism in the UV-visible region reflects the PLP 
microenvironment by monitoring the asymmetry of the bound cofactor.  Formation of an 
external aldimine results in the reorientation of the PLP cofactor which can be followed 
with CD spectroscopy (Moore, Dominici et al., 1995).  Spectra of the holo- and ligand-
 155
bound enzymes were collected (Figure 4.8).   Spectra of the free enzyme exhibited 
positive dichroic bands at ~330 and 420 nm with an increase in the 420 nm band with an 
associated decrease in the ~330 nm band observed in the variant.  The addition of glycine 
to ALAS or H282A resulted in comparable decrease in the ~330 nm dichroic band, while 
the ~420 nm band decreased 75% in the variant and disappeared in the ALAS spectra.  
The addition of a saturating concentration of ALA to ALAS or H282A had strikingly 
different effects on the relative chiral environment of the external aldimine in the two 
enzymes.  Specifically, the ~330 nm dichroic band was decreased and the ~420 nm band 
disappeared in the ALAS spectra, while the addition of ALA to H282A resulted in a 
moderate increase in the 330 nm and little change to the ~420nm band.  The CD spectra 
for ALAS and H282A between the 200-300 nm were similar, indicating that no 
significant changes occurred in the overall conformation as a result of the mutation (data 
not shown).  
Dissociation constants for the binding of PLP.   
To address the role of H282 in cofactor binding, the effect of the H282 to alanine 
mutation on Kd of PLP was studied. The titration of the H282A apoenzyme with PLP 
leads to the reconstitution of the holoenzyme, which can be monitored by following 
changes in the intensity of fluorescence emission at 510 nm upon excitation at 420 nm 
(Figure 4.6).  Theoretical saturation curves were generated from which the dissociation 
constant of PLP from H282A was determined.  When compared to the wild-type enzyme, 
the Kd for PLP was increased ~9 fold by the H282A mutation, as reported in Table 4.1. 
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Discussion 
The crystal structure of Rhodobacter capsulatus ALAS reveals the existence of a 
hydrogen bond between H282 and the phenolic oxygen atom of the PLP cofactor (Astner, 
Schulze et al., 2005).  A clustal sequence alignment demonstrated that this histidine 
residue was perfectly conserved in over 70 known ALAS sequences from bacteria to 
mammals (data not shown).  The existence of one, and often two, hydrogen bonds 
between the enzyme and the PLP phenolic oxygen is common in fold type I PLP-
dependent enzymes, and is likely multifunctional.  The ALAS crystal structures suggest 
possible roles for H282 in binding and orientation of the cofactor within the active site, as 
well as control of the electronic status of the cofactor during catalysis(Alexeev, Alexeeva 
et al., 1998).  These possibilities led us to postulate that mutation of H282 should have 
multiple effects on substrate and cofactor binding, as well as catalysis.  In this 
communication, we constructed ALAS variants harboring the H282A, H282Y, and 
H282F mutations, of which only the H282A variant was recoverable as a soluble enzyme.  
The effects of the H282A mutation on the spectroscopic and kinetic properties of the 
enzyme were characterized in order to better understand the functional roles of H282 in 
the ALAS-catalyzed formation of ALA.  
The absorption spectra (Figure 4.2) indicate the mutation has a substantial effect 
on the electronics of the PLP cofactor.  A decrease in the absorbance of the 330 nm peak 
is accompanied by an increase in the absorbance of the 420 nm peak.  These changes are 
reflected in the cofactor fluorescence spectra.   In some transaminases, including 
aspartate aminotransferase and tyrosine aminotransferase, the corresponding absorbance 
peaks titrate as a function of pH with the long wavelength peak favored at low pH and the 
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short wavelength peak favored at high pH (Goldberg, Swanson et al., 1991; Chow, 
McElroy et al., 2004)   These are generally attributed to the ketoenamine and enolamine 
tautomers, respectively, which differ in the position of the proton shared between the 
phenolic oxygen and the Schiff base nitrogen atoms.  The changes in the absorbance 
spectra for H282A suggest that the mutation significantly alters the equilibrium of 
cofactor tautomeric structures to favor the ketoenamine, but this assignment is ambiguous 
because, unlike aspartate and tyrosine aminotransferases, the absorbance spectrum of 
ALAS is largely pH-independent and the H282A mutation did not alter this property 
(data not shown).   
In contrast to the absorption spectra, fluorescence spectra of ALAS upon 
excitation at 330 or 420 nm are pH-dependent (Zhang, Cheltsov et al., 2005). Upon 
excitation at 420 nm, the ALAS 510 nm fluorescence emission titrates with a single pKa 
of 8.05 ± 0.043, while in H282A a pKa of 9.02 ± 0.07 is observed under similar 
conditions (Figure 4.3).  The 385 nm fluorescence emission signal resulting from 
excitation at 330 nm, which occurs with a pKa of 8.4 ± 0.1 in the wild-type enzyme, is 
greatly diminished in the mutant, and an equivalent titration could not be performed. 
The two pKas observed in ALAS fluorescence spectra are presumably indicative 
of more complex chemistry than simple titration of the Schiff base nitrogen atom.  This is 
not unprecedented, as in dialkylglycine decarboxylase, three pKas are observed during 
absorbance spectra titrations, with both ketoenamine and enolamine species present in 
each ionization state (Zhou and Toney, 1999).  For both dialkylglycine decarboxylase and 
glutamate decarboxylase it has been proposed that the multiple ionizations observed 
reflect active site residues that regulate the distribution of ketoenamine and enolamine 
 158
tautomers through electrostatic effects (Chu and Metzler, 1994; Zhou and Toney, 1999).  
In ALAS, the ionizations observed in the fluorescence spectra, but not the absorption 
spectra, are also likely to be attributable to active site residues and not the Schiff base 
nitrogen.  Alterations observed in the H282A spectra may be due to changes in both 
tautomeric equilibria and the electrostatic interactions between the phenolic oxygen and 
other active site residues. 
The steady-state kinetic parameters of the variant indicate loss of H282 
interaction with the phenolic oxygen impairs both glycine binding and catalysis. The 
Gly
mK  increased 5-fold and the kcat decreased by two orders of magnitude.  Rapid-scanning 
stopped-flow analysis experiments were performed to further characterize the effect of 
the mutation.  A pre-steady-state burst of the quinonoid intermediate for the reaction of 
H282A-glycine and succinyl-CoA was not observed, presumably due to diminished 
absorption of the quinonoid intermediate that is typically observed with the wild-type 
enzyme (data not shown).   
The transimination reaction expected to occur during glycine binding involves 
nucleophilic attack of the protonated Schiff base internal aldimine by the deprotonated 
amine of glycine, to form a transient gem-diamine intermediate.  If the hydrogen bond 
donated by H282 to the phenolic oxygen of the cofactor is important in maintaining a 
protonated Schiff base, then the loss of this hydrogen bond in H282A might be expected 
to slow the rate at which glycine binds to the enzyme.  In the absence of succinyl-CoA, 
glycine binding to H282A is a two-step process (Figure 4.5).  Previous studies 
demonstrated that glycine also binds with ALAS in two steps; however, the rates 
associated with the fast phase were not slow enough to be resolved (Hunter and Ferreira, 
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1999).  The slow phase rate for H282A decreased 85% relative to ALAS.   The slower 
binding of glycine observed in H282A may be attributed to alterations in the electronic 
status of the Schiff base, but other interpretations are also possible.  One interesting 
possibility is that H282 is directly or indirectly involved in proton transfers that convert 
the internal aldimine and glycine to the reactive ionic states necessary to formation of the 
glycine external aldimine (Scheme 4.1, I).  In any case, these data, along with the data in 
Figure 4.6, indicate an important role for H282 in glycine binding.   
The pH-dependence of log kcat, log Glymcat /Kk  and log 1/
Gly
mK  were all diminished 
in H282A-catalyzed reaction, indicating that the mutation had severe catalytic 
consequences (Figure 4.4), but only the log kcat profile contained an ionization that was 
obviously changed by the mutation.  The appearance of a new pKa of ~7.3 for H282A in 
the acidic limb of both the log kcat and log GlydK , suggests that the mutation results in a 
substantial change to a pKa for the enzyme–glycine complex.  In ALAS kcat is known to 
be determined by release of ALA, or a conformational change associated with ALA 
release (Hunter and Ferreira 1999).  The appearance of an acid limb ionization in the log 
kcat vs. pH profile for H282A shifted the pH optimum from less than 6.5 to slightly over 
8.0, and indicates a change in the nature of the rate-determining step for catalysis, at least 
at lower pH values.  The further observation that a similar pKa is apparent in the log GlydK  
pH profile suggests that in H282A the rate-determining step at pH values less than 8.0 
may be associated with binding of glycine.   The ALAS spectroscopic pKa of 8.4 ± 0.1 
observed upon excitation at 330 nm is mirrored in the log 1/Km and the acidic limb of log 
kcat/Km pH profile of ALAS (Zhang, Cheltsov et al., 2005).  Although it was not possible 
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to titrate the equivalent species in the H282A spectra, the pH dependence of the log 1/Km 
and acidic log kcat/Km was shifted to ~7.9.  This ionization controls the reactive free 
enzyme species, and the disappearance or significant reduction of the equivalent species 
in the H282A spectrum suggests H282 stabilizes the reactive form of the internal 
aldimine. 
In ALAS, the binding of ALA results in the appearance of an ALA-quinonoid 
intermediate with a 510 nm absorbance (Gong, Hunter et al., 1998).  In H282A the 
addition of ALA results in a decrease in absorbance at 420 nm with an associated 
increase at 330 nm in addition to the appearance of a 510 nm absorbance, though the 
amplitude of the 510 nm absorption associated with the ALA-quinonoid species is 
markedly diminished. While Kd for ALA is minimally affected, the pKa of the ALA-
quinonoid intermediate is increased from 8.1 ± 0.1 in ALAS to 8.8 ± 0.1 in H282A.  The 
data suggest that proton abstraction from ALA is impaired in the variant.  One possible 
explanation is that the loss of the hydrogen bond between the phenolic oxygen and H282 
is likely to cause a net flow of electrons into the conjugated π-bond system, thereby 
disrupting the electron sink capacity of the cofactor.  
Additionally, it has been suggested that the process of ALA binding and 
quinonoid intermediate formation may involve some structural reorganization of the 
active site (Hunter and Ferreira, 1999).  In both the glycine and succinyl-CoA soaked R. 
capsulatus ALAS crystals, a 15o rotation of the pyridine ring around the C5-C5A bonds 
occurs such that the O3 and C4A atoms move away from the catalytic lysine (Astner, 
Schulze et al., 2005).  Upon the binding of product in AONS, a similar rotation of the 
pyridine ring occurs along with subtle rearrangement of the active site hydrogen bond 
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system (Webster, Alexeev et al., 2000) .  In ALAS, the movement of the O3 is tracked by 
the residue equivalent to H282 (Astner, Schulze et al., 2005), indicating H282 is probably 
involved in coordinating the movement of the pyridine ring with the reorganization of the 
hydrogen bond system occurring upon substrate binding.  H282 is tethered between the 
phenolic O3 of PLP and Y121 by way of hydrogen bonds between the imidazole Nε2 and 
Nδ1, respectively.  The loss of H282 hydrogen bonds with the cofactor and Y121 would 
likely affect the PLP movement and orientation within the active site that are presumably 
a crucial aspect of the catalytic process.   
The possibility that the PLP microenvironment is affected in solution by the 
H282A mutation was examined using CD spectroscopy, performed in the absence and 
presence of ALA or glycine.  The spectra for the ALAS and H282A holoenzymes are 
relatively similar and exhibit two positive dichroic bands around 330 and 420 nm (Figure 
4.8) which mirror the shift from the 330 to 420 nm species observed in the absorbance 
spectra (Figure 4.2).  In these holoenzyme spectra the cofactor is covalently anchored to 
the enzyme via the internal aldimine linkage with the active site lysine, and this 
attachment would be expected to maintain the orientation of the cofactor in the active 
site.  However, upon formation of an external aldimine with glycine or ALA, the 
attachment of the cofactor to the active site lysine is lost, and the resulting CD spectra 
diverge in the two enzymes.  Upon the addition of glycine, the 420 nm dichroic band 
disappears in ALAS, while the band continues to be observed in the H282A spectra (4. 
8). In ALAS, the binding of ALA results in the loss of the 330 nm band and a 
significantly diminished ~420 nm band.  In contrast, the binding of ALA to H282A 
results in a spectrum remarkably similar to the holoenzyme.  The divergence observed in 
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the ligand bound CD spectra of ALAS and H282A suggest that the reorientation of the 
PLP cofactor, observed with ALAS upon external aldimine formation, is blocked or 
diminished by the H282A mutation. This would influence both the cofactor position and 
interaction with key catalytic residues and could help explain the multiple effects caused 
by the mutation in the variant.  
In summary, H282 is involved in a hydrogen bond with the phenolic oxygen of 
the PLP cofactor.  The deletion of this interaction in the H282A variant has multiple 
effects on the spectral, binding, and kinetic properties of the enzyme that support the 
conclusion that H282 plays multiple roles in the enzymology of ALAS.  It may also be 
further concluded that the impaired function of the variant results from a combination of 
direct and indirect effects, including alterations in the protonation of the phenolic oxygen 
and changes to the stereoelectronic relationships between the cofactor and active site 
residues, through the disruption in the processional PLP positioning that normally occurs 
during catalysis.   
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FIGURE 4.1 
Spatial position of active site residues in the R. capsulatus ALAS holoenzyme crystal 
structure. This view highlights the interaction of the pyridinium ring of the cofactor with 
active site residues and the H282 imidazole Nε2 and Nδ1 hydrogen bonds between the 
cofactor phenolic oxygen and Y121.  The image was constructed using Pymol (DeLano 
2002) and PDB file 2BWN.  Residue numbering is relative to murine erythroid ALAS.  
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FIGURE 4.2 
Absorption and fluorescence spectra of ALAS and H282A variant.  (A) UV-visible 
absorption spectra. The inset includes the region from 250–300 nm.  Protein 
concentrations were adjusted to 13 μM in 20 mM Hepes, pH 7.5.  (B)  Fluorescence 
emission spectra of 5 μM ALAS and H282A in 20 mM Hepes, pH 7.5 containing 10% 
glycerol upon excitation at (B) 330 nm and (C) 420 nm.  For (A) – (C), ALAS (- -) and 
H282A (—).    
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FIGURE 4.3  
The pH dependence of fluorescence emission.  The fluorescence emission at 510 nm 
upon excitation at 420 nm for 2.0 μM ALAS (▲) and 3.5 μM H282A (●) at varying pH.  
Each of the line represents the nonlinear regression fit to equation 3. 
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FIGURE 4.4  
pH dependence of (A) log kcat , (B) log kcat/KmGly and (C) log 1/KmGly for ALAS (- -) and 
H282A (—).  The lines represent the nonlinear regression fits to equation 1 or 2 as 
described in Materials and Methods.  The profiles for the pH dependence of the steady-
state kinetic parameters for ALAS (- -) are from (Zhang, Cheltsov et al., 2005). 
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FIGURE 4.5 
Reaction of 60 μM H282A variant with glycine. (A) Spectra changes observed during the 
reaction of 300 mM glycine with H282A.  Spectra were collected at 1, 5, 11, 23, 41 and 
52 seconds and are shown sequentially with the lowest to the highest absorbance at 420 
nm. The ΔA420 were globally fit to a two-step model using the simulation software 
Dynafit. (B) The ΔA420 data for the time course reaction of 300 mM glycine is 
represented by circles, with the line representing the fitted data.  (C) The fit of the ΔA420 
data for glycine binding at 100, 125, 150, 200, 300, 400, 500 and 600 mM.    
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FIGURE 4.6  
pH dependence of the Kd for glycine for ALAS (▲) and H282A (●).  The data were fit to 
equation 5 (ALAS) or equation 6 (H282A) using non-linear regression analysis.   
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FIGURE 4.7 
 UV-visible absorption spectra of H282A in the presence of ALA and pH-dependence of 
ALA-quinonoid intermediate formation.  (A) Absorption spectra of H282A (—) and 
ALAS (- -) in the presence of 500 μM ALA.  (Inset) Absorption spectra of H282A (—) 
and ALAS (- -) in the presence of 300 μM ALA. Spectra were acquired at 30 °C and pH 
7.5.  (B) pH-dependence of quinonoid intermediate absorption upon addition of 20 mM 
ALA to either ALAS (- -) or H282A (—).  The lines represent theoretical curves based on 
the best fit of the data to equation 8.  
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FIGURE 4.8 
Circular dichroism spectra of ALAS- and H282A-ligand complexes.  Spectra of ALAS 
and H282A (A) Holoenzymes; (B) in the presence of 200 mM glycine; (C) in the 
presence of 300 μM ALA. Spectra were recorded in 20 mM Bis-Tris with 10% glycerol, 
pH 7.5, at an enzyme concentration of 100 μM.    
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FIGURE 4.9 
The ΔA420 were globally fit to a two-step model using the simulation software Dynafit. 
The ΔA420 data for the time course reaction of varying glycine concentrations represented 
by circles, with the lines representing the fitted data.   
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Chapter Five 
Summary and Conclusions 
Sequence and phylogenetic analysis of PLP-dependent α-oxoamine synthases and their 
role in identifying residues regulating enzyme specificity 
The CoA-dependent acyltransferases or α-oxoamine synthases constitute a small 
but widespread reaction-specific subfamily within the α-family of PLP-dependent 
enzymes; it is comprised of ALAS, AONS, SPT and KBL (Alexeev, Alexeeva et al., 
1998; Schneider, Kack et al., 2000; Schmidt, Sivaraman et al., 2001; Astner, Schulze et 
al., 2005; Yard, Carter et al., 2007).   Here we perform phylogenetic analysis of the α-
oxoamine synthase subfamily of PLP-dependent enzymes to understand the evolutionary 
progression of functional specialization and facilitate a better understanding of the 
mechanisms by which these enzymes enforce selectivity.   
Sequences were selected to represent the phylogenetic and taxonomic distribution 
of each member of the α-oxoamine synthase subfamily of PLP-dependent enzymes.  
Using the sequence alignment of the selected sequences, the evolutionary history was 
inferred and phylogenetic trees were constructed using three methods.  The data are 
consistent with the appearance of AONS function early in the evolutionary time line of 
the α-oxoamine synthases with the subsequent development of ALAS, KBL, SPT and 
SPT1/2 function.  This is not surprising given that AONS was likely the only α-oxoamine 
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synthase present in the universal ancestor cell and that AONS is one of only five PLP-
dependent enzymes found in all biological kingdoms (Mehta and Christen, 1998).   
Although the phylogenetic analysis was initially performed as a tool to help 
characterize the significance of amino acid changes in laboratory-evolved ALAS variants 
that were not realized, the alignments were utilized to identify residues in positions that 
may be significant for the regulation substrate specificity.  Of the 37 residues identified, 
all but four were located at or adjacent to the active site.  Interestingly, one third of the 
residues identified by our analysis were located at key active site positions in the ALAS 
crystal structure from R. capsulatus and/or were previously recognized to be mutated in 
ALAS-2 in patients with x-linked sideroblastic anemia. 
 
Functional Asymmetry for Active Sites of Single Chain Homo- and Chimeric Dimers 
of 5-Aminolevulinate Synthase and 8-Amino-7-Oxononanoate Synthase 
To determine whether the two active sites in ALAS/ALAS contribute equally to 
enzymatic activity, we characterized variants in which one of the two active sites had no 
measurable enzymatic activity due to a mutation of the conserved K313 residue that 
binds to the cofactor. Spectral characterization of ALAS/ALASK313A and 
ALASK313A/ALAS revealed asymmetric cofactor environments in the two active sites, 
which was also reflected in the disproportionate kinetic behavior of the two sites.   
The pre-steady-state burst results for the two K313A-containing variants indicate 
that the chemical rates were similar to ALAS/ALAS and WT ALAS and, like 
ALAS/ALAS and WT ALAS, were consistent with the rate-limiting step occurring after 
the reaction chemistry (Zhang and Ferreira, 2002; Zhang, Cheltsov et al., 2005).  In 
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ALAS, the rate-limiting step has been ascribed to a conformation change that occurs prior 
to the release of the ALA product (Zhang and Ferreira, 2002; Hunter, Zhang et al., 2007).  
The strain resulting from linking the remote N- and C-termini of two ALAS subunits 
appears to increase the energy barrier for product release at one site while decreasing the 
barrier at the other; that is, the steady-state enzymatic activity is enhanced at one active 
site and hindered at the other.  Consequently, the active sites contribute asymmetrically to 
enzyme function.  
Because the single-chain ALAS dimer showed structural plasticity and had 
increased activity, we wondered whether the structural plasticity would extend to single-
chain chimeras constructed from two members of the α-oxoamine synthase family, 
ALAS and AONS.  Both ALAS/AONS and AONS/ALAS chimeras had sufficient 
structural plasticity to achieve the conformations necessary to produce both enzymatic 
activities.   
Despite our initial hypothesis that the chimeric protein would create chimeric 
active sites with potentially novel enzymatic activities, both ALAS/AONS and 
AONS/ALAS appeared to function as chimeric homodimers with functionally 
independent ALAS and AONS modules.   Nonetheless, the dimerization of two chimeric 
polypeptides into a bifunctional homodimer with functionally independent active sites 
suggests that the structural plasticity observed in ALAS can be extended to other 
members of the α-oxoamine synthase family.   
 The ALAS/AONS chimera was purified for further analysis. The fluorescence 
spectra exhibited by the ALAS/AONS chimera were consistent with an enzyme 
exhibiting a mixture of ALAS and AONS spectroscopic characteristics.  The ALAS and 
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AONS steady-state kinetic activities were diminished by roughly one-half in the chimera, 
and the catalytic efficiencies were not impaired.  The pre-steady-state kinetic analysis for 
the ALAS reaction demonstrated that the reactivity of the ALAS sites in ALAS/AONS 
was similar to that of ALAS, with the rate-limiting step occurring after catalysis.   
Like ALAS/ALAS, the linking of the ALAS and AONS subunits appeared to 
change the energy barrier associated with the structural rearrangement that occurs upon 
ALA formation to allow product release.  It is likely that the use of the short dipeptide to 
link the ALAS C-terminus with the N-terminus of either ALAS or AONS introduced 
intermolecular strain which altered conformational flexibility.  Our studies involving the 
chimeras between ALAS and AONS demonstrate that the extensive structural plasticity 
seen in ALAS extends to another member of the α-oxoamine family, AONS. 
 
Histidine-282 in 5-Aminolevulinate Synthase Affects Substrate Binding and Catalysis 
A clustal sequence alignment demonstrated that a histidine residue was perfectly 
conserved in over 70 known ALAS sequences from bacteria to mammals and this 
histidine was also conserve among the α-oxoamine synthases. In murine ALAS-2, this 
conserved histidine corresponds to H282. The crystal structure of Rhodobacter 
capsulatus ALAS reveals the existence of a hydrogen bond between the equivalent 
histidine and the phenolic oxygen atom of the PLP cofactor (Astner, Schulze et al., 2005).  
A series of H282 murine ALAS-2 variants were constructed to characterize the role of 
this conserved residue, however H282A was the only variant recoverable as a soluble 
enzyme.   Though this residue was predicted to have multiple roles, including functioning 
as an acid catalyst during transaldimination (Webster, Alexeev et al., 2000; Zhang, 
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Cheltsov et al., 2005), positioning the PLP aromatic ring (Schmidt, Sivaraman et al., 
2001), and regulating the pKa of the imine nitrogen (Webster, Alexeev et al., 2000), we 
were surprised by the range of effects on the spectral, binding and kinetic properties that 
resulted from the replacement of H282 with alanine.   
The absorption and fluorescent spectra indicated that the mutation had a 
substantial effect on the electronics of the PLP cofactor and suggest that the mutation 
significantly alters the equilibrium of cofactor tautomeric structures to favor the 
ketoenamine.  The steady-state kinetic parameters of the variant revealed that the loss of 
the H282 interaction with the phenolic oxygen impairs both glycine binding and 
catalysis, reducing the catalytic efficiency for glycine 4505-fold.  The slow phase rate for 
glycine binding in H282A decreased 60% relative to ALAS, while the overall kinetic Kd 
increased 4.5 fold.  The rate-determining step is also altered in the H282A and is likely 
associated with glycine binding (at pH below 8.0) and not ALA release, as is observed in 
ALAS.  The pH dependence of the log 1/Km and acidic log kcat/Km provides evidence that 
H282 stabilizes the reactive form of the internal aldimine and is consistent with the 
change in tautomeric structures observed in the absorbance spectra.  In H282A the ALA-
quinonoid species is markedly diminished, while Kd for ALA is minimally affected.  
In the R. capsulatus crystal structure, H282 hydrogen bonds with both the 
phenolic oxygen of the PLP cofactor and Y121. We suspected that the loss of the H282 
hydrogen bonds with the cofactor and Y121 likely affect the PLP movement and 
orientation within the active site impacting multiple aspects of the catalytic process.  
Using CD spectroscopy, we determined that while the PLP microenvironment in the 
holoenzyme was similar in ALAS and H282A, the microenvironment diverged upon the 
 182
binding of the 5-aminolevulinate product and glycine substrate.  This alteration in the 
cofactor microenvironment would impact both cofactor position and interactions with key 
catalytic residues.  Therefore, we conclude that the multiple effects of the loss resulting 
from the loss of H282 results from a combination of direct and indirect effects, including 
alterations in the protonation of the phenolic oxygen and changes to the stereoelectronic 
relationships between the cofactor and active site residues, through the disruption in the 
processional PLP positioning that normally occurs during catalysis.   
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